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ABSTRACT 
 
 
 Tubulin inhibitors are widely used as chemotherapeutic agents, and their success 
is attributed to their ability to target microtubule dynamics and disrupt critical cellular 
functions including cell signaling, motility, intracellular trafficking, and mitosis. 
Interference with microtubule dynamics consequently disrupts mitotic progression and 
ultimately leads to apoptosis, validating microtubule dynamics as an excellent target for 
anticancer agents. While this class of drug has proven to be effective against many cancer 
types, the clinical efficacy of current tubulin inhibitors is often limited by the 
development of multidrug resistance. The most common form of resistance to these 
agents arises from the overexpression of drug efflux transporters. Extensive research 
efforts have attempted to develop colchicine binding site inhibitors, which are reported to 
be significantly less susceptible to multidrug resistance and have therapeutic advantages 
over agents that target the taxane and vinca alkaloid site. Herein, we evaluated the 
anticancer activity of novel small-molecules that target the colchicine binding site, 
focusing on the most promising compounds from several structural scaffolds including 
indolyl-imidazopyridines (DJ95 and DJ101), VERU-111 analogs with a modified indole 
moiety (10ab and 10bb) or 3,4,5-trimethoxyphenyl moiety (13f), and heterocyclic 
pyrimidines (4a, 6a, 5a, and 5b). We demonstrated the cytotoxic potency of these 
compounds against a variety of cancer cell lines, including malignant melanomas, taxane-
resistant prostate cancer cells, and drug efflux pump-overexpressing cell lines. Their 
mechanism of action was revealed through tubulin polymerization inhibition, disruption 
of microtubule networks and mitotic spindle formation, and confirmed through X-ray 
crystallography, which detailed their specific molecular interactions with tubulin in the 
colchicine binding pocket. Furthermore, these compounds exhibited hallmark 
characteristics of colchicine binding site agents, such as arresting cells in the G2/M phase 
of the cell cycle, inducing apoptosis in a concentration-dependent manner, and impeding 
cancer cell proliferation and migration. Finally, the compounds were efficacious in vivo 
against melanoma and taxane-resistant prostate cancer xenograft tumors. Several agents 
were evaluated for ability to prevent melanoma metastases to the lungs in experimental 
mouse models, and they potently inhibited the development metastatic foci. Safety 
assessment by pharmacological profiling demonstrated minimal interactions to 
physiologically important targets and pathophysiological analysis of major organs from 
the in vivo treatment groups did not expose apparent drug-related injury. Several of the 
investigated compounds also demonstrated vascular disrupting properties by targeting 
tumor vasculature and inhibiting capillary-like network formation of endothelial cells. 
Ultimately, these compounds exhibit strong anticancer efficacy, specifically target the 
colchicine binding site, and have great potential as cancer therapeutics, particularly for 
multidrug resistance phenotypes. 
 
 Another target we explored for anticancer intervention was survivin. Survivin is 
the smallest member the inhibitor of apoptosis protein family and its overexpression in 
tumor cells is been positively correlated with the development of multidrug resistance 
and radiation resistance. Because it is differentially expressed in healthy tissues and 
tumors, it is an attractive therapeutic target. Using the scaffold of UC-112, which was 
 vi 
previously identified through virtual screening, we evaluated a series of analogs designed 
to optimize potency and improve selectivity to survivin over other inhibitor of apoptosis 
proteins. We identified compound 10f, which was highly cytotoxic to melanoma and P-
glycoprotein overexpressing cell lines, induced apoptotic cascades in a concentration-
dependent manner, specifically downregulated survivin protein levels, and significantly 
inhibited tumor growth in vivo. Ultimately, these results validated our in-depth biological 
investigation of novel scaffolds of survivin inhibitors and verified the anticancer efficacy 
of 10f.  
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CHAPTER 1.    INTRODUCTION TO TUBULIN INHIBITORS 
 
 
Microtubule Dynamics as an Anticancer Drug Target 
 
 Microtubules are key components of the cellular cytoskeleton and have essential 
roles in proliferation, intracellular trafficking, migration, and mitosis. Microtubules are 
composed of α and β tubulin protein heterodimers that bind in a head-to-tail fashion and 
form cylindrical polymeric tubes of 13 protofilaments that measure approximately 25 nm 
in diameter (1, 2). Microtubules undergo stochastic phases of growth and shrinkage in a 
phenomenon termed “dynamic instability.” Dynamic instability includes the rates of 
polymerization and depolymerization and the frequencies of the transition between 
polymerization to depolymerization (“catastrophe”), and vice versa (“rescue”) (1). 
Another characteristic of microtubules involves “treadmilling,” or the net change in 
growth on one end and shrinkage on the opposite end of the protofilament. Each α and β 
tubulin subunit can accommodate one molecule of GTP; the α bound-GTP is not 
hydrolyzed or exchanged, but the GTP bound to the β tubulin can be hydrolyzed after 
being merged into the polymeric tubulin (3). Microtubules cycle through stages of adding 
GTP-tubulin dimers to their growing end, hydrolyzing GTP to GDP in the microtubule 
protofilament, and dissociating the GDP dimer from the microtubule, though the 
conformations affiliated with each of these mechanical states are complex. Free GTP-
tubulin dimers naturally have a 12 degree kink at the intradimer surface but convert to a 
straight, expanded conformation when they bind to the microtubule end, introducing 
strain energy into the microtubule lattice (4, 5). Once the GTP is hydrolyzed to GDP, 
there is a conformational change and an accompanying relaxation in strain energy (6). 
Figure 1-1 shows the cycling between microtubule polymerization and depolymerization 
states.  In the polymerization state, microtubules adapt a straight structure, stabilized 
through lateral interactions, but hydrolyzed GDP-tubulin in the depolymerization state 
bow outward from the protofilament (7). It is generally accepted that a GTP rich “cap” on 
the end of the microtubule will allow it to stabilize and grow, however, when the cap is 
lost through hydrolysis to GDP, the core of the unstable protofilament rapidly shortens as 
the GDP tubulin subunits are released from the microtubule ends (1, 8, 9). 
 
 Both polymerizing and depolymerizing microtubules are observed within a cell 
population, supporting that dynamics are an intrinsic property of the polymer, and while 
the exact biomechanics of the phenomenon are not completely understood, dynamic 
instability is linked to the hydrolysis of GTP (2, 3, 10). Microtubule dynamics are also 
governed by a variety of regulator proteins and mechanisms, and they function both 
spatially and temporally (11). Furthermore, they are essential for successful mitotic 
events governed by mitotic spindles and mitotic organizing centers. Mitotic spindle 
microtubules are significantly more dynamic than the interphase cytoskeleton 
microtubule networks. The mitotic spindles radiate outwards from centrioles and attach to 
the centromeres of sister chromatids in dividing cells (12).  This is followed by a 
simultaneous addition of tubulin at the kinetochore and is accompanied by a comparable 
rate of tubulin loss at the opposite poles (13, 14). If a chromosome is unable to achieve  
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Figure 1-1. Microtubule structure and dynamics.  
A) Conformational changes of microtubules during catastrophe and rescue phases. 
During polymerization, GTP-tubulin is added to the growing end of the microtubule. 
During depolymerization, GTP is hydrolyzed to GDP and the GDP-protofilaments peel 
away from the microtubule and are released. A GTP rich cap stabilizes the microtubule 
and acts as a primer for tubulin polymerization. B) Binding sites on the tubulin dimer. 
The α and ? tubulin dimer each contain a site that can accommodate a GTP molecule. 
The α tubulin has a non-exchange N site and the ? tubulin has an exchangeable E site. 
The vinca alkaloids bind near the E site on the ? tubulin dimer. Taxanes act at a site on 
the lumen of GDP- bound ? tubulin and promote the stable, straight conformation. The 
colchicine site is at the interface of the α and ? tubulin dimer and ligand binding causes 
interdimer bending that favors destabilization. 
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bipolar attachment to the spindle, the cell is unable to continue through the cell cycle and 
is blocked in the metaphase, eventually to succumb to apoptosis (15).  
 
 Interfering with microtubule dynamics is an attractive anticancer strategy, and 
many drugs employing this tactic are therapeutically effective in a wide range of 
malignancies. Mitotic arrest in the G2/M phase, a hallmark of microtubule targeting 
agents, is thought to occur through the perturbation of mitotic spindle machinery and 
failure to pass mitotic checkpoints. There are several sites on the tubulin heterodimer to 
which microtubule targeting agents can bind, the most common being the vinca alkaloid, 
taxane, and colchicine binding sites (Figure 1-1B). These drugs are generally divided 
into one of two classes; stabilizing agents, which enhance polymerization, or 
destabilizing agents, which inhibit tubulin polymerization.  
 
 
Stabilizing Agents 
 
 Stabilizing agents are able to promote polymerization of tubulin even when the 
unfavorable GDP molecule is bound and are more effective than endogenous 
microtubule-associated proteins at stabilizing the microtubule (16, 17). There are several 
drug categories within this class, including taxanes, epothilones, and laulimalide binding 
site agents (18). Representative drugs in this class can be found in Figure 1-2.  
 
 Taxanes.  The taxane binding site is located at the lumen of the β tubulin subunit 
in the intact heterodimer. Taxanes use the H6/H7 loop on β tubulin as a hinge to 
translocate from an intermediate position on the outside of the microtubule to the final 
binding site on the lumen of the microtubule (19).  This motion is supported by a 
hydrogen bond in Ser277 in the M loop present in most tubulin isoforms. However, in the 
class βIII isoform, this Ser277 is replaced by an arginine residue, and overexpression of 
the βIII tubulin isoform is associated with resistance to taxanes, which will be further 
explained in greater detail (19, 20). The first stabilizing agent identified, paclitaxel 
(Taxol), was approved by the FDA in 1992 and has been available clinically since 1996 
(17). Docetaxel (Taxotere), a semi-synthetic analog of paclitaxel, is another early 
generation taxane that was FDA approved for breast cancer in 1996, non-small-cell lung 
cancer in 1999, metastatic hormone-refractory prostate cancer in 2004, and head and neck 
cancer in 2006 (21). While these drugs achieved much success in treating various 
cancers, the development of drug resistance often limits their efficacy. Another issue 
hindering the clinical efficacy of taxanes is their limited solubility. Formulations such as 
Cremaphor EL and polysorbate are vehicles that allow for the solubilization of 
hydrophobic drugs but can induce a range of negative biological side-effects in patients 
(22). Development of Abraxane, also known as paclitaxel protein-bound, is a delivery 
method that has mitigated this problem to some degree. High toxicity, 
immunosuppression, and peripheral neuropathy that accompany long-term use of taxanes 
prove that there is still a great need to develop agents with higher specificity, improved 
efficacy, and minimal off-target toxicities for this class of drugs (23). 
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Figure 1-2. Examples of different classes of microtubule stabilizing and 
destabilizing agents. 
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 Pothilones.  Epothilones make up another class of tubulin targeting agents that 
are distinct from taxanes, though they share a common binding site. While epothilones 
compete with paclitaxel for β tubulin binding, their common pharmacophore differs in 
that each class exploits the binding pocket in an independent manner and involves 
distinct amino acids (24, 25). Epothilones, originally isolated from the myxobacterium 
Sorangium cellulosum, are more amenable to synthetic modifications than taxanes, more 
potent in taxane-resistant and sensitive cell lines, and are poor substrates for P-
glycoprotein (P-gp) drug efflux pumps (26). Epothilones contain a macrolide ring with a 
methylthiazole side chain, and naturally occurring epothilones are characterized as either 
epoxides (epothilone A, B, E, F) or olefins (epothilone C, D) (27). Semi-synthetic 
compounds have been developed to improve their pharmacologic properties and 
biological activities. For example, Ixabepilone, a second-generation derivative of 
Epothilone B, is less susceptible to degradation by carboxylesterase and has increased 
water solubility. It was the first epothilone derivative to be FDA approved for cancer 
treatment (25). Sagopilone is the first fully synthetic analog of Epothilone B and has 
reached phase II clinical trials (28, 29). 
 
 Laulimalide Binding Site Agents. Another binding site on tubulin is the 
laulimalide binding site. This site was discovered when it was observed that laulimalide 
possessed a similar mode of action as taxanes but was completely unable to inhibit the 
binding of [3H] paclitaxel or Flutax-2, paclitaxel derivative to tubulin, confirming that it 
did not compete with the taxane binding site (30, 31). Peloruside A also directly binds to 
tubulin without competing with paclitaxel but can be displaced by laulimalide, supporting 
that Peloruside A shares a binding site with laulimalide (32, 33).  Both laulimalide and 
Peloruside A synergistically enhanced microtubule assembly induced by stabilizing 
agents, including discodermolide, dictyostatin, paclitaxel, Epothilones A and B, 
eleutherobin, and cyclostreptin (32). Furthermore, laulimalide and Peloruside A stabilize 
the M loop at the taxoid binding site, which contributes to crosstalk and explains the 
observed synergism between these agents and taxane site ligands (34). 
 
 
Destabilizing Agents 
 
 The other class of microtubule targeting agents are the destabilizing agents and 
include drugs that bind to the vinca alkaloid binding site and colchicine binding site. 
Their major mechanism of action is to interfere with tubulin dynamics, as opposed to just 
reducing overall polymerization. Representative drugs in this class can also be found in 
Figure 1-2. 
 
 Vinca Alkaloids. Vinca alkaloids are a natural product or semi-synthetic 
extraction derivative from the periwinkle plant, Catharanthus roseus (35). The major 
vincas in clinical use are vinblastine, vincristine and semisynthetic derivatives 
vinorelbine, vindesine, and vinflunine. The last two are only approved for use in Europe, 
while the rest are FDA approved in the US. In addition to their microtubule 
depolymerizing effects, vincas have also been reported to increase oxidized glutathione, 
alter lipid metabolism and membrane lipid content, elevate cAMP, and inhibit cAMP 
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phosphodiesterase (36). Vincas bind near the exchangeable GTP site and inhibit GTP to 
GDP hydrolysis and GDP exchange, causing a change in the tubulin dimer from the 
straight conformation (which is favored for polymerization) to the curved confirmation 
(23). Maytansinoids and halichondrins also induce depolymerization of microtubules at 
the vinca site, while dolastatins, spongistatins, and cryptophycins bind to the “peptide 
site” of the vinca binding domain (23, 37). Though vincas are amongst the most 
commonly used microtubule targeting agents, they also are susceptible to development of 
drug resistant mechanisms and toxic side effects. 
 
 Colchicine Binding Site Agents. The final major category of tubulin inhibitors 
are colchicine binding site agents. Colchicine, from the meadow saffron Colchicum 
autumnale L., was the first agent discovered in this group as a tubulin depolymerizing 
agent. The colchicine binding domain is located at the interface between the α and β 
tubulin dimer. When colchicine binds in the binding domain, it displaces the M loop and 
then the bound colchicine-tubulin complex becomes incorporated into microtubule and 
interferes with the formation of lateral contacts at the end of protofilaments. This causes 
steric clashes and the tubulin can no longer maintain a straight conformation (38). As the 
concentration of colchicine increases, more lateral contracts are broken, ultimately 
leading to destabilization of microtubules. Colchicine and colchicine binding site 
inhibitors are therefore able to suppress tubulin dynamics at lower concentrations and 
induce destabilization of microtubules are higher concentrations. Colchicine itself is an 
approved drug for the treatment of gout and has implications in other inflammatory 
conditions such as familial Mediterranean fever pericarditis and Behçet's disease. 
However, there are currently no colchicine binding site agents that have been approved 
for cancer therapy due to limitations such as poor drug solubility, narrow therapeutic 
window, and harsh side effects including neurotoxicity. Despite these shortcomings, 
colchicine binding site agents have several advantages over other tubulin agents targeting 
different binding sites. First, drugs binding to the colchicine binding pocket may 
overcome mechanisms of drug resistance, which will be discussed herein. Also, 
colchicine binding site inhibitors can target tumor vasculature and prevent formation of 
new blood vessels or disrupt existing microvessels (39, 40). For these reasons, the 
colchicine binding site is an attractive target for the development of chemotherapeutic 
drugs and numerous scaffolds are being investigated. 
 
 Combretastatins are naturally occurring stilbenoid phenols isolated from the bark 
of Combretum caffrum (41). Combretastatins A-4 (CA-4) demonstrates cell-cycle 
dependent arrest, potent antiangiogenic activity, and cytotoxicity by apoptosis rather than 
necrosis (42, 43). The water soluble phosphate prodrug, CA-4P, phenostatin, and many 
other CA-4 derivatives have been developed to optimize its potency, vascular disrupting 
potential, drug-like properties, and anticancer efficacy (44). Based on the knowledge 
gained from combretastatin and phenostatin, 1,1-diarylethene isomers of combretastatin 
A were developed called isocombretastatin A (45). CC-5079, an isocombretastatin A 
analog, was determined to be an inhibitor of tubulin polymerization and TNFα. It showed 
cell cycle arrest in G2/M phase, increased phosphorylation of G2/M checkpoint proteins, 
and stimulated apoptosis. Additionally, its effect on TNFα production also diminished 
phosphodiesterase type 4 enzymatic activity (46). Alkenyldiarylmethanes are a class of 
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non-nucleoside reverse transcriptase inhibitors that are structurally related to CC-5079, 
and several compounds in this class also demonstrate potent tubulin destabilization (47).  
 
 2-Methoxyestradiol (2-ME), a metabolite of estradiol-17β, suppresses 
microtubule dynamics at the colchicine binding site, induces G2/M phase arrest, inhibits 
blood vessel formation at several stages in the angiogenic process, and has potent 
anticancer activity (48, 49). It inhibits tubulin assembly in a concentration-dependent 
manner, and higher concentrations are needed to depolymerize microtubules. In addition 
to showing efficacy in a variety of cancer types (breast, ovarian, lung, prostate, and 
colorectal carcinomas), 2-ME is active against estrogen-dependent and -independent 
cancerous cells. In addition to disrupting microtubule dynamics, 2-ME also acts through 
triggering the apoptotic cascade via reactive oxygen species, superoxide dismutase, and 
nitric oxide synthase (50).  
 
 Nocodazole is another natural product that inhibits tubulin polymerization by 
binding to the colchicine binding site as a reversible inhibitor (51). It also binds with 
varying affinities to the different tubulin isotypes, with the weakest affinity for βIII 
tubulin (52). Nocodazole did not advance through clinical trials due to toxic side effects, 
however, it is frequently used in cell culture to block mitosis and as a reference 
compound for colchicine binding site agents (16, 53). Several colchicine binding site 
agents have made it to clinical trials including ABT-751, BNC105 and verubulin (36, 54). 
One of the hallmarks of colchicine binding site agents is that they accommodate a wide 
range of structurally diverse scaffolds, and there is still much room for improvement to 
limit toxicities, improve solubility, and increase efficacies. Future directions for 
colchicine binding site agents aim to optimize structural based design, utilize targeting 
strategies, and increase specificity. 
 
 
Mechanisms of Multidrug Resistance  
 
 One of the major hurdles that continues to limit current anticancer agents is the 
development of drug resistance. Multidrug resistance (MDR) is the simultaneous 
resistance to a number of structurally and functionally unrelated chemotherapeutic drugs 
and is a substantial obstacle impeding the success of  anticancer agents (55). Many 
cancers initially respond well to chemotherapy early on during treatment but 
subsequently develop acquired resistance, and more than 90% of patients with metastatic 
cancer fail to respond to or relapse from chemotherapeutics (56). For these reasons, 
rigorous efforts have been devoted to elucidating both inherent and acquired MDR 
mechanisms over the past few decades. Although a complete understanding of MDR is 
still far from being uncovered, two major mechanisms have been proposed: non-cellular 
and cellular mechanisms.  
 
 Non-cellular drug resistance is the inherent capacity of tumor cells to survive 
chemotherapy. It  is always mediated by the tumor microenvironment and is typically 
associated with the unique properties possessed by solid tumors, such as heterogeneous 
tumor vasculature, high interstitial fluid pressure, acidic microenvironment, and increased 
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presence of non-cycling tumors caused by insufficient supply of nutrients and oxygen 
(57-61). Cellular MDR mechanisms arise inside solid tumors, and compared to non-
cellular MDR mechanisms, cellular MDR mechanisms are more important for novel drug 
development. Some examples in which cellular mechanisms are modified to escape drug 
action include elevated DNA repair, increased drug metabolism, altered apoptotic 
pathways to bypass drug targets, loss or change of drug target proteins, and increased 
efflux of anticancer drugs (e.g. altered activities of membrane transporters such as ATP-
binding cassette transporters)(62, 63) (Figure 1-3). Metabolic changes of drugs that 
promote drug degradation are also critical to MDR. For instance, overexpression 
glutathione, an important metabolic antioxidant, promotes MDR by converting drugs to 
drug-conjugates or by generating inactive metabolites that expel as waste (64). Mutation 
of key apoptotic regulators is another primary reason for cellular MDR. Tumor 
suppressor protein p53 is crucial to many physiological processes, especially in 
regulating apoptosis. Several studies have shown that mutation of p53 and overexpression 
of BAX, an anti-apoptotic protein in the Bcl-2 family, are involved in MDR (62, 65).  
 
 Among all the MDR mechanisms, the increase of drug efflux mediated by ATP-
binding cassette (ABC) transporters is the most significant factor leading to MDR. Many 
studies demonstrated that the ABC transporters comprise seven distinct classes of 
structurally related membrane proteins including ABCB, ABCC and ABCG. 
Overexpression of ABC transporters in tumor cells promotes MDR by reducing sufficient 
accumulation of anticancer drugs through increasing drug efflux. P-gp, encoded by the 
ABCB1/ MDR1 gene, is the best characterized transporter protein mediating drug 
resistance and many drugs (e.g. docetaxel, paclitaxel, doxorubicin, etoposide, vinblastine, 
vincristine, and teniposide) are susceptible to resistance incurred from elevated P-gp (65-
67). P-gp overexpression was reported to lead to failure of chemotherapy in various  
cancers, such as ovarian, lung, breast and acute myeloid leukemia cancer (68). 
ABCC1/Multidrug Resistance-Associated Protein 1 (MRP1) is responsible for 
transporting organic anions and phase II metabolic products and causes resistance to 
anticancer agents. It was first shown to be overexpressed in a doxorubicin-resistant cell 
line, but also accommodates a wide range of substrates in addition to doxorubicin, 
including anthracyclines, epipodophyllotoxins, vinca alkaloids, and camptothecins (69). 
Finally, ABCG2/Breast Cancer Resistant Protein (BCRP) is a well-defined efflux 
transporter first identified in a breast cancer cell line selected for resistance to 
mitoxantrone. Similar to the other MDR transporters, BCRP serves as an efflux pump for 
many diverse scaffolds of xenobiotics, including 7-ethyl-10-hydroxycamptothecin (SN-
38)(70), tyrosine kinase inhibitors (71), methotrexate (65, 72), and is involved in drug 
resistance in colon, breast cancer  and gastric carcinomas (73, 74). 
 
 
Strategies to Overcomer Multidrug Resistance  
 
 Strategies to overcome inherent or acquired drug resistance are essential to the 
treatment of cancers. Using inhibitors of ABC transporters is one of the common 
approaches to overcome P-gp-mediated MDR, rendering tumor cells more sensitive to  
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Figure 1-3. Drug-resistance mechanisms in tumor cells. 
1) Loss or change of surface receptor. 2) Mutations in drug targets. 3) Enzymatic 
deactivation. 4) Altered drug metabolism. 5) Change in apoptotic pathways. 6) Increased 
drug efflux. 7) Decreased drug influx (solute carriers). 8) Increased DNA repair. 
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chemotherapeutics. Some strategies for overcoming MDR include developing novel 
anticancer drugs that are not the substrates of P-gp, suppressing the MDR-related genes 
through destruction of mRNAs by using microRNA and RNA interference (75, 76), 
decreasing intracellular GSH levels via hammerhead ribozymes against glutamate 
cysteine ligase or L-buthionine-(S,R)-sulfoxime to repress glutathione synthesis (77, 78), 
targeting P-gp to reverse MDR with anti-P-gp monoclonal antibodies (e.g. MRK16 and 
MRK17), and using nanotechnology to deliver anticancer drugs to specific targets 
efficiently (79). Development of novel drugs that overcome MDR continues to be a major 
area of research in drug discovery and development. Herein, we briefly summarize some 
strategies in developing tubulin inhibitors that overcome MDR.  
 
 Taxane Binding Site. Paclitaxel and docetaxel, members of taxane family, are 
chemotherapeutics used to treat patients with various solid tumors, including ovarian, 
breast, head and neck, lung, and prostate cancers. However, severe adverse effects and 
development of MDR have largely compromised the use of paclitaxel and docetaxel. In 
addition to transporter-mediated resistance, overexpression of the class III β-tubulin 
isoform also limits efficacy of many taxanes. Differences between βI-tubulin, the most 
commonly represented and constitutively expressed isotype, and βIII-tubulin are limited 
to substitution within only a 13 amino acid region, where βIII has an Arg277 instead of 
the Ser277 present in βI-tubulin (80). This substitution prevents stable paclitaxel binding 
and creates more dynamic microtubules, minimizing the polymerization-inducing activity 
of taxanes and increasing resistance to stabilization (81). Creation of newer generations 
of taxanes that are poor substrates of P-gp such as cabazitaxel, drug combination therapy, 
and drug conjugates for tumor-targeted delivery are all strategies that attempt to address 
the issue of MDR and develop more effective treatments (21).  
 
 Ixabepilone (BMS-247550), an epothilone derivative, was first marketed under 
the trade name Ixempra for the treatment of drug-resistant metastatic breast cancer. The 
efficacy of ixabepilone in resistant tumors may result from its low susceptibility to 
alteration in tubulin isotypes, tubulin mutations, and overexpression of P-gp/MDR1 drug. 
In a phase II clinical trial of metastatic breast cancer patients treated with 40 mg/m2 
ixabepilone as a 3-hour infusion every 3 weeks, ixabepilone demonstrated promising 
antitumor activity and had an acceptable safety profile (82, 83).  Taccalonolides are 
taxol-like microtubule stabilizing agents isolated from plants of the genus Tacca that 
increase the density of cellular microtubules, block mitotic progression, and induce 
apoptosis. Similar to ixabepilone, taccalonolides can circumvent MDR mechanisms due 
to their low susceptibility to P-gp overexpression and tubulin alteration-mediated 
resistance (84, 85). Recently, new taccalonolides AF and AJ were obtained and 
demonstrated potent IC50 values of 23 nmol/L and 4 nmol/L in HeLa cell lines. 
Taccalonolides AF and AJ were generated from their parent taccalonolides A and B, by 
epoxidizing the C22–C23 double bond. This simple epoxidation dramatically increased 
the potency over 200- and 700-fold, respectively (86). Due to the unique structural 
characteristics and mechanism of taccalonolides, Susan l. Mooberry’s group modified the 
precursor structure and reported on a semi-synthetic derivative, taccalonolide AI, which 
showed an IC50 below 1 nM (87, 88). These studies are particularly informative for the 
synthesis of taccalonolide derivatives. Due to their strong cytotoxicity and unique 
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mechanisms of covalent bonding, taccalonolide semi-synthetic derivatives are a very 
promising generation of irreversible tubulin inhibitor for resolving the drug resistance 
dilemma.  
 
 Vinca Alkaloid Binding Site. Hemiasterlin, a natural product, is a member of tri-
peptides derived from marine sponges. Hemiasterlin and its analog HTI-286 bind to 
vinca-peptide site in tubulin, disrupt normal microtubule dynamics, and trigger the cell 
apoptotic process (89).  Total synthesis of hemiasterlin and its analogs has been 
accomplished and the SAR studies have been explored.  HTI-286 showed potent activity 
with an IC50 of about 2 to 5 nM against a panel of tumor cell lines and was less sensitive 
to the P-gp drug transporter pump than current anti-microtubule agents including 
paclitaxel, docetaxel, vinorelbine, and vinblastine (90). Additionally, resistance to HTI-
286 was not detected in cells overexpressing the multi xenobiotic resistance drug pump. 
However, side effects of HTI-286 included neutropenia, hair loss, and pain, which 
ultimately terminated phase II trials. Further optimization is needed to address the current 
limitations of anticancer therapies and side effects. 
 
 Tubulysins, originally isolated from myxobacterial cultures, are tetrapeptides 
composed of D-methylpipecolate, L-isoleucine, L-tubuvaline, and L-tubuphenylalanine 
residues (91). Tubulysin D demonstrated the most potent activity, exceeding other 
marketed chemotherapeutics such as Ixabepilone, vinblastine, and paclitaxel, by 20- to 
1000-fold.  The mechanisms of action of tubulysins resembled dolastatin-10 and 
hemiasterlin, which bind to the vinca domain site, arrest cancer cells in the G2/M phase, 
and trigger subsequent cell apoptosis (92, 93). Tubulysins are highly active in MDR cell 
lines that either overexpress P-gp pumps or have tubulin mutations, providing an 
alternative solution to treating MDR cancers.  
 
 Colchicine Binding Site. While microtubule targeting agents often face 
shortcomings due to the development of resistance, colchicine binding site agents have 
several advantages over other classes of tubulin inhibitors. First, many drugs in this class 
are less susceptible to MDR mechanisms that limit the efficacy of so many other tubulin 
inhibitors (54, 94). For example, one of the main mechanisms of drug resistance is due to 
the overexpression of the class III β tubulin that alters the conformation of the taxane 
binding site but does not confer resistance to colchicine binding site agents (95). Humans 
have at least 7 expressed β tubulin isoforms, and alterations in their expression are linked 
to acquired drug resistance (95). Furthermore, paclitaxel-resistant mutants often show 
elevated sensitivity to drugs that bind to alternative tubulin sites, such as colchicine site 
agents (95). There is also evidence that the efficacy of the vinca drug, vinorelbine, is 
reduced when βIII tubulin is overexpressed, whereas colchicine binding site agents were 
unaffected, suggesting that that the resistance from βIII tubulin isoforms are binding site 
specific (81, 96). This offers an advantage for chemotherapeutic drugs targeting the 
colchicine binding site. 
 
 To address conventional multidrug resistance to many microtubule-
inhibiting agents, there have been numerous efforts to develop colchicine binding site 
inhibitors because of their therapeutic advantages over taxanes and vinca alkaloids. 
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Recently, 2-aryl-4-benzoyl-imidazoles ABI-274 and ABI-231 were discovered by Miller 
and Li’s group and they specifically target the colchicine binding site (97, 98). The 
compounds exhibited similar potency to MDR cells compared to corresponding parent 
cells. (99).  They also demonstrated synergistic action through the combination of ABI-
274 and vemurafenib to overcome vemurafenib-acquired resistance in BRAF(V600E) 
melanoma. The combination treatment effectively decreased the levels of phosphorylated 
and total AKT, activated the apoptosis cascade, and reduced cleaved caspase-3 and 
cleaved PARP (100). These contributions offer new strategies to alleviate the problem of 
drug-resistance and they provide practical implications for further investigation of 
colchicine binding site agents. Bai et al. reported a similar colchicine binding site 
inhibitor, BZML, that showed potent cytotoxic activity against both A549 and 
A549/Taxol-resistant cells (99). Mechanistic studies showed that BZML decreased P-gp 
expression at the protein and mRNA levels. Cell morphology changes and the expression 
of apoptosis-related proteins denoted that BZML induced mitotic catastrophe to  
A549/Taxol-resistant cells in a p53-independent, apoptotic-like pathway, whereas BZML 
caused apoptosis to A549 cells (99).  Verubulin (MPC-6827) is a quinazoline derivative 
that showed potent antineoplastic activities against diverse tumors and promoted 
apoptosis in both sensitive and MDR cancer cell phenotypes (101). Other verubulin 
analogs have been developed in attempt to maintain potency and avoid resistance, and 
these compounds have reported vascular disrupting activities and low IC50 values against 
various cancer cells (102). Several other colchicine binding site inhibitors investigated 
include indanocine, millepachine, SSE15206, IMB5046, D4-9-31, and their respective 
synthetic derivatives. Indanocine is a derivative of indanone and a selective inducer of 
apoptosis to stationary multidrug-resistant cancer cells.  One approach to eradicate tumor 
cells involved combination therapy with indanocine, which was selectively cytotoxic to 
non-cycling, multidrug-resistant cells and other chemotherapeutic drugs, which targeted 
abnormalities of cell cycle tumors (103). Yang et al. reported the ability of millepachine 
to evade multidrug resistance in an A2780CP (P-gp overexpressing) model and 
demonstrated that it irreversibly interacted with the colchicine site of β-tubulin and 
retained full activity toward MDR cells (104). SSE15206 also circumvented drug 
resistance in KB-V1 and A2780-Pac-Res cell lines that overexpressed P-gp (105). 
IMB5046 was not a P-gp substrate and displayed potent cytotoxicity against a panel of 
tumor cell lines and multidrug-resistant cell lines that were resistant to colchicine, 
vincristine and paclitaxel treatment (106). D4-9-31, a pyridine-pyrimidine amide, showed 
strong efficacy in isogenic paclitaxel-resistant breast cancer cells and also evaded P-gp-
mediated drug efflux (107). Another major mechanism of drug resistance to tubulin 
inhibitors that is a critical clinical concern is due to the overexpression of certain β-
tubulin isoforms. Humans have at least 7 expressed  β-tubulin isoforms, and alterations in 
their expression is linked to acquired drug resistance (95). Studies have shown that 
overexpression of class III β-tubulin reduces the efficacy of taxanes and vinca alkaloids, 
but drugs that target the colchicine binding site may circumvent resistance (81).  
 
 Further efforts evaluating novel tubulin inhibitors will help elucidate the drug 
resistance mechanisms and thus guide drug design that can overcome inherent or 
acquired drug resistance. In addition, discovery of tubulin inhibitors with different 
inhibition mechanisms (such as targeting two pathways with one compound) will open 
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alternative avenues to bypass the problem of drug resistance. Another strategy involves 
utilizing antibody-drug conjugates of tubulin inhibitors for targeted drug delivery to 
circumvent MDR, improve the therapeutic window, and limit toxicities (108). While 
significant strides have been made to address MDR, resistance is often multifactorial and 
heterogeneous.  Therefore, efforts to gain insight into tumor dependence and the 
relationship of the individual drug resistance effectors may assist in combating the 
complex phenomenon of MDR (109). 
 
 
Microtubule Targeting Agents’ Potentiation of Immune Response and Implications 
in Cancer 
 
 
Dendritic Cells: Induction of Maturation and T Cell Priming 
 
 In addition to their antimitotic effects, microtubule targeting agents can also affect 
many non-mitotic mechanisms, including eliciting an immune response following the 
disruption of intact microtubules.  The perturbance of microtubules from anti-tubulin 
agents can then induce anti-inflammatory responses and leukocyte action (110). For 
example, dendritic cells (DC) are antigen-presenting cells and are important regulators in 
the initiation of innate and adaptive immunity. While they have long been heralded for 
their defensive action to foreign pathogens, they are more recently being appreciated for 
their role in regulation of antitumor response. However, tumor-altered DC differentiation 
can interfere with their ability to potentiate an immune response  (111). This can lead to 
DCs and their precursors accumulating in the tumor microenvironment and exacerbate 
the immunosuppressive action of the tumor. Therefore, intervening and converting the 
immature DCs to mature antigen presenting cells is an important target for immune-
therapy based cancer treatment (112).  Microtubule destabilizing agents including 
ansamitocin P3, dolastatin, and antibody-drug conjugates containing dolastatin 10 
analogs have been shown to induce functional DC maturation and activation, and also 
increase the capacity of priming antigen-specific CD4+ and CD8+ T cells (113, 114). It 
has also been reported that other classes of microtubule-destabilizing agents can activate 
DCs, unlike microtubule stabilizing agents which only invoked minimal activation in 
murine cells and caused no observed effect in DCs (112). Another group also investigated 
the effects of microtubule destabilizing agents on DC maturation and T-cell activation in 
relation to immunogenic tumor cell death. They reported that dendritic cell vaccines 
pulsed with colchicine- or 2-phenyl-4-quinolone analog- treated cell lysates mitigated 
tumor growth, revealed cytotoxic T-lymphocyte activity in tumors, and extended survival 
of treated mice inflicted with tumor xenografts (115).   
 
 
Inflammation 
 
 Inflammation can play a role in malignant transformation, cancer progression and 
pathogenesis in numerous tissues. For example, inflammatory bowel diseases such as 
ulcerative colitis and Crohn’s disease contribute to the development of colon cancer, 
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because chronic inflammation can endorse the production of tumors. It has been reported 
that the use of nonsteroidal anti-inflammatory drugs lowers mortality caused by sporadic 
colon cancers, representing a link between cancer and inflammation (116-118). The 
interaction of tumor cells with a variety of aspects within the tumor microenvironment, 
including macrophages, B and T cells, mast cells, fibroblasts, myofibroblasts and 
extracellular matrix components, has been shown to propagate tumor progression. 
Furthermore, tumors are capable of secreting cytokines, chemokines, growth factors, and 
proteases to remodel the stroma microenvironment (119). Inflammation is driven by these 
soluble factors from the tumor cells or from cells recruited to the tumor microenviron- 
ment such as macrophages and mast cells, which can then drive tumor cell growth, 
interfere with differentiation, and increase cancer cell survival. Elevated influx of 
angiogenic cytokines from the surrounding immune cells to the tumor microenvironment 
can also contributing to tumor metastasis (120). Since levels of cytokines such as Tumor 
necrosis factor α (TNFα), IL-8, IL-6 and vascular endothelial growth factor are often 
elevated in the serum of colorectal carcinoma patients, they represent potential anticancer 
therapeutic targets (121, 122). Oncogenic signaling pathways are also activated by 
cytokines that induce NF-κB signaling and turn on oncogenic mediators that promote 
inflammation (119). While aberrantly expressed inflammation is linked to cancer 
promotion and disease progression, targeting pro-apoptotic signals from an inflammatory 
immune response to induce apoptosis of tumor cells could utilize these targets in 
anticancer treatment. Cell death imposed by an immune response can be from cell killing 
by cytotoxic T cells and natural killer cells, and can also be stimulated by apoptotic 
ligands, such as TNFα. There have been reports on microtubule targeting agents 
sensitizing cells to TNFα and other inflammatory apoptotic ligands (123, 124). AK301, a 
colchicine binding site tubulin inhibitor, was found to cause treated cells to express 
elevated levels of TNF receptor 1 (TNFR1) on the cell surface and increase caspases-8, -
9, and -3 activation in the presence of TNFα. It also induced Fas- and Tumor necrosis 
ligand -dependent apoptosis (123). Interestingly, it caused greater TNFα sensitization 
than other tubulin binding agents including colchicine, nocodazole, and vincristine, 
though it achieved a lower degree of tubulin polymerization inhibition from tubulin 
binding assays. Nonetheless, these studies explore the relationship between microtubules 
and apoptotic ligand-sensitizing agents and how these agents can exploit immune 
response elements for cancer therapy. This may be particularly useful for colon or other 
cancers that have high levels of inflammatory cell infiltrate or following treatment with 
an immune stimulant or vaccines.  
 
 Colchicine, which is historically used in the treatment of gout, has been shown to 
induce an anti-inflammatory response through destabilization of microtubules, which 
subsequently interferes with the assembly of the NOD-like receptor pyrin domain 
containing 3 (NLRP3) inflammasome (125).  Activation of the NLRP3 inflammasome 
within macrophages is commonly implicated in innate immune inflammatory response 
(125).  NLRP3 uses a mitochondrially-bound adaptor protein (apoptosis-associated 
speck-like protein) containing a caspase recruitment domain to recruit caspase-1 to the 
complex, followed by autocatalytic processing and activation, ultimately facilitating the 
cleavage of pro-inflammatory cytokines IL-1β and IL-18 to their activated forms (126). 
The generation of optimal sites for activation of the NLRP3 inflammasome, correct 
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localization, and its direct activation is mediated by microtubules, and microtubule 
disrupting agents block inflammasome activation (127). 
 
 
Polyploidy and Micronucleation 
 
 Another way that microtubule targeting agents may provoke an immune response 
is related to their ability to cause polyploidization (128-130). This can happen through a 
process called mitotic slippage, where cells arrested in the M phase can enter interphase 
without undergoing proper chromosome segregation and cytokinesis, resulting in 
tetraploid multinucleated cells (131). An increase in the number of chromosome sets (>4) 
has been shown to elevate endoplasmic reticulum stress and cause translocation of 
calreticulin to the cell surface. This exposure promotes phagocytosis of stressed cells by 
macrophages and dendritic cells of the immune system and stimulates 
immunosurveillance (130). 
 
 Microtubule targeting agents induce mitotic arrest via disruption of the 
mitotic spindle, and interestingly, they have achieved greater success than mitosis-
specific inhibitors.  This may be in part attributed to their multifaceted roles in other 
interphase functions including intracellular trafficking, migration, angiogenesis, and 
cell signaling, suggesting that their anticancer efficacy is due to their roles in both 
mitotic and non-mitotic events (132, 133).  A relatively new theory as to why tubulin 
targeting agents, particularly those in the taxane class, have achieved greater clinical 
success than mitosis-specific inhibitors is their capacity to promote multiple 
micronuclei (134). These form from chromosome segregation errors during mitosis 
and recruit a nuclear envelope during telophase which does not incorporate into the 
main nucleus. This phenomenon happens when cells are treated with subtoxic drug 
concentrations that fail to induce complete mitotic arrest. These micronuclei formed 
from double stranded DNA breaks can initiate the activation of cyclic GMP–AMP 
synthase (cGAS) inflammatory signaling (135). While this may only occur in a small 
population of dividing cells, it can have substantial implications on whole tumor 
regression through amplified inflammatory activation. Micronucleated cells can 
accumulate within the tumor and are not cleared by phagocytosis in the same manner 
as apoptotic cells. Fragmented DNA is exported through nuclear pores into the 
cytoplasm and binds to the cytosolic DNA sensor cGAS. CGAS consequently turns 
on the endoplasmic reticulum membrane protein STING through the synthesis of 
2′3′-cGAMP (136). This activation triggers the transcription factors NF-κB and IRF3 
through the kinases IKK and TBK1, eventually leading to the activation of 
inflammation. The cGAS-STING pathway activation has been shown to restrain 
oncogenes and increase pro-inflammatory genes in cancer cells (137). Ultimately, 
cGAS–STING-dependent inflammatory signaling can play a role in antitumor drug 
response. 
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Summary 
 
 Because of their major role in mitosis and other critical cellular processes, 
targeting microtubules is an excellent strategy for developing anticancer agents. While 
some microtubule targeting agents that exploit the taxane and vinca alkaloid binding sites 
have been FDA approved for cancer treatment, there are still many hurdles to overcome 
to find a more satisfactory treatment. Targeting the colchicine binding site on tubulin may 
circumvent many MDR mechanisms affiliated with taxanes and vinca alkaloids, such as 
overexpression of drug efflux pumps and alterations in β tubulin isoforms. Although 
there are currently no marketed anticancer agents that target the colchicine binding site, 
immense efforts have been made to advance small molecules in this class. Additionally, 
drugs targeting this site often are effective as vascular disrupting agents and can 
accommodate a large range of structurally diverse scaffolds. While these drugs show 
promise for the future of anticancer therapeutics, poor solubility, metabolic stability, and 
dose limiting neural and cardiotoxicities continue to be major issues limiting their clinical 
potential. While the search for acceptable compounds targeting microtubules continues, 
newer generations of tubulin inhibitors will need to optimize efficacy, capitalize on 
combination therapies, and effectively escape the shortcomings of current anticancer 
drugs. 
 
 
Hypotheses for Novel Tubulin Inhibitors 
 
 
 In the following Chapters 2-4, we disclose the properties and anticancer activities 
of newly synthesized tubulin inhibitors with the following hypothesis in mind: Tubulin 
inhibitors that target the colchicine binding site will be able to potently inhibit tubulin 
polymerization and disrupt microtubule dynamics, interfere with cellular processes such 
as migration and proliferation, evade multidrug resistance, and show strong efficacy in 
animal models harboring cancer xenografts and taxane-resistant tumors. This is the 
overall goal for each of the different series of compounds evaluated, but we specifically 
tested different scaffolds in each of the chapters.  
 
 In Chapter 2, we investigated two novel indolyl-imidazopyridines. These new 
analogs were designed from diaryl-ketone chemotypes that were shown to possess 
tubulin polymerization inhibition properties (138-142). To optimize this scaffold, the 
ketone was cyclized to a pyridine ring and further introduced an imidazole, leading to a 
series of series of indolyl-imidazopyridines. We previously reported that the lead 
compounds in this series caused substantial cytotoxicity against several cell lines and 
enhanced the metabolic stability in liver microsomes (143). Therefore, based on those 
initial findings, we were determined to expand our biological assessment and explore the 
drugability of the two most promising compounds, DJ95 and DJ101. We hypothesized 
that these compounds would show broad anticancer action in expanded cell lines and 
disrupt microtubule networks and mitotic spindle formation. We also hypothesized that 
they would optimally target the colchicine binding site, maintain a low resistance index 
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against ABC transporter overexpressing cell lines, and show significant efficacy against 
taxane-resistant tumors in animal models.  
 
 In Chapter 3, we explored a different scaffold in a similar manner. Previously, we 
reported the discovery of the 2-aryl-4-benzoyl-imidazole (ABI) scaffold (140). 
Subsequent structural optimization of the benzoyl moiety, the aryl moiety, and the 
imidazole fragment in this scaffold resulted in analogs with improved antiproliferative 
activities and tubulin inhibiting properties (98, 141, 143, 144). ABI-231 (VERU-111) 
was determined to be the most potent from those modifications, and it is currently under 
clinical development by VERU Healthcare. We hypothesized that we could improve on 
VERU-111 by focused structural-based optimization of the indole moiety and the 3,4,5-
trimethoxyphenyl moiety. In doing so, we hypothesized we could obtain analogs with 
lower IC50s, enhanced tubulin depolymerization capabilities, and strong efficacy against 
melanoma and taxane-resistant prostate cancer xenograft tumors in mice without causing 
toxicity or eliciting off-target adverse reactions.  
 
 In Chapter 4, we unveil the final anti-tubulin series we evaluated, which was 
based off the Azixa (Verubulin/MPC-6827) scaffold (101). We chose this scaffold 
because of Azixa’s potent tubulin depolymerization properties and its vascular disrupting 
attributes (39, 40, 101, 102). Other reported indole derivatives of Azixa demonstrated 
significant disturbance of tumor vasculature and induced necrosis (102). We selected our 
starting point from an Azixa derivative with reduced conformational flexibility compared 
with other Azixa analogs (145). Because it showed strong potency and tubulin 
depolymerization action but poor metabolic stability and high toxicity, it provided us 
with an opportunity for significant improvement. Therefore, we hypothesized that we 
could optimize this scaffold and identify novel compounds with greater metabolic 
stabilities and reduced toxicities. We also surmised that these compounds would 
demonstrate significant efficacy against clinically relevant MDR xenograft models and 
display drastic morphological changes to tumor vasculature, similar to other vascular 
disrupting agents.  
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CHAPTER 2.    INDOLYL-IMIDAZOPYRIDINES DJ95 AND DJ101 ARE 
TUBULIN INHIBITORS THAT OVERCOME MULTIDRUG RESISTANCE1 
 
 
Introduction to DJ95 and DJ101 
 
 Microtubules are cytoskeletal structures that are essential for a multitude of 
cellular events including movement, intracellular transport, cell signaling, and mitosis 
(146-149). Microtubules are composed of α- and β-tubulin proteins, which readily 
undergo polymerization and depolymerization in a phenomenon known as dynamic 
instability (150). They also form the highly dynamic mitotic spindles that are responsible 
for the alignment and segregation of chromosomes in the cell during mitosis (151). 
Interference with microtubule dynamics consequently disrupts mitotic progression and 
ultimately leads to apoptosis and cell death (152). Therefore, interfering with microtubule 
dynamics by targeting tubulin is a validated anticancer strategy, and many agents are 
already used clinically or are undergoing development (148, 153-155).  
 
 Tubulin inhibitors can be broadly classified as stabilizing or destabilizing agents. 
Currently, all approved tubulin inhibitors for cancer therapy target the taxane or vinca 
alkaloid binding site. However, many tubulin inhibitors, including paclitaxel (Taxol®), 
are associated with MDR mechanisms such as overexpression of drug efflux pumps or 
the βIII tubulin isoform (54, 156-158). Drug efflux mediated by ABC transporters is the 
most commonly observed mechanism responsible for inhibiting the intracellular 
accumulation of therapeutic agents in resistant cell lines (72). Of the known human ABC 
transporters, resistant melanoma cells have been shown to overexpress ABCB1 (MDR1, 
P-gp), ABCC1 (MRP1), ABCC2 (MRP2), and ABCB5 amongst others (159-162). 
ABCG2 (BCRP) is also well-characterized and its overexpression causes resistance to a 
variety of anticancer drugs including paclitaxel and docetaxel(163, 164). Extensive 
research efforts have addressed the issue of MDR, and numerous studies have 
demonstrated that colchicine binding agents can overcome ABCB1 overexpression and 
βIII tubulin-mediated drug resistance (81, 94, 97, 165-169). While colchicine is not 
employed as an anticancer agent due to its toxic side effects, other colchicine binding 
inhibitors have demonstrated promising potential and some are currently being 
investigated as anticancer candidates (23, 54). 
 
 More recently, there has been increasing interest in the vascular-disrupting 
capabilities possessed by some microtubule binding agents (40, 170, 171). It is well-
known that tumor progression is dependent on blood vessels to supply oxygen, essential 
nutrients, and growth factors. Vascular disrupting agents act on the tumor endothelium 
and induce destructive changes that decrease blood flow, promote vascular collapse, 
                                                 
 
1 Modified with permission from American Association for Cancer Research. Kinsie E. Arnst, Yuxi Wang, 
Dong-Jin Hwang, Yi Xue, Terry Costello, David Hamilton, Qiang Chen, Jinliang Yang, Frank Park, James 
T Dalton, Duane D. Miller and Wei Li. A Potent, Metabolically Stable Tubulin Inhibitor Targets the 
Colchicine Binding Site and Overcomes Taxane Resistance. Cancer research. 2018; 78(1): 265-277. 
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initiate hypoxia within the tumor, and cause necrosis (171). There is accumulating 
evidence that microtubule binding agents can act selectively on tumor endothelial cells, 
and this supports the pursuit of targeting tumor vasculature (170). 
 
 We previously reported the discovery of diaryl-ketone chemotypes, including a 
phenyl ring as linker (I-387) (138), 4-substituted methoxybenozyl aryl thiazoles 
(SMART)(142), phenylaminothiazoles (PAT) (139), arylbenzoylimidazoles (ABI) (98), 
and reverse arylbenzoylimidazoles (RABI)(141),  that interfere with tubulin 
polymerization by binding to the colchicine domain. While these compounds displayed 
potent anticancer activity in human melanoma and prostate cancer cell lines, the ketone 
moiety in their structure presented a metabolically labile site (172). Further structural 
optimization to incorporate this metabolic soft spot into a stable ring produced a novel 
class of indolyl-imidazopyridines, with DJ95 and DJ101 representing the two most 
promising drug candidates in this series (structures shown in Figure 2-1) (143, 173). 
DJ95 and DJ101 not only possessed excellent metabolic stability as designed, they also 
showed improved anticancer potency in initial cytotoxicity testing and strong 
polymerization effects in a cell-free tubulin assay(143, 174, 175).   
 
 To further preclinically evaluate the DJ compounds, we expanded our 
investigation to additional malignant melanoma cell lines, the NCI-60 cell line panel, 
taxane-resistant cell lines, and ABC-transporter overexpressing cell lines. We also 
evaluated their effect on cancer cell migration, clonogenic potential, and endothelial cell 
tube formation in vitro. Their depolymerization effects were demonstrated through 
visualization of the microtubule networks as well as mitotic spindles formation. The 
binding of both DJ95 and DJ101 to the colchicine site was confidently confirmed through 
X-ray crystallographic analyses. Prior to in vivo studies, compounds were screened by 
separate pharmacological profiling services to identify potential off-target interactions to 
physiologically important targets. Antitumor efficacy was demonstrated for both 
compounds in a melanoma xenograft model, and DJ101 was also evaluated in a 
metastatic melanoma model and taxane-resistant prostate cancer xenograft model. To 
determine if the compounds possess vascular disrupting properties, 
immunohistochemistry (IHC) analysis of the tumor sections was utilized to determine 
alterations to the tumor endothelium. 
 
 
Materials and Methods  
 
 
Cell Culture and Reagents 
 
 Human melanoma cell lines, A375, RPMI-7951, WM-164, WM115 and SK-
MEL-1, and adult primary dermal fibroblasts cells  (American Type Culture Collection or 
ATCC, Manassas, VA, USA) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Corning, Manassas, VA) supplemented with 10% (v/v) fetal bovine serum 
(FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic/antimycotic mixture  
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Figure 2-1. Structures of compounds DJ95 and DJ101 
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(Sigma-Aldrich, St. Louis MO).  Murine melanoma B16F10 cells (ATCC, Manassas, 
VA, USA) were cultured in Minimum essential medium (Invitrogen, Carlsbad, CA), 
supplemented with 5% heat-inactivated Hyclone FBS (Thermo Scientific, Rockford, IL), 
1% antibiotic-antimycotic mixture (Sigma-Aldrich, St. Louis MO), 1% Mem-sodium 
pyruvate (Invitrogen, Carlsbad, CA), 1% Mem-vitamin (Invitrogen, Carlsbad, CA), L-
Glutamine (2 mM final concentration) (Invitrogen, Carlsbad, CA), and 1% Mem NEAA 
(Invitrogen, Carlsbad, CA). Parental prostate cancer PC-3, its paclitaxel-resistant 
daughter line PC-3/TxR, parental prostate cancer DU-145, and its docetaxel-resistant 
daughter line DU-145/TxR were gifts from Dr. Evan Keller at the University of Michigan 
Medical School. PC-3 and DU-145 cell lines were cultured in RPMI 1640 media 
(Gibco® by Life Technologies, Carlsbad, CA) supplemented with 10% (v/v) fetal bovine 
serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic/antimycotic 
mixture (Sigma-Aldrich, St. Louis MO). Taxane-resistant PC-3/TxR and DU-145/TxR 
cell lines were cultured in the same media and additionally supplemented with 10 nM 
paclitaxel or docetaxel, respectively. Paclitaxel or docetaxel was not included in the 
media for PC-3/TxR or DU-145/TxR for at least one week prior to in vitro and in vivo 
testing. HUVECs were cultured in Endothelial Cell Growth Medium containing growth 
supplement (Promocell, Heidelberg, Germany) and 1% antibiotic/antimycotic mixture 
(Sigma-Aldrich, St. Louis MO). The human epidermoid carcinoma cell line KB-3-1, its 
drug-selected ABCB1-overexpressing KB-C2 cell line (maintained in medium with 2 
?g/mL colchicine) and ABCC1-overexpressing KB-CV60 cell line (maintained in 
medium with 1 mg/mL of cepharanthine and 60 ng/mL of vincristine) (176) were kindly 
provided by Dr. Shinchi Akiyama at Kagoshima University, Japan.  The human non-
small cell lung cancer cell line NCI-H460 and its mitoxantrone-selected ABCG2-
overexpressing NCI-H460/MX20 cells (maintained in medium with 20 nM of 
mitoxantrone) (177), and the  transfected cell lines HEK293/pcDNA 3.1, 
HEK293/ABCB1, HEK293/ABCC1, and HEK293/ABCG2-R482 were kindly provided 
by Drs. Susan E. Bates  at Columbia University, NY, and Robert W. Robey (NIH, 
Bethesda, MD). These cell lines were established by transfecting HEK293 cells with 
either the empty pcDNA3.1 vector or the vector containing full length ABCB1, ABCC1, 
and wild type ABCG2, respectively(178).  These cell lines were cultured in DMEM, 
penicillin/streptomycin (Corning, Manassas, VA) and FBS or Hyclone bovine calf serum 
(GE Healthcare Life Science, Pittsburgh, PA). All cell lines were authenticated by ATCC 
by short tandem repeat profiling.  Cultures were maintained to 80-90% confluency at 37 
°C in a humidified atmosphere containing 5% CO2. Compounds were dissolved in 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) to make a stock solution of 
20 mM. Compound solutions were freshly prepared by diluting stocks with cell culture 
medium before use.   
 
 
Cytotoxicity Assays  
 
 The cytotoxic effect against melanoma and fibroblast cell lines was previously 
described (179). Briefly, cells were seeded in 96-well plates at a density of 1,000–3,500 
cells per well, depending on the growth rate of the cell line. After overnight incubation, 
test compounds were added to the wells at 10 concentrations ranging from 0.03 nM to 1 
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μM plus a media-only control for 72 hrs in four replicates. Following treatment, the MTS 
reagent (Promega, Madison, WI) was added to the cells and incubated in dark at 37 °C 
for at least 1 hour. Absorbance at 490 nm was measured using a plate reader (BioTek 
Instruments Inc., Winooski, VT).  
 
 IC50 values were calculated by nonlinear regression analysis using GraphPad 
Prism (GraphPad Software, San Diego, CA).  In addition, DJ101 and DJ95 were 
evaluated in one dose and five dose assays against the NCI-60 cell line panel by the 
National Cancer Institute Developmental Therapeutics Program (NCI/DTP). 
 
 The cytotoxic effects of DJ95 to KB-3-1, KB-C2, KB-CV60, NCI-H460 and 
NCIH460/MX20 cell lines, and the transfected cell lines HEK293/pcDNA3.1, 
HEK293/ABCB1, HEK293/ABCC1, and HEK293/ABCG2-R482, was obtained by Zi-
Ning Lei (St. John’s University). The IC50 was determined using the MTT reagent 
(Thermo Fisher Scientific Inc., Haverhill, MA)  as previously described (180). Known 
tubulin inhibitors with different mechanisms of actions, including paclitaxel 
(microtubule-stabilizing agent, targeting the taxane-binding site in tubulin), colchicine 
(microtubule-destabilizing agent, targeting the colchicine-binding site in tubulin), and 
vincristine (microtubule-destabilizing agent, targeting the vinca alkaloid-binding site in 
tubulin) (148, 166), were selected as positive controls for comparison with DJ59. 
Paclitaxel, colchicine and vincristine, which are existing substrates of ABCB1 and 
ABCC1(181-183), also served as positive substrate controls for the experiments 
involving ABCB1- or ABCC1-overexpressing cell lines in this study. Mitoxantrone, a 
known substrate of ABCG2(184), was used as positive substrate control in ABCG2-
overexpressing cells. Cisplatin was used as negative control since it is not a substrate of 
ABCB1, ABCC1 or ABCG2 (180).  
 
 
Colony Forming Assay 
 
 Two plating methods were used. To test the effects of DJ95, A375 cells were 
seeded in 6 well plates at a density of 500 cells/well (n=4). To test the effects of DJ101, 
A375 and RPMI-7951 cells were seeded in 24 well plates at a density of 200,000 
cells/well (n=4). After overnight incubation in at 37 °C cells were treated with the 
compound or media only control and incubated for 10 days. Cells were then fixed with 
methanol and stained with 0.5% crystal violet. Images were taken, and colony area was 
quantified with ImageJ software (NIH, Bethesda, MD).   
 
 
Scratch Migration Assay 
 
 A375 and RPM-I7951 cells were seeded in 24 well plates (200,000 cells/well) in 
replicates of four and incubated overnight. A 200 μL pipette tip was used to scratch a 
straight line through the cell monolayer to remove an area of cells, then washed several 
times to remove any debris and uprooted cells. Media was replaced containing equivalent 
vehicle (DMSO) control or DJ compounds at 25 nM concentrations. Images were 
 23 
obtained at the start of the experiment and after 24 hrs with Evos Fl Imaging System 
(LifeTechnologies, Carlsbad, CA). The analysis was performed with ImageJ software 
(NIH, Bethesda, MD).   
 
 
Endothelial Cell Tube Formation Assay  
 
 Matrigel (Corning, Manassas, VA) was thawed on ice overnight then diluted with 
serum-free media for a final concentration of 10 mg/mL. Matrigel was plated in 48 well 
plates and incubated at 37 °C for 1 hour. Low passage number HUVECs (<5) in 
logarithmic growth phase were trypsinized and suspended in endothelial cell growth 
media. Cells (7 x104) were plated on the Matrigel plates in quadruplicate containing the 
desired drug concentrations. Images were captured after 6 hr incubation with Evos Fl 
Imaging System (LifeTechnologies, Carlsbad, CA). Analysis was performed with 
angiogenesis tool plug-in with ImageJ software (NIH, Bethesda, MD). 
 
 
Immunofluorescent Staining 
 
 A375, RPMI-7951, or WM-164 cells were seeded 2.5x105 - 5x105 on glass 
coverslips in 6 well plates and incubated overnight.  Media was changed, and cells were 
treated with DJ95, DJ101, paclitaxel, docetaxel or media only control for 18 hrs. Cells 
were then fixed with 4% paraformaldehyde, permeabilized in 0.1% Triton X (Sigma-
Aldrich, St. Louis MO) in Phosphate Buffered Saline (PBS) (Thermo Fisher Scientific 
Inc., Haverhill, MA) and blocked with 3% Bovine serum albumin (Cell Signaling 
Technology, Danvers, MA) prior to staining. Microtubules and mitotic spindles were 
visualized after incubating with anti-α-tubulin antibody (Thermo Scientific, Rockford, 
IL) and Alexa Fluor 647 goat anti-mouse IgG (Molecular Probes, Eugene, OR). The 
coverslips were mounted with Prolong Diamond Antifade mounting media containing 
DAPI (Invitrogen, Eugene, OR) and images acquired with a Keyence BZ-X700 
fluorescence microscope and BZ-X analyzer software (Keyence, Osaka, Japan). 
 
 
X-Ray Crystallography 
 
 Protein Expression and Purification. X-Ray crystallography was performed by 
Dr. Yuxi Wang (Sichuan University, in China). The clones of the stathmin-like domain of 
RB3 and TTL were generous gifts provided by Dr. Benoît Gigant (CNRS, France) and 
Dr. Michel O. Steinmetz (PSI, Switzerland). The stathmin-like domain of RB3 (RB3-
SLD) from rat was transformed into and overexpressed in E. coli. The protein was 
purified by anion-exchange chromatography and gel filtration chromatography. The peak 
fractions from the gel filtration column were concentrated to 10 mg/mL and stored at -80 
°C (51, 154, 185). The TTL protein from chicken was expressed and purified from an E. 
coli expression system as described previously (186). Briefly, the protein was expressed 
in E. coli using LB, purified through Ni-NTA affinity chromatography and gel filtration 
chromatography (buffer: Bis-Tris Propane pH 6.5, 200 mM NaCl, 2.5 mM MgCl2, 5 mM 
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βMe, 1% glycerol). The peak fractions were concentrated to 20 mg/mL and saved at -80 
°C. The SDS-PAGE was performed to check the purity of RB3 and TTL. Porcine brain 
tubulin (Catalog # T-238P) (Cytoskeleton Inc., Denver, CO) was supplied at 10 mg/mL 
in G-PEM (General tubulin buffer:80 mM PIPES pH 6.9, 2 mM MgCl2, 0.5 mM EGTA 
and 1 mM GTP) as a frozen liquid and saved at -80 °C until use.  
 
 Crystallization and Crystal Soaking. The previously published process of 
obtaining crystals of the tubulin-RB3_SLD-TTL (T2R-TTL) complex was applied (186, 
187). In brief, tubulin (10 mg/mL), TTL (20 mg/mL) and RB3 (10 mg/mL) were mixed at 
the molar ratio of 2:1.3:1.2 (Tubulin: RB3_SLD: TTL) and incubated on ice with 1 mM 
AMPPCP, 5 mM tyrosinol and 10 mM DTT, and the mixture was concentrated to 20 
mg/mL at 4 °C. The crystallization of the T2R-TTL complex was carried out at 20 °C 
using the sitting-drop vapor diffusion method by mixing an equal volume of protein 
complex and crystallization buffer containing 6% PEG 4000, 5% glycerol, 0.1 M MES, 
30 mM CaCl2, 30 mM MgCl2, pH 6.7. Seeding was used to obtain the well diffracting 
crystals. Initial crystals were observed after two days of incubation and reached a final 
length of 200-300 ?m within 3-5 days. Morphologically superior crystals were selected, 
cryoprotected with crystallization buffer containing 20% glycerol, and flash frozen in 
liquid nitrogen. 
 
 X-Ray Data Collection and Structure Determination. Diffraction data were 
collected at 100K on the beamlines BL19U1 at Shanghai Synchrotron Radiation Facility 
(SSRF) in Shanghai, China. The native dataset was collected at a wavelength of 0.97853 
Å using MX225 CCD detector. Data were indexed, integrated and scaled using HKL2000 
(188).  The initial phase was determined by molecular replacement using the apo 
structure T2R-TTL (PDB code: 4I55) as the searching model. The structure of T2R-TTL-
DJ95 was determined by molecular replacement using the previously published T2R-TTL 
structure (PDB ID: 4I55) as a search model. The rotation and translation function 
searches were performed by the program PHASER (189). The model was further built 
with Coot (190) and refined using the phenix.refine module Phenix (191). The model 
quality was checked with PROCHECK and shows a good stereochemistry according to 
the Ramachandran plot. PyMol was used to generate the figures. Analysis was 
determined in coordination with Dr. Stephen White’s group (St. Jude Children’ Research 
Hospital). 
 
 
Pharmacological Profile Screening 
 
 Screening of potentially significant off-target effects to DJ95 binding and enzyme 
targets was performed via SafetyScreen44 offered by Eurofins Cerep-Panlabs. DJ95 was 
tested at 1.0E-07 M. Compound binding was calculated as a % inhibition of the binding 
of a radioactively labeled ligand specific for each target. Compound enzyme inhibition 
effect was calculated as a % inhibition of control enzyme activity. Results showing an 
inhibition (or stimulation for assays run in basal conditions) higher than 50% are 
considered to represent significant effects of the test compounds. Results showing an 
inhibition (or stimulation) between 25% and 50% are indicative of weak effects. Results 
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showing an inhibition (or stimulation) lower than 25% are not considered significant and 
mostly attributable to variability of the signal around the control level. In each 
experiment, the respective reference compound was tested concurrently with DJ95, and 
the data were compared with historical values determined at Eurofins. The experiment 
was accepted in accordance with Eurofins validation Standard Operating Procedure. 
Assessment of potentially significant off-target effects of DJ101 to 47 major physio-  
logically important targets was performed by DiscoverX (DiscoverX Corporation, 
Fremont, CA) in 78 assays using its Safety47™ Panel and standard protocols. DJ101 was 
assayed at 1 μM concentrations in two replicates. Hit responses < 70% are considered 
negligible. 
 
 
LC-MS/MS Plasma Concentration Analysis 
 
 LCMS/MS Parameters. The LC-MS/MS data was obtained by Dr. Dejian Ma 
(UTHSC). The LC-MS/MS system comprised a Sciex (Framingham, MA) 5500 triple 
quadrupole mass spectrometer, equipped with a Turboionspray™ ionization interface and 
Analyst software version 1.6.3. Chromatographic separation was carried out using a 
ZORBAX SB-C18 column of 150 x 4.6 mm i.d., and 3.5 μm particle size (Agilent 
Technologies, Santa Clara, CA) maintained at 35°C using Shimadzu (Columbia, MD) 
Nexera XR HPLC system and SIL-20ACXR autosampler. The mobile phase (A: Milli-Q 
water, B: methanol) was eluted at a flow rate of 0.5 mL/min. The gradient started at 50% 
of mobile phase B and maintained for 0.5 min, then linearly rose to 100 % B over 1 min. 
Subsequently, the eluent composition was maintained at 100% B from 1.5 to 6 min 
before it was decreased to initial condition 50 % mobile phase B for re-equilibration in 
0.1 min. The total run time was 6.5 min plus a pre-equilibrate of 0.5 min. A switching 
valve directed the mobile phase to the MS system between 4.5 and 6.1 min. The 
electrospray ion source was operated in a positive ionization mode for all the 
experiments. The typical parameters were: capillary 5.5 kV; entrance potential (EP) 10 V; 
channel electron multiplier (CEM) 1800 V; source temperature 600°C.  
 
 LC/MS Sample Preparation. Protein precipitation was used to extract DJ95 
from plasma. Plasma (50 μL) was added in 150 μL precipitation solution, methanol 
including 26.5 nM ABI-231 as IS, vortexed for 15 seconds, and then centrifuged for 15 
minutes at 4°C (circa 12,000 rpm). Supernatant (120 μL) was then transferred to a 96-
well plate and 1 μL sample was injected into the LC-MS/MS system. Calibration 
standards were prepared by mixing DJ95 stock solution in pooled human plasma, 
resulting in matrix concentrations of 1, 10, 100, 200, 1000, 2000, 10,000 nM. Blank 
samples were prepared using blank plasma. All samples were stored at -20⁰C prior to use. 
The lowest standard of 1 nM was not detected. The LLOQ was determined to be 10 nM. 
 
 
In Vivo Mouse Models and Treatments 
 
 All animal experiments were carried out in accordance with the Guide for the 
Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National 
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Institutes of Health and were approved by the Institution’s Animal Care and Use 
Committee (IACUC) at the University of Tennessee Health Science Center (UTHSC, 
Memphis, TN). All animals were maintained in a room with a 12 h light/dark cycle and 
provided food and water ad libitum. 
 
 Plasma Concentration and Pharmacokinetic Analysis. Thirty CD-1 ICR mice 
from Charles River Laboratories (Wilmington, MA) of approximately 6 weeks of age 
were used for the study. Both males and females were used, and at least one animal of 
each sex was collected at each time point. Animals (n=3 per time point) were dosed with 
15 mg/kg DJ95 via intraperitoneal injection and drug vehicle was PEG300 (Sigma-
Aldrich, St. Louis MO) and PBS at a 1:1 ratio.  
 
 Blood was collected at the following time points: 0, 15, 30, 60, 90, 180, 360, 480, 
720 and 1440 min. A blood volume of 0.6 mL was collected from each mouse at 
respective time point via cardiac venipuncture using heparinized syringes and collected 
into lithium heparinized tubes. Samples were centrifuged at 3,000 rpm for 10 min. 
Plasma was collected into 1.5 mL centrifuge tubes and frozen at -80C until analysis by 
LC/MS. Pharmacokinetic parameters area under the curve (AUCinf), half-life (t1/2), 
clearance, volume of distribution and maximum concentration (Cmax) were measured. 
 
 MTD and Xenograft Studies. We first performed an acute maximum tolerable 
dose (MTD) study for DJ101 formulated in the vehicle (equal parts PEG300: PBS) by 
progressively increasing daily injection doses via i.p. route to ICR mice (n=2) (Evigo 
Corporation, Denver, CO), and estimated the MTD to be at least 65 mg/kg. To ensure a 
safety margin during the repeated treatment, the dose was scaled down to 30 mg/kg in the 
animal experiments. We also performed a longer MTD study by subjecting nude mice 
(Evigo Corporation, Denver, CO) to 30 mg/kg doses of DJ95 or DJ101 formulated in the 
vehicle by i.p. injection for 5 consecutive days. Because mice receiving DJ95 treatment 
began to show signs of toxicity beyond this time point, we scaled the dose back farther to 
15mg/kg for the xenograft study. 
 
 Nude mice, age 6–8 weeks old, were purchased from Evigo Corporation (Denver, 
CO) for the xenograft studies. Logarithmic growth phase A375, PC-3, or PC-3/TxR cells 
were prepared in phenyl red-free, FBS-free media and mixed with thawed matrigel prior 
to injecting into mice. Tumors were established by injecting 100 μL of matrigel/cell 
suspension containing 2.5×106 cells subcutaneously in the hind flank of each mouse. 
After tumors were established, mice were ranked on tumor size and randomized into 
control or treatment groups, with each group receiving half males and half females. 100 
μL of the drug treatment or vehicle control solution was administered via i.p. injection 5x 
a week for the duration of the studies. 
  
 Tumor volume was measured three times a week with a caliper and calculated by 
using the formula a×b2×0.5, where a and b represent the larger and smaller diameters, 
respectively. Tumor growth inhibition (TGI) at the conclusion of the experiments was 
calculated as 100 – 100 ×((T − T0)/(C − C0)), where  T, T0, C and C0 are the mean 
tumor volume for the specific group on the last day of treatment, mean tumor volume of 
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the same group on the first day of treatment, mean tumor volume for the vehicle control 
group on the last day of treatment and mean tumor volume for the vehicle control group 
on the first day of treatment, respectively (100). Animal activity was monitored, and body 
weights were recorded throughout the study to assess potential acute toxicity. At the end 
of the experiment, mice were sacrificed, and the tumors were dissected out, weighed, and 
fixed in in 10% neutral buffered formalin solution prior to pathology staining analysis.  
 
 B16F10 Melanoma Lung Metastasis Model. C57BL/6 mice from Charles River 
Laboratories International, Inc., age 7–8 weeks old, were used to study the inhibition 
effect of DJ101 on lung metastasis of melanoma cells. Murine B16F10 melanoma cells 
growing in a logarithmic growth phase were suspended in the conditioned media at a 
density of 1 × 106 per mL. Each mouse was inoculated with the tumor cells (100 μL 
containing 1 × 105 cells) via the lateral tail vein. The treatment started on the third day 
after the inoculation to ensure the initiation of metastasis before beginning treatment. 
DJ101 (30 mg/kg) and vehicle were formulated as described above. Doses (100 μL) of 
DJ101 or vehicle solution were administered via i.p. injection every other day for 2 
weeks. Animal activity and body weights were monitored during the entire experiment 
period to assess acute toxicity. Mice were sacrificed 15 days after the initiation of the 
experiment, and the lungs were separated, expanded and preserved in 10% neutral 
buffered formalin. The number of lung metastasis nodules was recorded. Major organs 
were also preserved in the same manner for subsequent toxicological examination. 
 
 
Histology and Immunohistochemistry 
 
 The fixed tumor xenograft tissues were embedded in paraffin. Serial sections were 
obtained for Hematoxylin and Eosin (H&E) and immunohistochemistry (IHC) analysis. 
Staining was performed with rabbit anti-cleaved caspase 3 antibody (Cell Signaling 
Technology Inc., Danvers, MA) and rabbit anti-CD31 (Cell Signaling Technology Inc., 
Danvers, MA) following ABC-DAB methods. Antigen retrieval was performed with H-
3300 antigen unmasking solution (Vector Laboratories, Burlingame, CA). Images were 
captured with a Keyence BZ-X fluorescent microscope (Keyence Corporation, Itasca, IL) 
at 10x and 20x magnification. Five representative fields of view from three tumors per 
group at 20x magnification were analyzed in ImageJ to calculate positive stained area.  
Pathological tissue sections from major organs (heart, liver, kidney, lung and spleen) 
were examined similarly to identify any potential drug-related effects by Dr. Frank Park 
(UTHSC).  Images were obtained with EVOS XL Core microscope (Life Technologies, 
Carlsbad, CA). 
 
 
Statistical Analysis  
 
 Data were analyzed using Prism Software 5.0 (GraphPad Software, Inc., San 
Diego, CA). IC50 values were calculated by nonlinear regression. The statistical 
significance (P < 0.05) was calculated by one-way analysis of variance (ANOVA) 
followed by Dunnett’s multiple comparison test, comparing each treated group to the 
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corresponding control group for studies comparing 3 or more groups. An unpaired 
Student’s t-test was used to calculate significance for studies comparing two groups.  
 
 
Results 
 
 
Potency Against Malignant Melanomas and the NCI-60 Cell Panel 
 
 Our preliminary studies showed that DJ101 and DJ95 have potent cytotoxic 
activity against a variety of melanoma and prostate cancer cell lines (143). To expand 
upon this observation and determine their in vitro efficacy against additional metastatic 
melanoma cell lines that harbor clinically relevant mutations, we first performed 
cytotoxicity assays for the DJ compounds against a panel of human metastatic melanoma 
cell lines including A375, RPMI-7951, WM-164, WM115, and SK-MEL-1 (Table 2-1). 
These cell lines possess diverse genetic complexity and contain genomic mutations in one 
or more of the following genes: BRAF, CTNNB1, CDKN2A, PTEN, and TP53.  DJ101 
demonstrated comparable potency against these lines to colchicine, with IC50 values 
ranging from 7-12 nM in each of the tested cell lines. DJ95 was the most potent against 
A375 cells, though less potent than DJ101 or colchicine. 
 
 DJ95 and DJ101 were also tested in the NCI-60 cell panel, assaying a diverse 
selection of cancer types, in a single-dose and 5-concentration assay to see if they were 
effective against other kinds of cancer (Appendix Figures A-1 and A-2). DJ compounds 
were highly active and demonstrated low GI50 values for the majority of melanoma cell 
lines, and were especially potent against leukemia, colon, CNS, and prostate cancers. The 
average total growth inhibition (TGI) and LC50 was greatest for colon cancer and 
melanoma. The dose-response curves of each individual melanoma cell line tested 
revealed that the cell lines most sensitive to DJ95 treatment were LOX IMVI and SK-
MEL-5 and to DJ101 were MDA-MB-435 and also SK-MEL-5.  
 
 
DJ Compounds Overcome Taxane Resistance and ABC Transporter-Mediated 
Resistance 
 
 In addition to melanoma cell lines, we also tested DJ compounds against prostate 
cancer cell lines, including parental PC-3 and DU-145, paclitaxel-resistant PC-3 (PC-
3/TxR) and docetaxel-resistant DU-145 (DU-145/TxR) cell line pairs to understand if 
DJ95 can overcome mechanisms associated with taxane resistance (Table 2-2). In the 
PC-3 cell line, DJ95 and DJ101 were mildly less toxic (8.5 ± 0.7 and 17.0 ± 2.6 nM) than 
the colchicine-treated cells (5.31 ± 1.86 nM). Paclitaxel and docetaxel treatment 
demonstrated greater cytotoxicity, with IC50s of 3.7 ± 0.3 and 0.5 ± 0.1 nM, respectively. 
However, in the paclitaxel-resistant PC-3/TxR cell line, DJ101 and DJ95 were much 
more potent than in the parental cell line (8.5 ± 0.7 and 4.8 ± 1.7 nM) and even 
outperformed colchicine (28.1 ± 1.2 nM). There was a drastic reduction in efficacy for  
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Table 2-1. Cytotoxic effects of DJ compounds against malignant melanoma 
cancer cell lines.  
 
Treatment 
IC50
 
± SEM (nM) 
A375 RPMI-7951 WM-164 WM115 SK-MEL-1 
DJ95 19.2 ± 2.3 46.0 ± 6.5 92.2 ± 12.7 92.2 ± 12.7 62.5 ± 9.9 
DJ101 7.6 ± 0.5 10.1 ± 0.9 12.1 ± 2.4 10.3 ± 1.8 9.6 ± 0.4 
Colchicine 11.7 ± 0.4 17.8 ± 1.9 7.8 ± 0.9 7.8 ± 0.9 8.3 ± 1.9 
 
 
 
 
Table 2-2. Cytotoxic effects of DJ95 and DJ101 against parental and taxane-
resistant prostate cancer cell lines.  
 
Treatment 
IC50 ± SEM (nM) 
aRI  
IC50 ± SEM (nM) 
RI  
PC-3  PC-3/TxR  DU-145  DU-145/TxR  
DJ95 17.0 ± 2.6 4.8 ± 1.7 0.3 32.4 ± 9.7 222.9 ± 28.0 6.9 
DJ101 8.5 ± 0.7 6.4 ± 0.3 0.75 18.2 ± 0.9 63.3 ± 7.2 3.5 
Colchicine  8.0 ± 0.8 28.1 ± 1.2 3.5 25.7 ± 1.4 >1,000 >40 
Paclitaxel  3.7 ± 0.3 110.7 ± 3.7 30 1.1 ± 0.1 >1,000 >1,000 
Docetaxel  0.5 ± 0.1 27.9 ± 1.1 55.8 0.10 ± 0.01 352.3 ± 118.2 >3,523 
 
 a RI: resistance index is calculated by dividing the IC50 value of compound in resistant 
cell lines by the IC50 in the corresponding parental cell lines. 
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the taxanes, showing 30-fold increase in resistance to paclitaxel and a 55.8-fold increase 
for docetaxel. The DJ compounds demonstrated substantially better resistance indexes 
(RI) of 0.3 for DJ95 and 0.8 for DJ101. Similar results were observed in the DU-145 and 
DU-145/TxR cell pair except that the differences were more profound: while paclitaxel 
and docetaxel had IC50s of 1 nM or less, and the DJ compounds were slightly less potent 
than in the PC-3 cell lines,  the taxanes showed greater than 1000 fold decrease in 
efficacy to the DU-145/TxR cells while DJ101 had only a slight increase in the resistance 
index to 3.5. DJ95 showed some resistance, but much less than colchicine, which showed 
more than a 40-fold increase in resistance DU-145/TxR compared to the parental cells. 
These results demonstrate that DJ compounds, particularly DJ101, can overcome some 
mechanisms of taxane resistance that developed by cancer cells. 
 
 Because we were particularly interested in the ability of DJ95 to overcome 
transporter-mediated drug resistance, we tested DJ95 against genetically engineered 
HEK293 cells lines, that stably transfected full length ABCB1, ABCC1, wild type 
ABCG2, or the pcDNA3.1 blank vector. Cisplatin, which is not a substrate for any of 
these ABC transporters, was used as negative control. Greater than 100-fold resistance 
was observed for the ABCB1 overexpressing HEK293 cells against paclitaxel, 
colchicine, and vincristine (Table 2-3). On the other hand, HEK293/ABCB1 resistant 
cells showed virtually no resistance to DJ95. Slight resistance (RI= 3.7) was revealed for 
the ABCC1 overexpressing HEK293 transfected cells against DJ95 compared to the 
vector-only cells, but all other microtubule targeting drugs that were tested (paclitaxel, 
colchicine, vincristine) demonstrated significantly increased resistance, with IC50s greater 
than 10 μM against HEK293/ABCC1. Similarly, against the HEK293/ABCG2-R482 
cells, resistance was evident for all tubulin inhibitors, though less resistance was 
developed against the DJ95 compound (about 8.7-fold). This was still lower than 
mitoxantrone, a known substrate of ABCG2, showing about 11.2-fold decrease in 
potency in the ABCG2 overexpressing cell line. 
 
 We also wanted to assess the effects of DJ95 against drug-selected resistant cell 
lines. From the parental epidermoid carcinoma cell line KB-3-1, the colchicine 
resistant/ABCB1-overexpressing (KB-C2) cell line and vincristine resistant/ABCC1-
overexpressing (KB-CV60) cell line were developed. The mitoxantrone-selected 
ABCG2-overexpressing cell line NCI-H460/MX20 was generated from the parental non-
small cell lung cancer cell line NCI-H460 and utilized to further evaluate the effects 
against ABCG2 upregulation. Compared to the existing tubulin inhibitors paclitaxel, 
colchicine and vincristine, DJ95 exhibited greater cytotoxicity against drug-selected 
ABCB1-overexpressing KB-C2 cells and ABCC1-overexpressing KB-CV60 cell lines, 
with IC50 values of 719.54 ± 181.48 nM and 35.90 ± 4.50 nM, respectively (Table 2-4). 
Although there was still some increase in resistance against the KB-C2 (colchicine 
selected/ABCB1 overexpressing) cells compared to the parental KB-3-1 cells, both KB-
C2 and KB-CV60 were much less resistant to DJ95 than they were against the three other 
tubulin inhibitors tested. Since no resistance to DJ95 was revealed from ABCB1 
transfected cell line, the increase in resistance observed for DJ95 against the colchicine-
selected KB-C2 may be related to mechanisms affiliated with the colchicine binding site 
and not solely ABCB1 overexpression.   
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Table 2-3. Cytotoxic effects of DJ95 against gene transfected ABCB1-, ABCC1- 
or ABCG2-overexpressing cancer cell lines. 
 
Treatment 
IC50 ± SD (nM) 
HEK293/ 
pcDNA3.1 
HEK293/ 
ABCB1 
HEK293/ 
ABCC1 
HEK293/ABCG2
-R482 
DJ95 330.0 ± 44.1 314.7 ± 73.1 1213.9 ± 241.6 2869.2 ± 123.3 
Paclitaxel 34.6 ± 6.3 3496.0 ± 657.8 >10000 >10000 
Colchicine 112.1 ± 41.5 >10000 >10000 >10000 
Vincristine 99.4 ± 23.1 >10000 >10000 >10000 
Mitoxantrone 108.0 ± 27.5 — — 1209.7 ± 111.4 
Cisplatin 2510.1 ± 362.6 2583.1 ± 474.5 2584.1 ± 151.8 2475.3 ± 127.4 
 
Data obtained by Zi-Ning Lei (St. John’s University). 
 
 
 
 
Table 2-4. Cytotoxic effects of DJ95 against parental and drug-selected ABCB1-, 
ABCC1- or ABCG2-overexpressing cancer cell lines. 
 
Treatment 
IC50 ± SD (nM) 
KB-3-1 
KB-C2 
(ABCB1) 
KB-CV60 
(ABCC1) 
NCI-H460 
NCI-
H460/MX20 
(ABCG2) 
DJ95 23.5 ± 2.2 719.5 ± 181.5 35.9 ± 4.5 673.0 ± 111.7 5361.5 ± 645.5 
Paclitaxel 9.2 ± 2.1 1918.5 ± 106.3 120.0 ± 14.6 >10000 >10000 
Colchicine 23.9 ± 4.9 7445.3 ± 446.3 91.7 ± 7.7 >10000 >10000 
Vincristine 1.3 ± 0.2 748.8 ± 99.8 218.6 ± 1.9 >10000 >10000 
Mitoxantrone — — — 118.7 ± 40.2 2456.5 ± 420.4 
Cisplatin 2024.5 ± 463.7 2871.2 ± 115.3 1796.5 ± 198.8 2226.6 ± 179.5 2870.6 ± 281.7 
 
Data obtained by Zi-Ning Lei (St. John’s University).  
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 In both NCI-H460 and its mitoxantrone-selected ABCG2 overexpressing cell line, 
DJ95 demonstrated better anticancer activities than paclitaxel, colchicine and vincristine, 
with IC50 values of 673.04 ± 111.71 nM and 5361.50 ± 645.45 nM, respectively, whereas 
IC50 values of the three other tubulin inhibitors were higher than 10,000 nM in both cell 
lines. However, low resistance against DJ95 was observed in NCI-H460/MX20 cell line 
compared to its parental cell line (about 8-fold resistance), though the resistance index 
was not as high as that of the substrate control mitoxantrone (about 20-fold resistance). 
The results from the drug-selected resistant cells are consistent with those obtained from 
transfected ABCG2-overexpressing cell line HEK293/ABCG2-R482 and its vector 
control, which indicated that DJ95 might be a weak substrate of ABCG2. Further study is 
needed to verify if ABCG2 would be a factor mediating resistance to DJ95. 
 
 
Interaction at the Colchicine Binding Site on Tubulin 
 
 We previously reported the design and synthesis of DJ95 and DJ101(143) and a 
number of potent tubulin inhibitors related to this scaffold (98, 141, 142). While 
mechanistic studies suggested that these agents produce their antitumor activities by 
interacting with the colchicine binding site on tubulin, the detailed molecular interactions 
had not previously been fully elucidated. Recently, high-resolution (<3.0 Å) crystal 
structures of tubulin in complex with several known colchicine site inhibitors were 
reported (51, 192). Using these newly established procedures, we obtained the high-
resolution X-ray crystal structure of DJ101 in complex with ??-tubulin (deposited to the 
Protein Databank with PDB code: 5H7O, resolution 2.8 Å). This high-resolution crystal 
structure confirms the direct binding of DJ101 in the colchicine binding site (Figure  
2-2A). DJ101 forms three hydrogen bonds with the ??-tubulin dimer: one hydrogen bond 
from T179 in loop five in the ?-monomer to the imidazole nitrogen, one hydrogen bond 
from N349 in loop nine in the ?-monomer to the indole nitrogen, and one hydrogen bond 
between the oxygen of the 4-methoxyl moiety and the thiol moiety in C241 in helix seven 
of the ?-monomer (Figure 2-2B). A tight hydrophobic “sandwich” formed by sidechains 
from C241, L255, L248, and N258 wraps the trimethoxyphenyl and the imidazopyridine 
moieties firmly in the colchicine binding domain. Additionally, the sidechain M259 in 
helix eight of the ?-monomer serves as a “wedge” between sheet 9 and DJ101 to lock its 
curved conformation. It is also evident that DJ101 overlaps with colchicine at its binding 
site (Figure 2-2C).  These results provide the first direct evidence of DJ101’s direct 
interaction with the colchicine binding site in tubulin to inhibit tubulin polymerization.  
 
 We also determined the crystal structure of the T2R-TTL complex bound with 
compound DJ95 at 2.5 Å resolution, and the coordinates and structure factors have been 
deposited in the Protein Data Bank with the PDB ID: 6C77. In the crystal structure, the 
compound is bound only at the interface of the first ?- and ?-tubulin heterodimer, unlike 
colchicine where the interfaces of both ?- and ?-tubulin heterodimers were occupied 
(Figure 2-2D). In the case of the unliganded T2R-TTL complex reported earlier, the ?-
T7 loop of ?-tubulin at the interface of the ?- and ?-tubulin heterodimer is in a closed 
conformation (PDB ID: 4I55).  The DJ95 binding pocket is created by the outward  
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Figure 2-2. X-ray crystal structures of DJ101 and DJ95 in complex with tubulin protein.  
A) Surface representation of the overall structure of α-tubulin (black) and β-tubulin (grey). DJ101 is shown in sphere representation 
(cyan). B) Detailed molecular interactions between the DJ101 molecule (cyan) and the tubulin dimer. Hydrogen bonds are indicated 
with black dash lines. C) Superimposition of the binding sites for DJ101 (cyan)-tubulin complex (5H7O) with colchicine (yellow)-
tubulin complex (4O2B). D) Cartoon showing the organization of ?-tubulin (green), ?-tubulin (salmon), RB3-SLD (cyan), TTL (grey) 
proteins, GTP, GDP, and DJ95. E) 2Fo-Fc electron density map for DJ95 contoured at 1 sigma shown as blue mesh, and hydrogen 
bonds are shown as red dashed lines. F) Superimposed tubulin–DJ95 (green sphere) complex and tubulins as found in straight 
protofilaments (PDB ID: 1JFF; cyan) showing that binding is not compatible with the straight conformation. Conformational changes 
of the secondary elements are labeled. Crystallographic data obtained by Yuxi Wang (Sichuan University, China) and interpreted by 
Dr. Stephen White and Dr. Gyanendra Kumar (St. Jude Children’s Research Hospital). 
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movement or opening of this loop and the same motion has previously been observed 
when colchicine binds (PDB ID: 4O2B). Looking closely at the bound DJ95, we find that 
the 3-methoxyphenyl group of DJ95 occupies a deep pocket in the ?-tubulin subunit that 
is lined with residues Val236, Cys239 and Leu253 (Figure 2-2E). The side chain of 
Leu253 makes a pi-H interaction with the phenyl ring of 3-methoxyphenyl group. The 
imidazopyridine ring forms two hydrogen bond interactions; a nitrogen atom with the 
main chain NH of ?-tubulin Asp249 and an NH with the main chain carbonyl oxygen of 
Thr179 from ?-tubulin across the interface. Finally, the indole ring of DJ95 sits in a 
pocket lined by Asn347, Lys350, Asn256 and Met257 of ?-tubulin and Val181 from ?-
tubulin. The electron density is consistent with this ring having two conformations 
rotated by ~180° – one where the nitrogen faces the Met257 from ?-tubulin, and the other 
where the nitrogen faces the Val181 from ?-tubulin.  The refinement suggests that the 
latter conformation is preferred 2:1 over the former.  Comparison with the unliganded 
T2R-TTL complex revealed that a significant conformational change not only occurs in 
loop β-T7 to accommodate DJ95 but also in loop α???(Figure 2-2F). These two loop 
conformations are incompatible with the ‘straight’ structure of the tubulin filament and 
are therefore consistent with DJ95 acting as a destabilizer of filament formation.   
 
 
Disruption of Microtubule Networks and Spindle Formation 
 
 To characterize their effects on microtubule networks and cell morphology, we 
used confocal microscopy to visualize several melanoma cell lines treated for 18 hours 
with either DJ compounds or a microtubule stabilizing agent such as paclitaxel or 
docetaxel, which promote polymerization. The alteration in microtubule rearrangement in 
the treated cells can clearly be observed (Figure 2-3A). Control cells appeared to exhibit 
well-organized microtubule networks extending throughout the cell to the cell periphery. 
Treatment with DJ95 or DJ101 led to fragmented microtubule networks and an increase 
in soluble, cytoplasmic tubulin. At higher concentrations, there appeared to be very little 
polymeric tubulin framework left intact. These observations are consistent with a 
mechanism of action of tubulin depolymerization. In contrast, taxane-treated cells 
demonstrated highly condensed, polymeric tubulin. With increasing concentrations, the 
aggregation of the filaments was more pronounced, consistent with increased 
stabilization of microtubules.  
 
 Microtubules also make up the mitotic spindle and utilize the dynamic properties 
for chromosome segregation during mitosis (151). Therefore, tubulin targeting agents 
also interfere with the formation and organization of mitotic spindles (193-196). We 
investigated the effects of DJ95 in a concentration-dependent manner compared to 
untreated control cells (Figure 2-3B). While control cells exhibited normal, bilateral 
spindle formation extruding from centrosomes, DJ95 treatment caused aberrant spindle 
development as evidenced by multi-polar and disorganized spindle morphology. These 
abnormalities were exacerbated with increasing drug concentrations. This is further proof 
that DJ95 inhibits the progression of mitosis by interfering with microtubule dynamics. 
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Figure 2-3. DJ compounds interfere with microtubule networks and mitotic 
spindle organization.  
A) Microtubule networks of melanoma cells (either A375, RPMI-7951, or WM-164) 
after treatment with DJ101, DJ95, docetaxel or paclitaxel at 40x magnification. The 
concentration of the drug treatment is indicated in the bottom of each image. The top row 
of images are the untreated control cells for comparison. B) The effect on mitotic spindle 
organization of cells undergoing mitosis obtained at 63x magnification. All confocal 
images of all cells were obtained after 18 hr drug treatment. Tubulin (red) is visualized by 
α-tubulin primary antibody and Alexa Fluor 647 secondary antibody and DNA (blue) is 
stained with DAPI. 
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Inhibition of Colony Growth and Cell Migration 
 
 DJ95 and DJ101 were tested separately in colony-forming assays to evaluate the 
long-term inhibitory growth effects on different melanoma cell lines.  We first tested the 
ability of DJ95 to inhibit colony formation in a concentration-dependent manner 
compared to untreated A375 control cells. (Figure 2-4A). A significant decrease was 
observed for all treated cells, and concentrations as low as 10 nM caused a 26.78 ± 1.9% 
inhibition of colony area compared to control (P < 0.001) and higher concentrations of 25 
nM and 50 nM inhibited colony formation by 44.73 ± 1.9% and 65.01 ± 3.08%, 
respectively (P <0.0001). At 100 nM, DJ95 almost completely eliminated colony 
formation, and only 1.25 ± 0.07% of the area compared to the control remained. 
 
 We also tested DJ101 and colchicine in both A375 and RPMI-7951 cells lines 
using lower concentrations (Figure 2-4B and 2-4C). Treatment with 4 nM of DJ101 
resulted in colonies covering only 30.6% ± 0.8% of the total surface area, representing a 
59.5% ± 2.0% inhibition compared to the untreated control cells, which inhabited 75.6% 
± 3.7% of the total area.  Colchicine was used as a reference control because its ability to 
potently and persistently inhibit colony formation is well-documented (197, 198). The 
effect of DJ101 on A375 cell colony formation was similar to colchicine at the same 
concentration, which had colonies covering a total area of 34.7% ± 1.5% (54.1% ± 3.5% 
inhibition). Control RPMI-7951 cells formed colonies occupying a surface area of 83.2% 
± 2.1% and comparable reductions in colony formation were measured for treated cells, 
where DJ101-treated cells occupied 47.1% ± 5.7% (43.5% ± 11.8% inhibition) and 
colchicine-treated cells covered 50.9% ± 3.4% (38.8% ± 7.0% inhibition). Higher 
concentrations (20 nM) of DJ101 or colchicine resulted in complete colony obliteration. 
Dunnett’s multiple comparison tests after one-way ANOVA analysis gave an overall P 
value of less than 0.0001 for each treated group compared to the control, indicating that 
they are statistically different.  
 
 To demonstrate that the DJ compounds interfere with cell migration through 
microtubule destabilization, we performed scratch migration assays against A375 and 
RPMI-7951 cell lines. Cells were treated with 25 nM of the drug and images were taken 
at 0, 12 and 24 hours (Figure 2-4D and 2-4E). After 24 hours, untreated A375 cells 
migrated into 83.8% ± 6.1% of the wound channel, nearly closing the gap. DJ101 and 
DJ95 treated cells migrated into only 40.8% ± 6.0% and 35.6% ± 1.4%, respectively. A 
greater reduction in cell migration was observed in the RPMI-7951 cell line, where 
control cells reclaimed 86.4% ± 10.5% of the wound channel and DJ compound treated 
cells occupied less than 25% of gap area. Similar but less inhibition of the scratch area 
was observed colchicine-treated cells, achieving 52.0% ± 2.7% closure for the A375 cell 
line and 52.3% ± 3.4% for the RPMI-7951 cell line. One-way ANOVA analysis of both 
cell lines gave P values in both cell lines were less than 0.0001. There was no significant 
difference in the scratch channel area for each group at the beginning of the experiment 
(time 0), and the % closed was based on this average area. Taken together, these in vitro 
studies demonstrate that the DJ compounds strongly reduce aberrant cancer cell 
proliferation at low concentrations and hinder cell migration at least as efficiently as 
colchicine in these melanoma cell lines.
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Figure 2-4. Inhibition of cell proliferation and migration.  
A) Colony formation assay of A375 cells treated with DJ95 or colchicine (n=3). Colony area was quantified by VisionWorks software 
and represented by total area (in pixels) ± SD. B) Colony assay formation of A375 and C) RPMI-7951 cells treated with DJ101 or 
colchicine (n=4). Colony area is represented as percent of the total surface area ± SD as determined by ImageJ software. Colony 
assays were treated for 10 days in 6-well plates. D) Scratch migration assay of A375 and E) RPMI-7951 cell lines (n=4). Cell 
migration is presented as mean percent of the area closed ± SD after 24 hrs compared to the scratch area at time 0. ImageJ software 
was used to calculate the total scratch area at each of the time points. Scale bar = 1000μm. Statistical significance was determined by 
one-way ANOVA followed by Dunnett’s multiple comparison test, comparing each treatment group to the control group for the above 
experiments. (**p< 0.01, ***p< 0.001, ****p< 0.0001).  
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Anti-Angiogenic Activity on HUVEC Tube Cell Formation 
 
 In recent years, there has been extensive research on the vascular disrupting 
properties of tubulin targeting agents and their ability to selectively target tumor 
vasculature (39, 40, 97, 199-201). To see whether DJ95 would exhibit these 
characteristics, we tested the in vitro effect on the formation of capillary-like networks of 
human umbilical vein endothelial cells (HUVECs) plated on Matrigel. The Matrigel 
basement membrane allows endothelial cells to form tubules with tight cell-to-cell and 
cell-to-membrane contacts (202). After 6 hrs of incubation in the presence of the test 
compounds, it was clearly observed that both DJ95 and colchicine disrupted the tube cell 
formation in a concentration-dependent manner (Figure 2-5). At concentrations of 100 
nM and 200 nM, DJ95 disrupted networks by 35.7% ± 5.6% and 51.8% ± 3.3% based on 
total calculated network length (P < 0.01 and 0.0001, respectively). This was similar to 
the effect observed from colchicine treatment at the same concentrations, inhibiting 
HUVEC tube cell formation by 60.4% ± 9.0% and 81.6% ± 8.0%, respectively (P < 
0.0001). Since this result was observed in a short timeframe, we expect that the drug 
action on tube cell formation was not a result of antiproliferative activity but rather from 
anti-angiogenic action.  
 
 
Pharmacological Profiling 
 
 In vitro pharmacological profiling is increasingly being used to identify 
undesirable off-target activity profiles early in the drug discovery process. It involves 
screening the compound of interest against a wide range of targets such as receptors, ion 
channels, transporters and enzymes other than the intended therapeutic target in order to 
identify specific interactions that may elicit adverse drug-related side effects (203). About 
3/4ths of all adverse drug reactions are dose-dependent, and pharmacological profiling of 
the drug of interest can predict the risk and help reduce drug attrition rate. To further test 
for potentially significant off-target effects and determine the drug safety profile, DJ101 
was evaluated at 1 μM in the Safety47™ Panel using functional assays for human targets 
(Figure 2-6A). This in vitro pharmacological profiling service includes the assessment of 
the functional response of 47 major physiologically important targets across 78 assays to 
the drug of interest, normalized to respective controls. Only a value higher than |70%| 
response is considered significant. DJ101 only showed hit responses in 2 of the 78 assays, 
namely norepinephrine transporter (NET) blocking and glucocorticoid receptor (GR) 
antagonism. Since the concentration tested was about 100 times greater than the average 
IC50 value for DJ101, which is expected to be well above its practical physiological 
concentration, results from this Safety47™ Panel screening strongly suggest that DJ101 
has minimal potential off-target effects. 
 
 DJ95 also underwent pharmacological profiling for off-target assessment but was 
screened through a different safety panel. DJ95 was evaluated in binding and enzyme 
uptake assays performed by Eurofins Cerep Panlabs. DJ95 demonstrated nominal specific 
binding inhibition or stimulation against 37 radioactive labeled ligand targets (Figure  
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Figure 2-5. In vitro inhibition of angiogenesis.  
Representative images of HUVEC capillary-like formation on Matrigel taken after 6 hr incubation with indicated concentrations of 
DJ95 or colchicine. Quantification of total tube length was performed with ImageJ analysis and expressed as mean ± SD (n=4). 
Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparison test. (**p< 0.01, ****p< 
0.0001).  
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Figure 2-6. Pharmacological profiles for DJ95 and DJ101. 
A) Assessment of DJ101 in the Safety47™ panel. Graph represents mean percent 
response ± SD. Values in between -70% and +70% (indicated with dashed lines) are 
considered insignificant. B) Assessment of DJ95 in the SafetyScreen 44 panel. DJ95 
binding was calculated as a % inhibition of the binding of a radioactively labeled ligand 
specific for each target. Compound enzyme inhibition effect was calculated as a % 
inhibition of control enzyme activity. Results showing an inhibition or stimulation less 
than 50% are considered insignificant. Both screens were performed in duplicate at 1μM 
concentrations.  
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2-6B). Additionally, DJ95 did not induce significant alterations in enzyme function for 
COX1, COX2, PDE3A, PDE4D2, Lck kinase or ACHE.  Results showing an inhibition 
or stimulation higher than 50% are considered significant in this panel, none of which 
were observed at any of the targets studied in this screening. These results from 2 
separate off-targeting screening services suggest that the DJ compounds minimally 
interact with some of the key off-target liabilities responsible for cessation of clinical 
drug development.  
 
 
Pharmacokinetics and Plasma Concentration 
 
 Based on the preliminary in vitro data suggesting that DJ compounds are potently 
active against melanoma cell lines and do not significantly interfere with off-targets, we 
investigated their in vivo anticancer activity. We determined that concentrations up to 30 
mg/kg of DJ95 or DJ101 administered by i.p. injection daily was well-tolerated for at 
least 5 days in nude mice, but additional treatments with DJ95 caused a decrease in 
mouse weight and decline in behavioral activity. Therefore, we scaled back the dose to 15 
mg/kg of DJ95 for the pharmacokinetic and xenograft study. To determine if DJ95 could 
reach therapeutically relevant biological concentrations at doses of 15 mg/kg, we 
collected blood samples from 15 minutes to 24 hrs following i.p. injection of the drug and 
analyzed the plasma concentrations by LC-MS methods. The Cmax for DJ95 was 13.65 
uM and the detected concentrations stayed above 13 uM for at least 1.5 hrs in mouse 
plasma (Figure 2-7A). While the concentration of DJ95 gradually decline over the course 
of the 24 hrs during when samples were collected, there was still an average of 126.5 nM 
at 12 hrs and 8.1 nM at 24 hrs. This data, along with the AUC (50500 hr*nM) suggests 
acceptable exposure for DJ95 over the course of a day. We also determined additional 
pharmacokinetic parameters including half-life (3.28 hrs), volume of distribution to (3.51 
L/kg), and clearance (0.744 L/hr/kg). We reasoned that these results supported a dosing 
regimen of 5 treatments/week, allowing for 2 recovery days to avoid accumulating 
toxicities.  
 
 
Tumor Growth Inhibition and Reduction of Metastasis in Melanoma Models in 
Mice  
 
 The antitumor efficacy of the DJ compounds was determined in an A375 
xenograft model in nude mice. Tumors were established by subcutaneous inoculation of 
A375 cells, and treatment began after viable tumors developed. Groups were dosed by 
i.p. injection with either 15 mg/kg treatments of DJ95, 15 or 30 mg/kg of DJ101, or 
vehicle solution only. After 2 weeks and a total of 10 treatments, the group of mice 
receiving 15 mg/kg doses of DJ95 or DJ101 had an average tumor growth inhibition 
(TGI) of 61.4% and 66.4%, respectively (Figure 2-7B). At the higher doses 30 mg/kg of 
DJ101, the treatment group averaged 92.8% inhibition compared to vehicle control. 
Dunnett’s multiple comparison test indicated that treatments with 15 mg/kg of DJ95 (P < 
0.01), 15mg/kg of DJ101 (P < 0.001), and 30 mg/kg doses of DJ101 (P < 0.0001), were  
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Figure 2-7. Inhibition of tumor growth and metastasis in melanoma mouse 
models. 
A) Plasma concentrations at each timepoint following i.p. injection 15 mg/kg 
concentration of DJ95 shown as individual replicates connected by mean (n=3 per time 
point). B) A375 melanoma xenograft model in nude mice. Mice were dosed by i.p. 
injection 5 times a week for 2 weeks with 15 mg/kg DJ95, 15 or 30 mg/kg of DJ101, or 
vehicle solution only. Statistical significance was determined using one-way ANOVA 
followed by Dunnett’s multiple comparison test for the final tumor volumes compared to 
the control. C) Mean mouse weight change ± SD in the xenograft model. D) B16F10 
melanoma lung metastasis model in C57BL/6 mice. Mice were dosed by i.p. injection 5 
times a week for 2 weeks with 30 mg/kg of DJ101 or vehicle solution only. Graph 
represents mean number of nodules with individual number for each mouse plotted ± SD 
(n=11). Representative photos of lungs with melanoma nodules (black dots) are shown 
below. Statistical significance (P=0.0001) was determined with an unpaired student’s t-
test. E) Mean mouse weight change ± SD in the metastasis model.     
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significantly better than the vehicle based on the percent increase in final tumor volume. 
Animal behavior and mouse body weights were measured and recorded throughout the 
course of the experiment to assess for acute toxicities, and major deviations were not 
observed (Figure 2-7C). This in vivo study demonstrates the antitumor efficacy of DJ 
compounds in a melanoma xenograft model, and DJ101 for further in vivo experiments 
because of its enhanced antitumor activity without dose-limiting toxicities.  
 
 Since a major obstacle in treating melanoma is tumor metastasis, we next assessed 
the efficacy of DJ101 in suppressing melanoma metastasis using a B16F10 experimental 
lung metastasis model in mice. After two weeks of treatment with 30 mg/kg doses of 
DJ101, the average number of tumor nodules that developed on the lungs was 1.7 ± 0.3, 
whereas the vehicle-treated group averaged 10.5 ± 2.0 nodules, demonstrating a 6.2-fold 
decrease in lung metastasis for those receiving DJ101 treatment (Figure 2-7D). An 
unpaired Student’s t-test gave a P value of < 0.001, representing a significant decrease in 
lung metastasis for the treatment group. Body weights and physical activities of mice 
were normal in both groups (Figure 2-7E). These results demonstrate that DJ101 is well-
tolerated for doses up to 30 mg/kg in mice and can efficiently reduce the potential for 
lung metastasis of murine melanoma.  
 
 
Overcoming Paclitaxel Resistance In Vivo 
 
 We next compared the efficacy of DJ101 and paclitaxel in vivo using both PC-3 
and PC-3/TxR xenograft models. Both paclitaxel (15 mg/kg) and DJ101 (30 mg/kg) 
inhibited tumor growth in the parental PC-3 xenograft model as determined by average 
tumor volume (Figure 2-8A, left panel). The TGI for the group receiving paclitaxel 
treatment was 101.1% and 78.8% for the DJ101 treated group in PC-3 xenografts (P 
values of < 0.0001). Their efficacy against tumors was also evident based on final tumor 
weight (Figure 2-8B) and representative tumor images (Figure 2-8C), where the DJ101- 
and paclitaxel-treated groups showed a 47.1% (P < 0.001) and 79.3% (P < 0.0001) 
reduction in tumor weight compared to the control group, respectively. No acute 
toxicities were observed based on physical activity and body weights (Figure 2-8D). In 
contrast, using the same dosing regimen and frequency as we did in the parental PC-3 
model, DJ101 caused a TGI of 104.0%, remarkably demonstrating an overall reduction in 
tumor volume in the PC-3/TxR xenograft model, whereas paclitaxel only modestly 
inhibited tumor growth by 37.8% (Figure 2-8A, right panel). These results were 
corroborated by final tumor weights, where DJ101 caused a 77.3% reduction (P < 
0.0001) and paclitaxel showed only a 35.6% reduction (P < 0.05) compared to the control 
group (Figure 2-8B). No acute toxicities were observed in this model based on body 
weight (Figure 2-8D).  
 
 
Elevated Apoptosis and Vascular Disruption in Xenograft Tumors 
 
 Hematoxylin and eosin (H&E) stains of representative tumor sections in the 
vehicle control group showed aggressive growth with numerous mitotic cells in different 
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Figure 2-8. Inhibition of taxane-resistant prostate cancer tumors in mouse 
models.  
A) Tumor volumes for PC-3 (left panel) and PC-3/TxR (right panel) xenograft model in 
nude mice. Graphs represent mean tumor volume percent increase ± SEM (n=7). B) Final 
tumor weights ± SEM for PC-3 and PC-3/TxR mice. C) Representative images for PC-3 
and PC-3/TxR tumors. D) Mouse weight change ± SEM for PC-3 and PC-3/TxR mice.  
One-way ANOVA analysis was performed for final tumor volumes and weight followed 
by Dunnett’s multiple comparison test of each treated group with the corresponded 
results of vehicle group. (*p< 0.05, **p< 0.01, ****p< 0.0001) 
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stages (Figure 2-9A). The increase of metaphase cells and decrease of anaphase cells in 
the DJ101 treatment groups indicate mitotic blocking in the G2/M phase, consistent with 
our previous cell cycle analysis (143). Tumor sections from both low and high dose 
treatment groups showed significantly less proliferation, and there were abundant 
apoptotic cells showing dense nuclear pyknosis and cytoplasmic karyorrhexis. There was 
also extensive central tumor necrosis in the treatment groups. Additionally, CD31 labeled 
endothelial cells in the vehicle control tumor sections exhibited well-developed networks 
of capillaries or small blood vessels around tumors, while the DJ101 treatment groups 
displayed severely distorted blood vessels or absence of CD31 positive stains, suggesting 
potential vascular disrupting properties of DJ101. Finally, cleaved caspase-3 IHC staining 
of tumor sections in the control group showed very few positive regions, but tumor 
sections from the DJ101 treatment groups showed a profound increase in positive labeled 
cells, confirming enhanced apoptosis due to DJ101 treatment. 
 
 Separate and more extensive analysis of tumor vasculature was performed on the 
DJ95 treated xenografts. CD31 staining of tumor sections revealed the change in 
microvessels of the DJ95 treated group compared to the control group (Figure 2-9B). 
The control group displayed more abundant and in-tact microvessels throughout the 
tumors, whereas DJ95 treatment tumors showed vessel fragmentation and decreased 
overall density and occupied area. Quantification of the positive CD31-stained area 
revealed that there was a 50.5% decrease in total microvessel area, representing a 
significant difference (P= 0.0038) (Figure 2-9C). These findings validate the in vitro 
results and suggest that the anti-vascular capacities portrayed by DJ95 and DJ101 may 
contribute to their anticancer efficacy. 
 
 
Toxicology Analysis of Major Organs 
 
 To assess whether DJ101 treatment produces potential organ toxicities, 
pathological analysis was performed on major organs collected from both melanoma in 
vivo studies including the heart, kidney, liver, lung and spleen. H&E stained sections 
revealed no apparent drug-related injury or pathological changes in the cellular structure 
of the various tissues in the melanoma xenograft mouse models (Figure 2-9D) and the 
experimental lung metastasis mouse model (Figure 2-9E), providing further support of 
an overall acceptable safety profile. 
 
 
Discussion 
 
 
Importance of Overcoming Drug Resistance 
 
 Melanoma is the most aggressive form of skin cancer and is one of the most 
rapidly increasing cancers worldwide (204). Malignant melanoma is characterized by 
resistance to chemotherapy and is incurable in most affected patients (205, 206). Despite  
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Figure 2-9. Immunohistochemistry analysis of tumors and pathological assessment of major organs.  
A) IHC of DJ101 treated A375 tumors. H&E insert (2 fold) shows white arrows indicating metaphase and black arrows indicating 
anaphase. CD31 expression shows blood vessel disruption and expression of cleaved caspase-3 is indicative of apoptosis. B) 
Representative IHC images of DJ95 treated tumors stained with CD31 (10x magnification). C) CD31 area represented as mean pixels 
± SD. Statistical significance was determined by student’s t test (20x magnification,5 images per tumor, 3 separate tumors per group) 
(**p< 0.01). D) Representative images of H&E stained sections of major tissues (heart, kidney, liver, lung, and spleen) from the A375 
xenograft and E) B16F10 lung metastasis study. 
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recent advances in treating melanoma with targeted therapies and immunotherapies, 
significant obstacles still exist for finding satisfactory treatments. Intrinsic and acquired 
resistance are the major causes of treatment failure, and it is crucially important to 
discover and develop agents that can overcome drug resistance, improve response rates, 
and extend survival for melanoma patients. 
 
 Interfering with tubulin dynamics is a validated approach for anticancer treatment 
and many antimitotic microtubule stabilizers and destabilizers are widely used clinically 
or are undergoing clinical development (207). However, many of these agents cause 
neurotoxicity, exhibit chemical instability, or have elevated metabolic clearance (172). 
Additionally, the clinical efficacy of many FDA approved tubulin inhibitors is often 
limited by drug efflux pumps or overexpression of certain tubulin subtypes, most notably 
the βIII tubulin isotype (54). Design and development of new tubulin inhibitors targeting 
the colchicine binding site represent an attractive approach for improving and advancing 
tubulin inhibitors.  
 
 We previously identified DJ95 and DJ101, small-molecule tubulin destabilizing 
agents, synthesized from a series of indolyl-imidazopyridines, that demonstrated high 
potency and improved metabolic stability in vitro (143). Because genetic heterogeneity 
among cancer cell lines of the same cancer type has emphasized the necessity to study 
multiple cell lines in a panel, we expanded our investigation of the compounds in a more 
extensive array of malignant melanomas with varying degrees of genetic complexity 
based on genomic mutations (BRAF, CTNNB1, CDKN2A, PTEN, or TP53)(208). The 
DJ compounds were also screened in the NCI-60 panel, which includes numerous 
extensively characterized cell lines from nine different tumor types, providing additional 
evidence to support their broad-spectrum anticancer efficacy.  
 
 While taxanes are some of the most clinically effective chemotherapy drugs 
available, their clinical success is often limited by the emergence of intrinsic and acquired 
drug resistance (209).  One of the major culprits responsible for contributing to MDR is 
the overexpression of ABC transporters such as ABCB1 (MDR1), ABCC1 (MRP1), and 
ABCG2 (BCRP) (210). Agents that target the taxane and vinca binding sites of tubulin 
are particularly susceptible to resistance from the overexpression ABCB1 and are 
effectively extruded from the cell (209, 211-213). These agents are also substrates to 
MRP and BCRP proteins that also decrease their intracellular concentrations (214). We 
discovered that DJ95 had a lower resistance index than the other tested tubulin inhibitors 
in both the drug-selected and gene-transfected cell lines overexpressing ABCC1. While it 
did not show resistance to the transfected ABCB1 overexpressing cells, it did display 
some resistance to KB-C2 drug-selected cell line overexpressing ABCB1. This might be 
due to the more complex MDR mechanisms in drug-selected MDR cells in comparison 
with gene-transfected cells. As KB-C2 cells were established by continuous selection 
with colchicine (2 μg/mL), they may have incurred additional drug-resistance 
mechanisms besides ABCB1 upregulation. For example, mutations to the colchicine 
binding domain could account for the cross-resistance to DJ95 or other agents targeting 
this site. 
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 We also investigated the effect of DJ compounds against drug-selected taxane 
resistant cell lines. In the paclitaxel-resistant PC-3/TxR prostate cancer cell line, more 
than 200 genes are upregulated, in addition to P-gp overexpression, which representing 
numerous paclitaxel resistance mechanisms (174, 175). Both DJ compounds maintained 
potency in the resistant PC-3/TxR cell line and had significantly lower resistance indexes 
to both PC-3/TxR and DU-145/TxR cells than did colchicine and paclitaxel. We also 
demonstrated the excellent potency of DJ101 against PC-3/TxR xenograft tumors in 
mice. Other groups have reported elevated sensitivity of paclitaxel resistant cancer cells 
to colchicine binding site drugs. One such study investigated a variety of microtubule 
targeting agents that bind to the taxane site, vinca alkaloid binding site, and colchicine 
binding site for docetaxel resistant MCF-7 breast cancer cells. They reported that while 
MCF-7TXT  cells demonstrated cross-resistance to vinca alkaloids, they were more 
sensitive to colchicine binding site agents, including 2MeOE2, ABT-751, CA-4P, and 
colchicine, than the non-resistant counterpart MCF-7 cells (215). This also supports the 
notion that colchicine binding agents such as the DJ compounds, particularly DJ101, may 
be an alternative treatment when tumors acquire resistance to treatment by taxanes.  
 
 
Optimizing Scaffolds Through X-Ray Crystallography 
 
 Tubulin inhibitors interacting with the colchicine binding site have widely diverse 
structures. Thus, it has been very challenging to reliably decipher the molecular 
interactions between an inhibitor and tubulin using molecular modeling with crystal 
structures containing a different class of tubulin inhibitors. Furthermore, available X-ray 
crystal structures often have low resolution which further impedes reliable molecular 
modeling studies.  
 
 We obtained the high-resolution X-ray crystal structures of DJ101 and DJ95, 
showing their interaction with colchicine binding pocket at the interface of ?- and ?-
tubulin heterodimer. These X-ray crystallography results not only provide the structural 
basis for the anticancer mechanism of action of the DJ compounds, they underline the 
benefit of utilizing high-resolution crystal structures over molecular modeling in guiding 
structure optimizations for tubulin inhibitors interacting at this site. For example, three 
hydrogen bonds formed between DJ101 and the tubulin dimer and additional strong 
hydrophobic interactions from surrounding residues firmly anchored DJ101 in this 
colchicine binding site. Interestingly, our previous molecular modeling studies using the 
crystal structure of 1SA0 showed a different binding pose for DJ101, in which the top 
portion of DJ101 was rotated (143). Examination of the crystal structures of 1SA0 and 
the current DJ101 complex clearly revealed significant conformational changes for the 
T4 loop in the tubulin α-subunit and T7 loop in the tubulin β-subunit. It is apparent that 
the “closing up” of the T4 loop to the colchicine binding pocket in the 1SA0 structure 
prevented the top moiety of DJ101 in adopting its true binding pose, and thus forced its 
top moiety to rotate 180 degrees.  
 
 It is well known that while the colchicine site can accommodate a wide variety of 
structurally distinct molecules, and seemingly insignificant changes to many of these 
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compounds can result in a total loss of activity (54, 94). These results highlight critical 
contributions to the optimal bindings of different scaffolds at the colchicine site in 
tubulin. The detailed crystallographic analysis presents opportunities for designing better 
analogs of these compounds that may show improved potency. 
 
 
Targeting Microtubule Dynamics 
 
 The main function of microtubule targeting agents is to inhibit mitosis through 
disruption of microtubule dynamics, leading to mitotic arrest and eventual apoptosis.  
Paclitaxel and docetaxel are microtubule stabilizing agents that target the taxane site 
within the lumen of polymerized microtubules and alter their conformation to the more 
stable GTP-bound β-tubulin structure, thereby locking them in the polymerized state (23) 
The DJ compounds are destabilizing agents that bind to the colchicine site, which causes 
interdimer bending and promotes destabilization (23). To further confirm the mechanism 
of action of the DJ compounds and evaluate the physical change in microtubule networks, 
we performed immunofluorescent imaging studies of melanoma cells that had been 
treated with the DJ compounds or taxanes. In the untreated cells, the microtubule 
networks displayed an arrangement of organized, fibrous microtubules extending 
throughout the elongated cells. Treatment with the DJ compounds led to fragmented 
microtubules and a dramatic decrease of visible tubulin filaments. On the contrary, 
paclitaxel treated cells demonstrated rigid and condensed polymeric microtubules. The 
immunofluorescent images clearly differentiated the stabilizing and destabilizing effects 
on microtubule structure and cellular framework by these two opposing classes of 
compounds.  
 
 Microtubules constitute the mitotic spindle in cells undergoing mitosis. Disruption 
of the mitotic spindle through suppression of treadmilling and dynamic instability are the 
primary means by which microtubule inhibitors thwart cellular functions and induce 
apoptosis (216). Typical features of mitotic spindle suppression and aberrant formation 
such as multiple asters in mitotic cells were evident in the DJ95 treated cells, whereas the 
control cells demonstrated polar spindle formation and centrally aligned chromosomes.  
 
 In addition to their well-defined roles in supporting cellular structure and their 
involvement in mitosis, microtubules are also implicated in cell migration and motility. It 
has been suggested that the dynamic instability imposed on the microtubules by 
suppressing and interfering with tubulin behavior causes cell immobility, as the cell is 
less able to remodel and respond to change the cell shape demanded for cell migration 
(198). The antimitotic and anti-migratory effects of the DJ compounds were 
demonstrated by their ability to inhibit anchorage-dependent colony propagation and 
suppress cell motility in a wound healing assay. The cessation of colony formation and 
cell movement was attributed to disruption of microtubule dynamics, though additional 
studies are needed to further elucidate the mechanism of microtubule binding drugs on 
different facets of cellular function.  
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Minimizing Failure in Drug Development 
 
 Off-target adverse drug reactions often contribute to the high attrition rate in the 
drug discovery and development process. Reducing the failure rate of potential 
pharmaceutical drug candidates is an important step in drug discovery and development 
and will help to mitigate the risk of expensive failure in late stages. Identification of off-
target, adverse drug reactions for drug candidates to important pharmacological targets 
such as GPCRs, drug transporters, ion channels, nuclear receptors, kinases and non-
kinase enzymes through the use of predictive safety panels is supported by major 
pharmaceutical companies such as AstraZeneca, GlaxoSmithKline, Novartis and Pfizer 
(203). DJ101 and DJ95 underwent this pharmacological profiling in two separate panels 
(DiscoveRx Safety47™ Panel and Eurofins SafetyScreen44™ Panel). DJ95 did not show 
significant inhibition or activation to of the receptors or enzymes tested in the screening, 
DJ101 only elicited a functional response to NET and GR antagonism when tested at 
concentrations significantly higher than its IC50. This suggests that the DJ compounds 
minimally interact with or activate some of the key targets that potentially cause adverse 
drug reactions, suggesting a good safety profile for this scaffold. 
 
 
Anticancer Efficacy 
 
 We proceeded with in vivo studies and found that the DJ compounds were able to 
hinder melanoma tumor growth at doses of 15 mg/kg, and at higher concentrations of 30 
mg/kg, DJ101 dramatically inhibited tumor growth and reduced metastasis without 
causing signs of toxicity.  
 
 DJ101 was able to induce tumor regression in a taxane-resistant prostate cancer 
xenograft models in mice, whereas paclitaxel had almost no effect. Other groups have 
also reported elevated sensitivity of resistant cancer cells to colchicine binding site drugs. 
One such study investigated a variety of microtubule targeting agents that bind to the 
taxane site, vinca alkaloid binding site, and colchicine binding site for docetaxel resistant 
MCF-7 breast cancer cells. They reported that while MCF-7TXT  cells demonstrated cross-
resistance to vinca alkaloids, they were more sensitive to colchicine binding site agents 
including 2MeOE2, ABT-751, CA-4P, and colchicine than the non-resistant counterpart 
MCF-7 cells (215). This also supports the notion that colchicine binding agents such as 
DJ101 may be an alternative treatment when tumors acquire resistance to treatment by 
taxanes.  
 
 Because antimitotic drugs exploit different sites on tubulin and microtubules, 
synergistic combinations could be investigated to optimize their clinical usefulness. This 
assertion is supported by several reported studies that combined paclitaxel with other 
tubulin targeting drugs (217-220). It will also be important to combine novel tubulin 
inhibitors such as the DJ compounds with agents exploiting different cancer targets. 
Towards this end, we previously demonstrated that strong synergy can be achieved by 
combining ABI-274 (a less metabolically stable analog of DJ101) and vemurafenib in a 
BRAF inhibitor resistant-melanoma xenograft model (100). Continued exploration of 
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combination therapies is warranted to maximize the clinical potential of the DJ 
compounds. 
 
 
Dual Inhibitors of Tubulin and Tumor Vasculature 
 
 It is well-appreciated that tumor growth and metastasis require a reliable system 
of blood vessels to support the tumor microenvironment, and interfering with this process 
is an attractive strategy for inhibiting tumor growth (39, 221). This has prompted research 
in the development of anti-angiogenic and vascular disrupting agents, and many tubulin 
inhibitors that target the colchicine binding site demonstrate this capability (39, 40, 97, 
222). Microtubule stabilizing agents such as paclitaxel, Peloruside A, and laulimalide 
also have reported vascular disrupting properties, but they have other shortcomings, such 
as the development of resistance and dose-limiting toxicities (223-226). We demonstrated 
that DJ95 treatment suppressed capillary-like networks in vitro in HUVECs in a 
concentration-dependent manner. We also discovered vascular disrupting action evident 
in mouse xenografts after treatment with the DJ compounds, where there was significant 
disturbance of endothelial vasculature and an overall decrease in microvessel area for 
these treatment groups compared to control tumors. These in vitro and in vivo data 
support the dual role of the DJ compounds as tubulin inhibitors and vascular disrupting 
agents, and they may exert their anticancer effects through multiple mechanisms.  
 
 
Conclusions 
 
 In our examination of DJ101 and DJ95, we found that they were potent against a 
variety of melanoma cell lines and other cancer types and were able to overcome ABC-
transporter mediated drug resistance and acquired taxane resistance. We obtained the 
high-resolution crystallography of both compounds in complex with tubulin, confirming 
their direct interaction with the colchicine binding domain and demonstrated their 
depolymerizing effect microtubule morphology, which was distinct from stabilizing 
agents. Both compounds show antitumor efficacy in melanoma xenograft models without 
causing apparent toxicity to major organs and display good pharmacological safety 
profiles. DJ101 treatment also reduced lung metastasis nodules in a metastatic model and 
caused tumor reduction in the paclitaxel-resistant xenograft model. The DJ compounds 
also disrupted endothelial cells and tumor vasculature, indicating that they may play a 
role as vascular disrupting agents in addition to tubulin inhibitors. There are currently no 
colchicine binding site inhibitors approved for chemotherapy, and intervention with the 
DJ compounds could prove to be an effective alternative treatment when other tubulin 
inhibitors fail to show efficacy due to MDR. 
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CHAPTER 3.    OPTIMIZING VERU-111 ANALOGS FOR IMPROVED 
ANTICANCER EFFICACY2 
 
 
Introduction to VERU-111 Analogs 
 
 The microtubule targeting agents have achieved great success in cancer treatment 
in the last decade. However, acquired drug-resistance is often developed over the course 
of treatment and becomes a tremendous obstacle. It is estimated that 22 million new 
cancer cases will be diagnosed worldwide in the coming two decades, and therefore an 
urgent need exists to develop new anticancer agents to treat resistant phenotypes (157, 
227). Mechanisms that mediate drug-resistance against microtubule targeting agents 
include, but are not limited to, the overexpression of membrane-bound drug efflux 
proteins, such as P-glycoprotein; the overexpression of β-tubulin isotypes; and 
microtubule mutations (146, 228).  
 
 Colchicine binding site inhibitors target tubulin at the interface between α and β-
tubulin heterodimers and mechanistically decrease cellular motility, alter cell 
morphology, impair protein assembly, and arrest mitosis (229, 230). Colchicine has wide-
scope mechanisms of action, but unfortunately, it induces systemic toxicities and 
multiorgan dysfunction that have prevented its clinical use for cancer treatment (229). 
Other colchicine binding site inhibitors have also been disclosed in the last decade. 
Encouragingly, extensive preclinical studies have proven that drugs targeting the 
colchicine binding site may suppress overexpression of tubulin isotypes and surmount 
drug-resistance mediated by P-gp, MRP1, and MRP2 (81, 94, 231).  
 
 The 3,4,5-trimethoxyphenyl (TMP) is a common moiety shared by many drugs 
targeting the colchicine site and is crucial for maintaining suitable molecular 
conformations that are needed for optimal interactions with tubulin and for producing the 
maximum antiproliferative activities (232). Attempts to modify this TMP moiety usually 
lead to significantly reduced anticancer potency (94, 97, 165, 233). For example, 
substituting the methoxy with a bulky group or demethylating the methoxy on the TMP 
moiety of colchicine were reported to reduce the potency (234, 235). In addition, 
removing or adding methoxy to TMP significantly impaired the antimitotic activity (>10-
fold) (236). However, some isosteric modifications of the TMP in colchicine or CA-4 
have been shown to maintain the potency to that of parent natural products. For instance, 
Semenov et al. have demonstrated that isosteric replacement of the TMP of CA-4 with 
[1,3]dioxole or [1,4]dioxane did not significantly reduced antimitotic activity (236). 
                                                 
 
2Modified with permission from American Chemical Society. Qinghui Wang*, Kinsie E. Arnst*, Yuxi 
Wang*, Gyanendra Kumar, Dejian Ma, Hao Chen, Zhongzhi Wu, Jinliang Yang, Stephen W. White, Duane 
D. Miller, and Wei Li. Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin 
Inhibitor VERU-111 Leads to Improved Antiproliferative Activities. Journal of Medicinal Chemistry. 
2018; 61 (17), 7877-7891. 
*Equally contributing authors. 
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Cornigerine, a [1,3]dioxole analog of colchicine, displayed equipotent antimitotic activity 
to that of the parent compound (237).  
 
 In our prior reports, we described the discovery of several scaffolds of potent 
tubulin inhibitors, including the discovery of a 2-aryl-4-benzoyl-imidazole (ABI) scaffold 
(140). Subsequent structural optimization of the benzoyl moiety, the aryl moiety, and the 
imidazole fragment in this scaffold resulted in analogs with improved potency (98, 141, 
143, 144). VERU-111 is the best analog from that series of structural optimizations. 
VERU-111 is currently under clinical development as 3rd line hormonal therapy by 
VERU Healthcare. Interestingly, it also exhibits potent antiproliferative activities against 
melanoma cell lines and acts as a colchicine binding site tubulin inhibitor. Due to an 
unproductive chemical synthesis, its in-depth medicinal programmatic investigation was 
nevertheless hampered. The TMP moiety in VERU-111, like many other colchicine 
binding site inhibitors with this shared moiety, is critical for its high binding affinities to 
tubulin.  
 
 In this chapter, we report the extensive structure-activity relationship (SAR) study 
of VERU-111 analogs by focusing modifications to the indole moiety and TMP moiety, 
leading to the identification of the 3 most potent compounds, 10ab, 10bb, and 13f. 
Mechanism studies confirmed that the new VERU-111 analogs inhibit tubulin 
polymerization and promote microtubule fragmentation and disassembly. Direct binding 
to the colchicine binding domain on tubulin is revealed through X-ray crystallography, 
and specific molecular interactions and overlay with colchicine are detailed. The 
compounds demonstrated good in vitro metabolic stability, and 10bb and 13f showed 
significant anticancer efficacy in melanoma mouse models without demonstrating 
toxicity to animals or significantly inducing off-target interactions based on 
pharmacological safety screening. Finally, 10bb was highly effective in a taxane-resistant 
prostate cancer xenograft model, suggesting its ability to overcome resistant mechanisms. 
Overall, these data demonstrate great potential for these VERU-111 analogs as anticancer 
drug candidates. 
 
 
Materials and Methods 
 
 
Cell Culture and Reagents  
 
 Human melanoma carcinoma cell lines A375, M14, RPMI-7951, and WM-164 
(American Type Culture Collection or ATCC, Manassas, VA, USA) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) (Corning, Manassas, VA) supplemented 
with 10% (v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 
1% antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Murine melanoma 
B16F10 cells (ATCC, Manassas, VA, USA) were cultured in Minimum essential medium 
(Invitrogen, Carlsbad, CA), supplemented with 5% heat-inactivated Hyclone FBS 
(Thermo Scientific, Rockford, IL), 1 % antibiotic-antimycotic mixture (Sigma-Aldrich, 
St. Louis MO), 1% Mem-sodium pyruvate (Invitrogen, Carlsbad, CA), 1% Mem-vitamin 
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(Invitrogen, Carlsbad, CA), L-Glutamine (2mM final concentration) (Invitrogen, 
Carlsbad, CA), and 1% Mem NEAA (Invitrogen, Carlsbad, CA). Parental prostate cancer 
PC-3, its paclitaxel-resistant daughter line PC-3/TxR, parental prostate cancer DU-145, 
and its docetaxel-resistant daughter line DU-145/TxR are gifts from Dr. Evan Keller at 
the University of Michigan Medical School. PC-3 and DU-145 cell lines were cultured in 
RPMI 1640 media (Gibco® by Life Technologies, Carlsbad, CA) supplemented with 
10% (v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1% 
antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Taxane resistant PC-
3/TxR and DU-145/TxR cell lines were cultured in the same media and additionally 
supplemented with 10 nM paclitaxel or docetaxel, respectively. Drugs were not included 
in the media for PC-3/TxR or DU-145/TxR for at least one week prior to in vitro testing. 
All cell lines were authenticated by ATCC by short tandem repeat profiling.  Cultures 
were maintained to 80-90% confluency at 37 °C in a humidified atmosphere containing 
5% CO2. Compounds were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. 
Louis, MO) to make a stock solution of 20 mM. Compound solutions were freshly 
prepared by diluting stocks with cell culture medium before use. 
 
 
Cytotoxicity Assays 
 
 Logarithmic growth phase cells were seeded in 96-well plates at a concentration 
of 1,000–5,000 cells per well, depending on growth rate of the cell line. After overnight 
incubation, the media was replaced, and cells were treated with the test compounds at 10 
concentrations ranging from 0.03 nM to 1 μM plus a vehicle control for 72 h in four 
replicates. Following treatment, the MTS reagent (Promega, Madison, WI) was added to 
the cells and incubated in dark at 37 °C for at least 1 h. Absorbance at 490 nm was 
measured using a plate reader (BioTek Instraments Inc., Winooski, VT). Percentages of 
cell survival versus drug concentrations were plotted, and the IC50 (concentration that 
inhibited cell growth by 50% of untreated control) values were obtained by nonlinear 
regression analysis using GraphPad Prism (GraphPad Software, San Diego, CA). The 
resistant index (RI) was calculated by dividing the IC50 of the resistant cell line with the 
IC50 of the parental cell line. 
 
 
X-Ray Crystallography  
 
 Protein Expression and Purification. X-Ray crystallography was performed by 
Dr. Yuxi Wang (Sichuan University, in China). Porcine brain tubulin (Catalog # T-238P) 
was obtained from Cytoskeleton, Inc. The stathmin-like domain of RB3(RB3-SLD) was 
transformed into and overexpressed in E. coli. The protein was purified by anion-
exchange chromatography and gel filtration chromatography. The peak fractions from gel 
filtration column were concentrated to 10 mg/mL and stored at -80 ? (51, 154, 185). 
TTL protein was expressed and purified from E. coli expression system as described in 
the previous reference (186). Briefly, the protein was expressed in E. coli using LB, 
purified through Ni-NTA affinity chromatography and gel filtration chromatography 
(buffer: Bis-Tris Propane pH 6.5, 200 mM NaCl, 2.5 mM MgCl2, 5 mM β- Me, 1 % 
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Glycerol). The peak fractions of the target protein were collected and concentrated to 20 
mg/ml and saved at -80 ?. Porcine brain tubulin was supplied at 10 mg/ml in G-PEM 
(General tubulin buffer: 80 mM PIPES pH 6.9, 2 mM MgCl2, 0.5 mM EGTA and 1 mM 
GTP) as a frozen liquid and saved at -80 ? until use.  
 
 Crystallization and Crystal Soaking. The process to getting crystals of T2R-
TTL followed the previously reported procedure (186, 187). Briefly, the complex 
containing tubulin (10 mg/ml), TTL (20 mg/ml) and RB3 (10 mg/ml) at the molar ratio of 
2:1.3:1.2 (tubulin:RB3:TTL) was incubated on ice with additional 1 mM AMPPCP, 5 
mM tyrosinol and 10 mM DTT, and then the final sample was concentrated to 20 mg/ml 
at 4 ?. Crystallization of T2R-TTL complex was carried out at 20 ? using the sitting 
drop vapor diffusion method by mixing equal volumes of the protein complex and 
crystallization buffer containing 6% PEG, 5% glycerol, 0.1 M MES, 30 mM CaCl2, 30 
mM MgCl2, pH 6.7. Seeding was used to optimizing the crystal conditions. Initial 
crystals were observed after two days and crystals reached their final size of 200-300 μm 
within 3-5 days. For crystal soaking, 0.1 μl of the ligand solution (13f dissolved in 100% 
DMSO) was added to the 2μl crystal-containing drop for 12 h at 20 °C. The best crystals 
were selected and frozen in liquid nitrogen in the presence of cryoprotectant 
(crystallization buffer containing 20? glycerol).  
 
 X-Ray Data Collection and Structure Determination. Crystals of the T2R-
TTL-13f complexes were mounted in nylon loops and flash-cooled in a nitrogen stream 
at 100 K. The diffraction data were collected on beamlines BL19U1 at Shanghai 
Synchrotron Radiation Facility (SSRF) in Shanghai, China. Data were indexed, 
integrated and scaled using the HKL2000 program package (188). The structure of T2R-
TTL-13f complex was solved by molecular replacement using the previously published 
T2R-TTL structure (PDB ID: 4I55) as the search model. The rotation and translation 
function searches were performed by the program PHASER. The model was manually 
built with Coot (190) and then refined using the phenix refine module of the Phenix 
program (191). The model quality was checked with the PROCHECK program showed 
good stereochemistry according to the Ramachandran plot. Analysis was determined in 
coordination with Dr. Stephen White’s group (St. Jude Children’ Research Hospital). 
 
 
Tubulin Polymerization Assay 
 
 Bovine brain tubulin (3 mg/ml final concentration) (Cytoskeleton, Denver, CO) 
was mixed with 10 μM of the test compounds and incubated in 100 μL of general tubulin 
buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, and 1 mM GTP) at pH 6.9. The 
absorbance of wavelength at 340 nm was monitored every 1 min for 40 min by the 
SYNERGY 4 Microplate Reader (Bio-Tek Instruments, Winooski, VT). The 
spectrophotometer was set at 37 °C for tubulin polymerization. 
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Fluorescence Microscopy  
 
 WM-164 cells were seeded and allowed to adhere on glass coverslips in 6 well 
plates (500,000 cells/well) overnight.  Cells were incubated for 18 hrs with 50 nM of 
10ab, 10bb, or docetaxel. DMSO was added to the cells in equivalent volume as a 
negative control. Microtubules were visualized with anti-α-tubulin antibody (Thermo 
Scientific, Rockford, IL) and Alexa Fluor 647 goat anti-mouse IgG (Molecular Probes, 
Eugene, OR). The coverslips were mounted with Prolong Diamond Antifade mounting 
media with DAPI (Invitrogen, Eugene, OR) and images acquired with a Zeiss 710 
Confocal microscope and Zen imaging software (Zeiss, Thornwood, NY). 
 
 
Colony Forming Assay 
 
 Cells were seeded in triplicate in 6 well plates at a density of 500 cells/well in full 
cell culture media and incubated at 37 °C overnight. Media was changed and cells were 
treated with 5 nM of the test compound and incubated for another week. At the end of 
this period, cells were fixed with chilled methanol (5 min), stained with 0.5% crystal 
violet solution (4 hrs), rinsed with sterile water, and air-dried overnight. Images were 
taken UVP ChemiDoc-It imager (Bio-Rad, Hercules, CA) and colonies were quantified 
with the corresponding VisionWorks software. 
 
 
Scratch Migration Assay 
 
 A375 and RPMI-7951 cells were seeded in 24 well plates in 4 replicates at a 
concentration of 200,000 cells/well and incubated overnight. This concentration allowed 
a confluent monolayer to form in the wells. Using a 200 μL pipette tip, a straight line was 
scratched through the cell monolayer to remove an area of cells. The plates were then 
washed several times with media to remove any debris and uprooted cells. Cells were 
treated with 25 nM of 10ab, 10bb or vehicle control. Images were obtained immediately 
after drug treatment and again after 18-22 hours with Evos Fl Imaging System 
(LifeTechnologies, Carlsbad, CA). Analysis was performed with ImageJ software (NIH, 
Bethesda, MD).   
 
 
Liver Microsomes Stability Assay 
 
 Liver microsome assays were performed by Dr. Lei Yang (St. Jude Children’s 
Research Hospital). The NADPH regenerating agent solutions A (catalog#: 451220) and 
B (catalog#: 451200) and mouse liver microsomes (CD-1, mixture of male, 
catalog#:452701, and female, catalog#: 452702) were obtained from BD Gentest 
(Woburn, MA). Liver microsomes stability assay was conducted following literature 
reports (238, 239). For each test compound, the mouse liver microsomal solution was 
prepared by adding 0.058 ml of concentrated mouse liver microsomes (20 mg/ml protein 
concentration) to 1.756 ml of 0.1 M potassium phosphate buffer (pH 7.4) containing 5 μL 
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of 0.5 M EDTA to make a 0.6381 mg/ml (protein) microsomal solution. Each test 
compound (2.2 μL of 10 mM DMSO solution) was added directly to 1.79 ml of mouse 
liver microsomal solution and 90 μL was transferred to wells in 96-well plates (0, 0.25, 
0.5, 1, 2, and 4 h time points each in triplicate). The NADPH regenerating agent was 
prepared by mixing 0.113 ml of NADPH regenerating agent Solutions A, 0.023 ml of 
solution B and 0.315 ml of 0.1 M potassium phosphate buffer (pH 7.4) for each tested 
compound. To each well of the 96-well plate, 22.5 μL of the NADPH regenerating agent 
was added to initiate the reaction, and the plate was incubated at 37 °C for each time 
point (0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The reaction was quenched 
by adding 225 μL of cold acetonitrile containing warfarin (4 mg/ml) as internal control to 
each well. All of the plates were centrifuged at 4000 rpm for 20 min and the supernatants 
(100 μL) were transferred to another 96-well plates for analysis on UPLC–MS (Waters 
Acquity UPLC linked to Waters Acquity Photodiode Array Detector and Waters Acquity 
Single Quadrupole Mass Detector) on Acquity UPLC BEH C18 1.7 mm (2.1x50 mm) 
column by running 90–5% gradient for water (+0.1% formic acid) and acetonitrile 
(+0.1% formic acid) in 2 minutes. The area under the single ion recording (SIR) channel 
for the test compound divided by the area under the SIR for internal control at 0 time 
concentration was considered as 100% to calculate remaining concentration at each time 
point. The terminal phase rate constant (ke) was estimated by linear regression of 
logarithmic transformed concentration versus the data, ke = slope × (−ln 10). The half-life 
t1/2 was calculated as ln 2/ke. The intrinsic clearance (CLint,app)= (0.693/in vitro t1/ 2) x 
(1ml incubation volume/0.5 mg of microsomal protein) x (45 mg microsomal 
protein/gram of liver) x (55 g of liver/kg body weight). 
 
 
In Vivo Experiments 
 
 All animal experiments were performed in accordance with the NIH animal use 
guidelines and protocol approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Tennessee Health Science Center (UTHSC, Memphis, TN).  
 
 Xenograft Models. Nude mice, 6–8 weeks old, were purchased from 
Harlan/Evigo. Logarithmic growth phase A375 or PC-3/TxR  (5 × 107 cells per ml) cells 
were prepared in phenyl red-free, FBS-free cell culture media and mixed at a 1:1 ratio 
with Matrigel. Tumors were established by injecting 100 μl of cell suspension 
subcutaneously in the dorsal flank of each mouse (2.5×106 cells). After 2 weeks, mice 
were randomly divided into control or treatment groups (n=8 for A375 model of 13f, 
n=10 for A375 model of 10bb, and n=8 for PC-3/TxR model of 10bb). Test compounds 
were dissolved in a 1:1 ratio of PEG300:PBS solution to produce desired concentrations. 
100 μl of the drug solution corresponding to 15 or 30 mg/kg doses were administered via 
i.p. injection once daily for the duration of the study. The control group was given only a 
vehicle solution of the same preparation and injected at the same frequency. 
  
 Tumor volume was measured three times a week with a caliper and calculated by 
using the formula a×b2×0.5, where a and b represented the larger and smaller diameters, 
respectively. Tumor growth inhibition (TGI) at the conclusion of the experiments was 
 58 
calculated as 100 – 100 ×((T − T0)/(C − C0)), where  T, T0, C and C0 are the mean tumor 
volume for the specific group on the last day of treatment, mean tumor volume of the 
same group on the first day of treatment, mean tumor volume for the vehicle control 
group on the last day of treatment and mean tumor volume for the vehicle control group 
on the first day of treatment, respectively (100). Animal activity and body weight were 
monitored during the entire experiment period to assess potential acute toxicity. At the 
end of the experiment, mice were sacrificed and the tumors and tissues were dissected out 
and fixed in 10% buffered formalin phosphate solution for more than 1 week before 
pathology staining analysis. 
 
 Lung Metastasis Model. C57BL/6 mice from Charles River Laboratories 
International, Inc., age 7–8 weeks old, were used to study the inhibition effect of 10bb on 
lung metastasis of melanoma cells. B16F10 melanoma cells growing in a logarithmic 
growth phase were suspended in the conditioned media at a density of 1 × 106 per ml. 
Each mouse was injected with 100 μL (1 × 105 cells) via the lateral tail vein. The 
treatment started on the third day after the inoculation to ensure the initiation of 
metastasis before beginning treatment. 10bb (30 mg/kg) was formulated as described 
above. All the treatment solutions were kept in the same volume (100 μl) and 
administered via i.p. injection for 2 weeks, 5 days a week. Vehicle control group was 
treated by i.p. injection with 100 μL of PEG300 and PBS in a 1:1 ratio. Mice were 
sacrificed after 15 days after the initiation of the experiment, and the lungs were 
separated, expanded and preserved in 10% neutral buffered formalin. The number of lung 
metastasis nodules was recorded. Major organs were also preserved in 10% neutral 
formalin buffer for subsequent examination of potential toxicities. Animal activity and 
body weight were monitored during the entire experiment period to assess acute toxicity. 
 
 
Results and Discussion 
 
 
SAR Investigation 
 
 VERU-111 Analogs of 3-Indolyls. To compare the cytotoxicity of VERU-111 
that was reported previously, new VERU-111 analogs were evaluated for their cytotoxic 
effect in human melanoma cell lines including A375, WM-164, and M14 or RPMI-7951. 
Colchicine was used as a positive control, and VERU-111 was used as a prototype for 
comparison. In the first series of compounds developed to optimize the potency and 
investigate the SAR of VERU-111 analogs, a substitution at the 2-position of the indole 
ring was introduced (Table 3-1). Compared to the prototype VERU-111, analog 10aa 
containing a bulky phenyl group on the 2-position of indole moiety showed markedly 
reduced activity and had IC50s more than 1 μM against three melanoma cell lines. This 
indicated that bulky substituent on the indole might not be tolerated. We next compared 6 
analogs with a substitution at the 4-position of the indole ring, including 10ab-10ag. The 
best inhibitory effect was observed in 4-methyl analog 10ab, which had IC50s ranging 
from 1.7-3.2 nM and was ~3-fold more potent than VERU-111. Analog 10ac had a small  
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Table 3-1. In vitro cytotoxicity of VERU-111 analogs modifying the indole 
moiety. 
 
Compound 
scaffold 
ID R 
IC50 ± SEM (nM) 
A375 M14 WM-164 
VERU-111 H 8.1 ± 1.6 5.6 ± 0.9 7.2 ± 0.9 
10aa 2-Ph >1000 >1000 >1000 
10ab 4-CH3 1.8 ± 0.2 1.7 ± 0.2 3.2 ± 0.3 
10ac 4-F 7.2 ± 0.7 8.2 ± 0.9 ND 
10ad 4-Br 13.8 ± 1.7 10.4 ± 1.2 67.1 ±14.5 
10ae 4-OCH3 >1000 >1000 >1000 
10af 4-OBn >1000 >1000 >1000 
10ag 4-OH 9.2 ± 1.4 8.6 ± 0.8 19.1 ± 1.8 
10ah 5-CH3 277.7 ± 36.3 177.4 ± 16.3 552.3 ± 108.3 
10ai 5-F 19.2 ± 1.5 18.0 ± 1.3 80.9 ± 16.6 
10aj 5-Cl 61.8 ± 9.3 64.9 ± 4.3 159.5 ± 24.1 
10ak 5-Br 164.2 ± 16.7 104.3 ± 5.9 441.7 ± 110.0 
10al 5-OBn >1000 >1000 >1000 
10am 5-OH >1000 >1000 >1000 
10an 6-CH3 21.1 ± 3.9 21.7 ± 4.7 23.7 ± 6.1 
10ao 6-F 17.5 ± 3.0 5.8 ± 0.8 10.3 ± 1.2 
10ap 6-Br 67.8 ± 10.5 41.2 ± 7.5 55.4 ± 7.4 
10aq 6-OCH3 793.4 ± 89.9 879.8 ± 88.2 >1000 
10ar 6-OBn >1000 >1000 >1000 
10as 6-OH >1000 >1000 >1000 
10at 7-CH3 13.1 ± 1.3 10.8 ± 1.0 61.3 ± 11.0 
10au 7-OCH3 38.3 ± 3.7 34.1 ± 3.5 115.4 ± 25.0 
10av 7-OBn >1000 >1000 >1000 
10aw 7-OH >1000 >1000 >1000 
10bb 4-indolyl 3.6 ± 1.0 3.7 ± 0.8 1.6 ± 0.3 
10bc 5-indolyl 8.6 ± 3.3 18.5 ± 3.7 6.1 ± 1.2 
10bd 6-indolyl 8.0 ± 1.0 6.1 ± 1.1 3.8 ± 0.5 
10be 7-indolyl 285.5 ± 78.7 240.6 ± 38.1 435.8 ± 171.3 
 Colchicine  14.1 ± 2.2 16.6 ± 1.5 10.8 ± 1.9 
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substituent (4-F) and displayed nearly equipotent antiproliferative activity to that of 
VERU-111 with its IC50 ranging from 7.2-8.2 nM. In contrast, 10ad, an analog with a 
larger halogen 4-bromo, was half as potent as VERU-111, having IC50s ranging from 
10.4-67.1 nM. For analogs 10ae with a 4-methoxy group and 10af with a 4-benzoxy 
group, considerable reductions of activities were observed, demonstrating IC50s of more 
than 1 μM. However, hydrogenation to a 4-hydroxy in compound 10ag rescued activity, 
with IC50s from 8.6-19.1 nM. 5-position substituted analogs (compounds 10ah-10am) 
showed decreased antiproliferative activities in comparison with their corresponding 4-
position substituted counterparts. For example, the 5-fluoro analog 10ai and 5-bromo 
analog 10ak were 2-fold and 10-fold less potent than 10ac and 10ad, respectively. We 
also observed that the activity decreased with halogen size, where the order of potency 
from F > Cl > Br substitutions on 10ai, 10aj, and 10ak, respectively. The activity 5-
methyl analog 10ah possessed approximately 100-fold decreased cytotoxicity compared 
to 10ab. The best activity was observed in 5-substitution set was the 5-fluoro analog 
10ai, which had IC50s ranging from 18.0-80.9 nM. Although a bulky benzyloxy led to 
completely lost antiproliferative activity (analog 10al), hydrogenation of benzyloxy to 
hydroxy (analog 10am) did not contribute to any improvement of activity, unlike what 
was observed in 10ag. Next, we compared analogs with a substitution at the 6-position of 
the indole ring and found analogs with bulky functional groups at this position such as 
10aq and 10ar also resulted in significant loss of activity, and hydrogenation of the 
benzyloxy to hydroxy on the 6-position (10as) did not provide any significant 
improvement of activity. Smaller substituents, however, had better cytotoxicity. For 
example, the best activity from a 6-position substitution was observed in the 6-fluoro 
analog 10ao, with IC50s ranging from 5.8-17.5 nM. At the final position for this series of 
3-indolyl analogs, 4 compounds were synthesized with substitutions at the 7-indole 
position (10at-10aw). 10at, containing a small methyl substitution, possessed the most 
potent inhibitory effect of the 7-indole substitutions, with IC50s ranging from 10.8-61.3 
nM. Interestingly, 10au with a bulky 7-methoxy substituent showed significantly stronger 
activity (IC50s of 34.1-115.4 nM) than its 4-methoxy and 6-methoxy counterparts (10ae 
and 10ap). Taken these data together, small substituent (e.g. fluoro and methyl) is 
preferred to bulky functional groups on the 3-indolyl moiety. By comparing different 
positions of substituted analogs, it was determined that 4-position is the most amenable to 
the introduction of a functional group. 
 
 VERU-111 Analogs with Indolyl Rotation. Hwang et al. have disclosed a series 
of indolyl-imidazopyridines that are tubulin inhibitors, and their SAR study revealed that 
indolyl rotation significantly affected the potency and antiproliferative activities. (143). 
We hypothesized that this concept would also apply to VERU-111 analogs, considering 
its structural similarity to indolyl-imidazopyridines. Therefore, we synthesized four 
VERU-111 analogs 10bb-10be demonstrate their cytotoxicity in Table 3-1. In this series, 
5- and 6-indolyl analogs 10bc and 10bd showed comparable antiproliferative activities to 
that of VERU-111and had IC50s ranging from 6.1-18.5 and 3.8-8.0 nM, respectively, 
while the 7-indolyl analog 10be showed a drastic decline in potency. 10bb, the 4-indolyl 
analog, demonstrated greater cytotoxicity than VERU-111, with IC50s ranging from 1.6-
3.7 nM against the tested cancer cell lines, and was one of the most potent of all the new 
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analogs. Overall, these data suggest that rotating the indole moiety is feasible to improve 
the antiproliferative activity of VERU-111. 
 
 VERU-111 Analogs with Modified 3,4,5-Trimethoxyphenyl Moiety. Based on 
our recently reported high resolution crystal structure of DJ101 (Figure 2-2) (199), a 
close analog of VERU-111, we discovered that: (1) only one methoxy of the TMP moiety 
in DJ101 was involved in the formation of a hydrogen bond interaction with the β-
Cys241 residue of tubulin; and (2) there is very limited space around the TMP moiety to 
accommodate any larger moieties (179). We hypothesized that two of the three methoxys 
of the TMP moiety could be modified to optimized activity without damaging the 
interactions to tubulin. We carried out a focused SAR investigation of VERU-111 by 
modifying the TMP moiety, specifically by linking two adjacent methoxy moieties into a 
conformationally restricted ring system (Table 3-2).  
 
 The benzo[4,5]-dioxane analog 13a lacks the 3-methoxy present in the TMP of 
VERU-111. It exhibited remarkable loss of cytotoxicity (IC50 ranges from 119 to 218 
nM). The ring contraction of the six-member benzo[4,5]-dioxane ring to the five-member 
benzo[4,5]-dioxole ring in analog 13b demonstrated showed comparable antiproliferative 
activity to that of 13a. In contrast to 13c, the 3-methoxybenzo substituted analog of 13a, 
demonstrated significantly increased potency, with IC50 values ranging from 11.3 to 29.2 
nM. This is consistent with our previous SAR, where we discovered that removing one or 
more of the methoxy groups in the TMP moiety negatively affects the antiproliferative 
potency for this scaffold (98). Similarly, introducing the 3-methoxy to the benzo[4,5]-
dioxole analog 13b led to the formation of 13d, which restored the potency (IC50 ranges 
from 3.5 to 5.6 nM, 30-fold more active than 13b). Interestingly, this five-membered ring 
analog was ~4-fold more potent than the six-membered ring analog 13c. Thus, while the 
3-methoxy was crucial for the activities of VERU-111 analogs, the size of the cyclic 
rings on the phenyl moiety also played an important role (13c vs 13d). Consistent with 
this, further increasing the ring size to a seven-membered ring resulted in 3-
methoxybenzo[4,5]dioxepin analog 13e, resulted in a moderate decrease in potency (IC50 
ranging from 32.2 to 47.7 nM). By comparing 13c, 13d and 13e, it was revealed that the 
activity for the size of this saturated ring is 5 > 6 > 7. 
 
 We next introduced an unsaturation to this ring by synthesizing 13f, a unique 3-
methoxybenzo[4,5]-dioxene analog. Interestingly, 13f exhibited the most potent 
antiproliferative activity among the TMP-modified analogs (13a-13f), with IC50 values 
ranging from 1.1 to 3.3 nM. To determine the combination modifications to both the 
TMP and indole moieties on 13f, we further produced analogs 19 and 25 (Table 3-2). 
While the 4-indolyl analog 19 exhibited ~ 11-fold reduced antiproliferative activity when 
compared to 13f, the 4-methyl-3-indolyl analog 25 (IC50 values ranging from 6.1 to 8.8 
nM) was only slightly less potent than 13f. Overall, our SAR result show that the TMP 
moiety in VERU-111 can be modified without negatively impacting antiproliferative 
activities. 
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Table 3-2. In vitro cytotoxicity of VERU-111 analogs modifying the TMP moiety. 
 
Compound 
Scaffold 
ID R 
IC50 ± SEM (nM) 
A375 M14 RPMI-7951 
 
13a 
 
158.7 ± 16.4 118.8 ± 14.3 213.7 ± 17.1 
13b 
 
190.6 ± 16.8 154.6 ± 10.4 235.6 ± 19.3 
13c 21.0 ± 1.6 11.3 ± 0.8 29.2 ± 1.7 
13d 
 
3.5 ± 0.4 5.6 ± 0.6 5.6 ± 0.5 
13e 
 
32.2 ± 3.4 38.2 ± 3.5 47.7 ± 3.9 
13f 
 
1.1 ± 0.1 1.2 ± 0.2 3.3 ± 0.3 
 
19 
 
17.1 ± 1.1 13.8 ± 0.9 34.8 ± 2.2 
25 
 
6.1 ± 0.2 6.1 ± 0.2 8.8 ± 0.5 
 VERU-
111 
 8.1 ± 1.6 5.6 ± 0.9 7.2 ± 0.9 
 
  
 63 
Lead Compounds Show Improved Potency to Resistant Cell Lines 
 
 To expand our assessment of the biological activity of the lead compounds, we 
chose the most potent compound from each modification series to move forward with for 
additional analysis. This included 10ab from the 3-indolyls, 10bb from indole rotation 
series, and 10f from TMP modification series.  Since other colchicine binding site 
inhibitors are reportedly less susceptible to taxane-related drug resistance, we wanted to 
determine if our analogs would still be efficacious in taxane-resistant models (54, 199, 
240). We tested our compounds against paclitaxel in PC-3, paclitaxel-resistant PC-3/TxR, 
DU-145, and docetaxel-resistant DU-145/TxR prostate cancer cell lines (Table 3-3). 
Paclitaxel was more potent in the parental PC-3 cell lines with an IC50 of 1.1 ± 0.2 nM 
compared to 5.2 ± 0.4, 89.9 ± 6.3, and 15.2 ± 1.3 nM for 10ab, 10bb, and 13f, which is 
not surprising given paclitaxel’s potency and clinical success. However, in resistant PC-
3/TxR cell lines, paclitaxel had a resistance index of 103.5 and an IC50 of 113.9 ± 4.3 nM 
whereas 10ab, 10bb, and 13f all showed a resistance index of less than 1, meaning they 
had improved potency against the resistant cell line. Along the same lines, paclitaxel was 
highly potent against the sensitive DU-145 cell line (1.5 ± 0.2 nM), however, no effect 
was observed at all against the paclitaxel-treated DU-145/TxR cells at concentrations up 
to 1μM. In contrast, all 3 compounds showed remarkably improved resistance indices, 
ranging from 1.8-2.2. These data support the continued investigation of this scaffold as an 
alternative treatment for cancers resistant to taxane treatment.  
 
 
Molecular Interactions of 10f with Tubulin 
 
 To understand the molecular basis for the strong interaction of the most potent 
TMP-modified analog, 13f, with tubulin, we obtained the crystal structure of the T2R-
TTL (consisting of α/β-tubulin, the stathmin-like domain of RB3, and tubulin tyrosine 
ligase) (186, 241) in complex with 13f at a resolution of 2.85 Å (PDB ID: 6D88). As 
expected, 13f occupies the colchicine binding site at the interface of the α- and β-tubulin, 
mostly confined in a deep pocket in β-tubulin opposite the GTP molecule that is bound in 
a pocket in the α-tubulin (Figures 3-1A). There are two α/β-tubulin heterodimers in this 
complex and both interfaces are occupied by the small molecule. In both heterodimers 
(Chain A/B and C/D), 13f forms virtually identical interactions. First, it forms three 
hydrogen bonds with the surrounding amino acids: an imidazole NH to carbonyl of 
Thr179 (α-tubulin); an indole NH to Ser178 (α-tubulin) and Asn347 (β-tubulin) via a 
water molecule; and a carbonyl linker to Asp249 (β-tubulin) (Figure 3-1B). Second, the 
3-methoxybenzo[4,5]-dioxene moiety is stacked between Cys239 and Leu253 from β-
tubulin, the latter making a pi-H interaction with the ring. Finally, the imidazole ring is 
surrounded by Leu246 and Asn256 from β-tubulin while the indole ring is surrounded by 
both Lys350 and Met257 from β-tubulin and Val181 from α-tubulin. Colchicine targets 
the β subunit and keeps the tubulin from adopting a straight conformation, thus inhibiting 
microtubule assembly, and 13f also blocks the curved-to-straight conformational change 
of tubulin by steric clashes with surrounding secondary structure elements (Figure 3-1C).  
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Table 3-3. In vitro cytotoxicity of 10ab, 10bb, and 10f against parental and 
taxane-resistant prostate cancer cell lines. 
 
treatment 
IC50 ± SEM (nM) 
aRI  
IC50 ± SEM (nM) 
RI  
PC-3  PC-3/TxR  DU-145  DU-145/TxR  
10ab  5.2 ± 0.4  3.9 ± 0.3  0.8 13.8 ± 1.0  25.2 ± 2.0  1.8 
10bb 89.9 ± 6.3  66.9 ± 4.4  0.7 169.1 ± 4.4  379.1 ± 80.0 2.2 
10f 15.2 ± 1.3 7.6 ± 0.5 0.5 42.2 ± 3.6 81.5 ± 11.6 1.9 
Colchicine  10.4 ± 0.5  37.4 ± 2.2  3.6 35.5 ± 3.5  >1,000  >28 
Paclitaxel  1.1 ± 0.2  113.9 ± 4.3  103.5 1.15± 0.2  >1,000 >869 
Docetaxel  0.5 ± 0.1  27.9 ± 1.1  55.8 0.10 ± 0.01  352.3 ± 118.2 >3,523 
 
aRI: resistance index is calculated by dividing the IC50 value of compound in resistant cell 
lines by the IC50 in the corresponding parental cell lines. 
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Figure 3-1. T2R-TTL in complex with 13f.  
A) Surface representation of the 13f-tubulin complex. Various components are marked 
with arrows. B) Close up view of first a/β-tubulin heterodimer interface occupied with 
13f. The compound is shown in ball & stick model with orange carbons. Water and Mg 
are shown in ball model, GTP in thick sticks and amino acids in thin sticks. 2Fo-Fc map 
of the compound drawn at 1.0 Å. sigma is shown as green mesh. C) Interference of 13f 
with the tubulin straight conformation. The close-up view of superimposition of the 
tubulin-13f complex (blue ribbons-orange carbon balls, PDB ID: 6D88) and tubulin as 
found in straight protofilaments (grey ribbons, PDB ID: IJFF) shows that 13f binding is 
not compatible with the straight conformation. Conformational changes of the secondary 
elements in both subunits upon binding of 13f are labeled. D) Conformational changes at 
the colchicine-binding sites between colchicine (PDB: 4O2B), and 13f (PDB code: 
6D88). Superimposition of tubulin bound with 13f bound (shown in yellow) and with 
colchicine bound (shown in salmon). Crystallographic data obtained by Yuxi Wang 
(Sichuan University, China) and interpreted by Dr. Stephen White and Dr. Gyanendra 
Kumar (St. Jude Children’s Research Hospital). 
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Finally, the superimposition of 13f and colchicine bound to tubulin demonstrates that it 
overlaps well with colchicine in the binding pocket and supports a shared mechanism of 
action between colchicine and 13f (Figure 3-1D). 
 
 
Inhibition of Tubulin Polymerization and Microtubule Dynamics 
 
 To further validate their mechanism of action, we tested the effect of 10ab, 10bb, 
and 10f on polymerization of purified tubulin in a cell-free assay. 10 μM concentrations 
of 10ab, 10bb, and 10f were evaluated against vehicle-only control, colchicine, and 
docetaxel, which is a well-documented enhancer of polymerization. All three new 
VERU-111 analogs potently inhibited tubulin polymerization, while the vehicle 
experienced an initial and rapid increase in polymerization and docetaxel strongly and 
consistently promoted polymerization (Figure 3-2A). Colchicine, which was used as a 
positive control, showed similar activity as the 3 new compounds in tubulin inhibition. 
 
 The effect on microtubule networks was then observed by immunofluorescence 
via confocal microscopy. Microtubule morphology in WM-164 cells was visualized after 
18 hrs of treatment of with 100 nM of 10ab, 10bb, docetaxel, or untreated control cells. 
Unlike the control cells, 10ab and 10bb effectively disrupted microtubules, resulting in 
fragmentation and disassembly (Figure 3-2B). Docetaxel demonstrated the opposite 
effect, causing hyper-polymerization and resulting in the formation of dense, aggregated 
bundles of microtubules. These mechanistic studies confirm that these compounds 
maintain a mode of action by inhibiting tubulin assembly and interfering with 
microtubule dynamics. 
 
 
Inhibition of Cancer Growth and Migration 
 
 The long-term inhibitory growth effects of 10ab and 10bb were tested in A375 
cells in an anchorage-dependent colony formation assay. While the control cells averaged 
199.3 ± 10.7 colonies after 12 days, 5 nM concentrations of 10ab and 10bb decreased 
colony number, resulting in an average of 81.7 ± 7.8 and 128.3± 9.1 colonies, 
respectively (Figure 3-3A). These compounds even out-performed colchicine, which 
averaged 150.0 ± 5.3 colonies. There was a significant reduction in colony number for 
each compound-treated group, where colchicine, 10bb, and 10ab treatment resulted in a 
24.7%, 35.6%, and 59.5% decrease, respectively. Tubulin and microtubule function are 
also implicated in cell migration and motility. Therefore, we assessed the effect of 10ab 
and 10bb in a wound healing assay. After removing a confluent monolayer of adherent 
A375 or RPMI-7951 melanoma cells, cells were treated for 18-22 hrs with 5 or 25 nM of 
10ab, 10bb, or colchicine and compared against an untreated control. The total closure 
was calculated as a percentage of the total wound area after treatment compared to the 
total area of removed cells immediately prior to treatment. In A375 and RPMI-7951 cell 
lines, the control cells were able to efficiently migrate into the wound channel, recovering 
60.7% ± 5.9% and 71.8% ± 1.8% of the area, respectively (Figure 3-3B). Following 5  
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Figure 3-2. New VERU-111 analogs inhibit tubulin polymerization.  
A) Polymerization of purified tubulin in a cell-free assay. Tubulin (3.33 mg/ml) was 
exposed to vehicle control or 10 μM of the compounds (n=2). Absorbance at 340 nm was 
monitored at 37 °C every minute for 40 min. B) Effect on microtubules of WM-164 cells 
following 18h exposure to 100 nM of 10ab, 10bb, docetaxel or vehicle control. Confocal 
microscopy was utilized to visualize the microtubules following immunofluorescent 
staining. Microtubules are shown in red and DNA is shown in blue. Scale bar = 20 μm. 
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Figure 3-3. Inhibition of colony proliferation and cancer cell migration.  
A) A375 colony formation for control or treated cells represented as mean ± SD (n=3). B) Scratch migration assay for A375 (top) or 
RPMI-7951 (bottom) cells after treatment with 5 or 25 nM concentrations of 10ab, 10bb, colchicine, or untreated control represented 
as mean ± SD (n=3). Area of the wound channel was calculated using ImageJ software. Statistical analysis was performed by one-way 
ANOVA followed by Dunnett’s multiple comparison test (*P < 0.05, ** P < 0.01, *** P < 0.001, ****P < 0.0001). 
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nM treatment with 10ab, 10bb or colchicine, A375 cells only migrated into 49.4% ± 
1.6%, 38.5% ± 3.9%, and 46.0% ± 2.5% of the wound area, respectively. At higher 
concentrations of 25 nM, a greater inhibition was observed, where cells recovered 25.9% 
± 2.8%, 27.5% ± 6.2%, and 20.7% ± 3.8% for each of the tested compounds (P < 
0.0001). A significant difference was also observed in RPMI-7951 cells treated at 25 nM 
of 10ab, 10bb or colchicine, leading to wound closure averaging 35.6% ± 6.6%, 35.0% ± 
7.8%, and 42.8% ± 5.8%, respectively (P =0.0004). Averaging the results from both cell 
lines, the average inhibition of migration of cells treated at 25 nM concentrations with 
10ab, 10bb, and colchicine was 56.1%, 55.3%, and 34.0%. Taken together, these results 
demonstrate that 10ab and 10bb potently inhibit proliferation and migration in vitro at 
low nanomolar concentrations. 
 
 
In Vitro Metabolic Stability of VERU-111 Analogs 
 
 To determine the most suitable candidates for in vivo studies, we examined the in 
vitro metabolic stabilities of the most potent analogs by measuring their half-life upon 
incubation with mouse, rat and human liver microsomes in the presence of an NADPH 
regeneration system. The parent compound VERU-111 was used for comparison and 
Verapamil was used as a positive control. Overall, all three new VERU-111 analogs 
exhibited moderate to good stabilities in three different microsome species.  (Table 3-4). 
Compared to the parental compound, 10ab showed an improved half-life and clearance in 
human liver microsomes (6.7 ± 0.8 hrs, 3.1 mL/min/kg), whereas VERU-111 showed a 
half-life of 5.1 ± 0.3hrs and a clearance of 4.1 mL/min/kg. 10bb showed better stability 
compared to VERU-111 in all 3 species and, compared to 10ab, demonstrated an almost 
identical half-life and clearance in human liver microsomes and better metabolic 
stabilities in mouse and rat liver microsomes. 13f showed a slightly less stable profile 
than the other compounds (2.7± 0.3 hours and 7.7 mL/min/kg in human liver 
microsomes) but still displayed greater stabilities than the reference control. Based on the 
in vitro and stability assessment, we selected 10bb to undergo testing in animal models. 
Because of its unique modification to the TMP moiety, 13f was also selected for in vivo 
evaluation to determine if the strong anticancer efficacy demonstrated in vitro would also 
be evident in animal models. 
 
 
Anticancer Efficacy in Melanoma Mouse Models Without Toxicity.  
 
 The antitumor efficacies of 10bb and 13f were evaluated in two melanoma 
xenograft mouse models. Nude mice bearing A375 melanoma tumors were treated every 
other day via i.p. injection with 15 mg/kg or 30 mg/kg doses of 10bb, 13f, paclitaxel, or 
given a vehicle solution only. The average TGI for the groups treated with 15 mg/kg and 
30 mg/kg of 13f was 54.8% and 73.9%, respectively. These results were similar to the 
paclitaxel-treated group, which showed an average TGI of 70.7% (Figure 3-4A).  In a 
separate in vivo study, the group receiving 15 mg/kg of 10bb achieved an average tumor 
growth inhibition of 82.3% and the group receiving the higher dose of 30 mg/kg achieved  
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Table 3-4. In vitro metabolic stabilities of compound 10ab, 10bb, and 13f in liver 
microsomes. 
 
Compound 
Metabolic Stability 
(Human) 
 Metabolic Stability 
(Mouse) 
 Metabolic Stability 
(Rat) 
 t1/2 
(hr) 
Clint  
(mL/min/kg) 
 t1/2 
(hr) 
Clint 
(mL/min/kg) 
 t1/2 
(hr) 
Clint 
(mL/min/kg) 
VERU-111 5.13 ± 0.26 4.05 
 
3.76 ± 0.24 15.20 
 
6.74 ± 0.59 6.94 
10ab 6.70 ± 0.82 3.10 
 
2.42 ± 0.15 23.60 
 
1.80 ± 0.09 25.98 
10bb 6.72 ± 0.74 3.10 
 
5.04 ± 0.30 11.34 
 
29.93 ± 7.82 1.56 
13f 2.69 ± 0.26 7.70 
 
1.42 ± 0.14 40.30 
 
3.57 ± 0.43 13.10 
Verapamil 1.68 ± 0.16 12.41 
 
0.94 ± 0.06 60.66 
 
1.29 ± 0.09 36.18 
 
Data obtained by Lei Yang (St. Jude Children’s Research Hospital). 
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Figure 3-4. Anticancer efficacy of VERU-111 analogs in melanoma mouse models.  
A) 13f and B) 10bb treatments in A375 xenograft models in nude mice represented as mean tumor volume ± SEM. (n=8 and n=10, 
respectively). Statistical significance for final tumor volumes in both studies was determined by one-way ANOVA analysis followed 
by Dunnett’s multiple comparison test for the treatment group compared with the corresponded results of the control group (*P < .05, 
** P < 0.01, *** P < 0.001, ****P < 0.0001). C) 10bb inhibits B16F10 lung metastasis in C57BL/6 mice. The graph represents the 
tumor index for mice (n=10) and error bars represent 95% CIs. An unpaired student’s t-test was performed to show statistical 
significance between the groups (P= 0.0013). Mouse body weights are represented as a percent of weight change compared to initial 
weight ± SEM for each study. 
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a TGI of 90.6% (Figure 3-4B). Both groups achieved significantly greater tumor growth 
inhibition than the paclitaxel group, which averaged a TGI of 68.6%. Because it showed 
the most potent effect on tumor growth inhibition, we investigated the ability of 10bb to 
inhibit metastatic potential in a lung metastasis mouse model at 30 mg/kg doses in 
C57BL/6 mice against a vehicle control group (Figure 3-4C.) After inoculation with the 
melanoma via the lateral tail vein, mice were treated for two weeks with the same dosing 
regimen. The average tumor index based on lung metastasis nodule size and the number 
was 13.6 ± 2.9 for the control group and 2.6 ± 0.6 for the 10bb treatment group. This was 
significantly less than the control based on an unpaired student’s t test (P = 0.0013) and 
represents an 80.9% decrease in metastasis. Mouse weight and activity were monitored 
and for both xenograft models and the lung metastasis model, and major weight 
deviations were not observed. Histopathology analysis was performed on major organs 
collected from both in vivo studies to assess for acute toxicities from 10bb treatment. 
H&E stained sections revealed no apparent drug-related injury or pathological changes in 
the cellular structure of the various tissues from both the xenograft mouse model and the 
experimental lung metastasis mouse model (Figure 3-5A). Additionally, in vitro 
pharmacological profiling was utilized to identify undesirable off-target effects and 
determine the safety profile. 10bb was evaluated at 1 μM in the Safety47™ Panel which 
includes the assessment of the functional response of 47 major physiologically important 
targets (Figure 3-5B). 10bb only showed positive responses (higher than |70%|) in 2 of 
the 78 assays, which were norepinephrine transporter (NET) and serotonin receptor 2B 
(HTR2B) antagonism. 
 
 
Circumventing Taxane Resistance 
 
 Because of its promising in vivo antitumor potency and initial findings 
demonstrating that taxane resistant cells were still highly sensitive to 10bb treatment, we 
wanted to confirm that 10bb could be an effective treatment to taxane-resistant tumors. 
We previously demonstrated that paclitaxel is an effective treatment against PC-3 
xenograft tumors in a nude mouse model but was ineffective against the taxane resistant 
PC-3/TxR xenograft tumors (previously shown in Figure 2-8A). We hypothesized that 
10bb would show high efficacy in the resistant xenograft model and that paclitaxel would 
fail, providing support for the development of 10bb in resistant chemotypes. Therefore, 
we proceeded to test 10bb at the same dosing concentration and frequency as in the 
previous models (30mg/kg, every other day via i.p. injection) in comparison to paclitaxel 
at 15 mg/kg, a dose that was shown to be highly effective against non-resistant cancer 
xenograft models. Paclitaxel showed a marked decline in anticancer capabilities, yielding 
a TGI of only 37.8% and a modest reduction in tumor weight of only 34.5% (Figure  
3-6A-C). In contrast, treatment with 10bb caused a significant reduction in tumor growth 
by 83.8% and decreased average tumor weight by 62.8%. ANOVA analysis (P < 0.0001) 
followed by Dunnett’s multiple comparison test confirmed a significant decrease in final 
tumor volume and weight (P < 0.0001) for the 10bb treated groups without causing 
significant loss of body weight or animal activity (Figure 3-6D). This further validates 
10bb as an alternative treatment to taxane-resistant cancers. 
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Figure 3-5. Toxicity and safety assessment for 10bb.  
A) Pathological sections of major tissues (heart, kidney, liver, lung, and spleen) were 
obtained from the A375 xenograft (top) and B16F10 lung metastasis (bottom) studies. 
Organs were H&E stained, and representative images of the tissues were captured. B) In 
vitro pharmacological profiling of 10bb to assess potential off-target effects to major 
targets at 1μM concentrations using the Safety47™ Panel (n=2). Graph represents mean 
% response ± range. Values in between -70% and +70% (indicated with dashed lines) are 
considered insignificant. 
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Figure 3-6. Antitumor efficacy of 10bb in a taxane-resistant xenograft model.  
A) Tumor volumes for the PC-3/TxR xenograft model shown as mean volume ± SEM 
(n=8). B) Final tumor weights for PC-3/TxR mice. Error bars represent 95% CIs. 
Statistical significance for final tumor volumes and weights were determined by one-way 
ANOVA analysis followed by Dunnett’s multiple comparison test (*P < .05, ****P < 
0.0001). C) Representative images of resected tumors at the end of the study. D) Mouse 
body weights represented as mean weight change as a percentage compared to initial 
weight ± SEM. 
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Conclusions 
 
 In this research, an extensive SAR investigation of VERU-111 focusing on the 
modification of the indole moiety is reported, revealing that 10ab and 10bb are more 
potent derivatives than prototype VERU-111. We also conducted SAR on the TMP 
modification series. While modifying the TMP moiety of colchicine binding site 
inhibitors is usually unsuccessful in improving antiproliferative activities, our results 
showed that isosteric (conformationally restricted) replacement of the TMP is feasible to 
significantly increase the potency in this scaffold. We identified the analog 13f, 
containing a unique 3-methoxybenzo[4,5]-dioxene moiety, that demonstrated more potent 
antiproliferative activity than VERU-111. Additionally, compared to paclitaxel, these 
lead compounds showed significantly improved resistance indexes against taxane-
resistance prostate cancer cell lines, suggesting their potential against drug-resistant 
phenotypes. 
 
 The X-ray crystal structure of tubulin in complex with 13f, the visualization of 
disrupted microtubule networks of cells after treatment with 10ab and 10bb, and the 
potent inhibition of tubulin polymerization by all 3 compounds in a tubulin assay all 
support that these compounds have the same mechanism of action as colchicine. The 
crystallographic analysis is particularly valuable because it revealed that the interactions 
between 13f and tubulin are centered on a hydrogen-bonding network, which provides 
potential avenues for future modifications to improve potency. 
 
 10bb and 13f were selected for in vivo efficacy studies and drastically inhibited 
tumor growth in melanoma xenografts. 10bb also reduced lung metastasis without 
causing signs of toxicity. Finally, 10bb treatment was effective in a PC-3/TxR prostate 
cancer model, suggesting its ability to circumvent certain MDR mechanisms that nullify 
paclitaxel action. In conclusion, we have developed improved analogs of VERU-111 by 
optimizing substitutions through SAR investigation and demonstrated the feasibility of 
modifying the TMP moiety for enhanced activity. We confirmed their mechanism of 
action and in vivo potency, supporting their development as potential new candidates 
targeting the colchicine binding site for cancer treatment.  
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CHAPTER 4.    NOVEL TUBULIN INHIBITORS WITH A HETEROCYCLIC 
PYRIMIDINE SCAFFOLD SHOW VASCULAR DISRUPTING PROPERTIES3  
 
 
Introduction  
 
 Disrupting tubulin dynamics is a well-validated strategy for anticancer therapy 
(54, 145, 172, 242-249). The three widely studied binding sites in tubulin are the 
paclitaxel site, the vinca alkaloid site, and the colchicine site (39, 54). Currently, all FDA 
approved tubulin inhibitors for cancer treatment target either the taxane site (e.g. 
paclitaxel, docetaxel) or the vinca alkaloid site (e.g. vinblastine, vincristine). Colchicine 
binding site agents have advantages over other classes of tubulin inhibitors, including 
reduced susceptibility to MDR from ABC transporter overexpression and upregulation of 
the βIII tubulin isoform (explained in detail in Chapter 1). However, the potential clinical 
applications of many colchicine site tubulin inhibitors have been halted due to significant 
toxicities, low solubility, and low bioavailability (23, 39, 54, 214, 244). There have been 
extensive research efforts to identify new small molecules capable of acting at the 
colchicine binding site with improved therapeutic indexes.  Additionally, there have been 
numerous reports that tubulin inhibitors targeting the colchicine binding site exhibit 
promising vascular disrupting effects in addition to inhibiting tumor cell invasion and 
metastasis (39, 98, 141, 145, 172, 243, 250). Vascular disrupting agents (VDAs) are 
known to rapidly disrupt existing tumor vessels resulting in prompt vascular collapse and 
tumor cell death (39, 40, 251). Thus, there has been substantial interest in this class of 
tubulin inhibitors, since newer generations of tubulin inhibitors can be developed that can 
overcome the limitations of the existing tubulin inhibitors by evading MDR and reducing 
toxicity (39, 40). 
 
 A number of small molecule vascular disrupting agents targeting the colchicine 
binding site are currently in clinical development as anticancer agents (Figure 4-1, 
compounds 1a-1c) (39, 40). Out these VDAs, Azixa/Verubulin (1a) and its derivatives 
have drawn considerable attention in the recent years (101). Azixa emerged a few years 
ago as a very potent tubulin polymerization inhibitor, and it has been observed to act as a 
VDA by introducing rapid shut down of tumor blood flow and consequently inhibits the 
tumor growth (39, 40, 101, 102). Azixa has demonstrated low nanomolar potency against 
diverse tumor models, including melanoma, brain cancer, ovarian cancer, small cell lung 
cancer, and prostate cancer (102, 252, 253). Recently, Mueller et al. reported an indole 
derivative of Azixa/Verubulin (1d) that induced significant vascular disruption in the 
1411 HP germ cell xenograft tumors, leading to rapid tumor necrosis (102). Gangjee et 
al. have reported Azixa derivatives (1e) that are dual inhibitors of tubulin and vascular  
                                                 
 
3Modified with permission from American Chemical Society. Souvik Banerjee*, Kinsie E. Arnst*, Yuxi 
Wang*, Gyanendra Kumar, Shanshan Deng, Lei Yang, Guo-bo Li, Jinliang Yang, Stephen W. White, Wei 
Li, and Duane D. Miller. Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors 
Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy 
Journal of Medicinal Chemistry. 2018; 61 (4), 1704-1718. 
*Equally contributing authors. 
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Figure 4-1. Recently developed VDAs that target the colchicine binding site. 
Three are currently in clinical trials (1a, 1b, and 1c) and three reported derivatives of 
Azixa/Verubulin are in pre-clinical development (1d, 1e, and 1f). 
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endothelial growth factor receptor-2 (VEGFR2) (242). These dual actions produced 
significant reduction in tumor size and disruption of vascularity in three mouse xenograft 
models. 
 
 However, most of the quinazoline analogs reported by Xie et al. have shown low 
metabolic stability in human liver microsomes (t1/2 ≤ 10 minutes) and substantial in vivo 
toxicity, with MTDs less than 4 mg/kg (145). Although Azixa and many of its derivatives 
are highly effective as tubulin inhibitors and VDAs, none of them have successfully made 
it through clinical trials. One of major concerns limiting the clinical progression of Azixa 
is the cardiovascular toxicities that it demonstrated in Phase I and Phase II studies (254). 
The identified cardiovascular toxicities include grade 1-3 hypertension, atrial fibrillation, 
grade 3-4 myocardial infarction, grade 4 non-ST-elevation myocardial infarction, and 
grade 3 cerebral haemorrhage (254, 255). Additionally, while Azixa demonstrates 
excellent potency against cancer cells, it also shows potential high toxicity to normal 
tissues. 
 
 To the improve the therapeutic index of tubulin inhibitors based on the scaffolds 
of Azixa or its reported analogs, we set the goal to design new Azixa analogs with: (a) 
equal or higher potency than existing Azixa analogs; (b) substantially reduced toxicities 
as tested in mouse models; (c) significantly improved metabolic stability; and (d) high 
efficacy against clinically relevant MDR models. We selected our starting point based on 
the 1f scaffold reported by Lee and Xie et al. because of its reduced conformational 
flexibility compared with all other Azixa analogs (145). We revealed the structural 
modifications from lead compound 1f that yielded highly potent heterocyclic pyrimidines 
and their comprehensive in vitro and in vivo anticancer activities. Lead compounds 4a, 
6a, 5a, and 5b were selected out of the series as the molecules with the greatest potential 
and underwent additional biological investigation. To confirm the direct binding of these 
new analogs to tubulin and determine their molecular interactions, we obtained the high-
resolution crystal structures of 4a, and 6a in complex with tubulin protein. To the best of 
our knowledge, this is the was the first X-ray crystal structure reported for Azixa analogs 
bound to tubulin. Importantly, contrary to all previously published molecular modelling 
studies for Azixa or its analogs, these high-resolution X-ray crystal structures reveal a 
different actual binding pose, along with significant conformational changes, in the 
colchicine binding pocket in tubulin (102, 145, 167, 250, 256). Results from this study 
provide important structural basis for the molecular interactions and enable future 
structure-based optimization for the general Azixa scaffold. Additional mechanistic 
studies of 4a, 6a, 5a and 5b reveal that they share the same mechanism of action as 
colchicine as tubulin polymerization inhibitors that arrest cells in the G2/M phase of the 
cell cycle, interfere with cellular functions such as migration and proliferation, and 
enhance apoptotic cascades. 4a was evaluated in two animal models against melanoma 
and paclitaxel-resistant tumors, emphasizing the potential of this scaffold to overcome 
multidrug resistance for cancer therapy. Finally, we confirmed ability of 4a to elicit 
vascular disrupting effects within tumors and against endothelial capillary-like network 
formation.  
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Materials and Methods 
 
 
Cell Culture and Reagents 
 
 Human melanoma cell lines (A375, M14, RPMI-7951, WM-164, SK-MEL-1, 
M14/MDR1) and breast cancer cell lines (MDA-MB-453, MDA-MB-231, MDA-MB-
468) (American Type Culture Collection or ATCC, Manassas, VA, USA) were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) (Corning, Manassas, VA) 
supplemented with 10% (v/v) fetal bovine serum (FBS) (Atlanta Biologicals, 
Lawrenceville, GA) and 1% antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis 
MO). Human lung cancer cell lines (A549, H460, H1299) American Type Culture 
Collection or ATCC, Manassas, VA, USA) were cultured in RPMI 1640 medium (Gibco 
by Life Technologies, Carlsbad, CA) supplemented with 10% (v/v) FBS and 1% 
antibiotic/antimycotic mixture (Sigma-Aldrich, St. Louis MO). Parental prostate cancer 
PC-3, its paclitaxel-resistant daughter line PC-3/TxR, parental prostate cancer DU-145, 
and its docetaxel-resistant daughter line DU-145/TxR were gifts from Dr. Evan Keller at 
the University of Michigan Medical School. PC-3 and DU-145 cell lines were cultured in 
RPMI 1640 medium supplemented with 10% FBS and 1% antibiotic/antimycotic 
mixture. Taxane-resistant PC-3/TxR and DU-145/TxR cell lines were cultured in the 
same medium and additionally supplemented with 10 nM paclitaxel or docetaxel, 
respectively. Paclitaxel or docetaxel was not included in the medium for PC-3/TxR or 
DU-145/TxR for at least 1 week prior to in vitro and in vivo testing. All cell lines were 
authenticated by ATCC by short tandem repeat profiling. Cultures were maintained to 
80–90% confluency at 37 °C in a humidified atmosphere containing 5% CO2. 
Compounds were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, 
MO) to make a stock solution of 20 mM. Compound solutions were freshly prepared by 
diluting stocks with cell culture medium before use. 
 
 
Cytotoxicity Assays 
 
 Cells were seeded in 96-well plates at a concentration of 2000–5000 cells per 
well, depending on growth rate of the cell line. After overnight incubation, the medium 
was replaced, and cells were treated with the test compounds at 10 concentrations ranging 
from 0.03 nM to 1 μM plus a vehicle (DMSO) control for 72 hrs in four replicates. 
Following treatment, the MTS reagent (Promega, Madison, WI) was added to the cells 
and incubated in dark at 37 °C for at least 1 hr. Absorbance at 490 nm was measured 
using a plate reader (BioTek Instraments Inc., Winooski, VT). IC50 values were 
calculated by nonlinear regression analysis using GraphPad Prism (GraphPad Software, 
San Diego, CA). 
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Microsomal Stability Assay 
 
 Liver microsome assays were performed by Dr. Lei Yang (St. Jude Children’s 
Research Hospital). For each test compound, the human liver microsomal solution was 
prepared by adding 0.058 mL of concentrated human liver microsomes (20 mg/mL 
protein concentration) to 1.756 mL of 0.1 M potassium phosphate buffer (pH 7.4) 
containing 5 μL of 0.5 M EDTA to make a 0.6381 mg/mL (protein) microsomal solution. 
Each test compound (2.2 μL of 10 mM DMSO solution) was added directly to 1.79 mL 
of human liver microsomal solution, and 90 μL was transferred to wells in 96-well plates 
(0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The NADPH regenerating agent 
was prepared by mixing 0.113 mL of NADPH regenerating agent solution A, 0.023 mL 
of solution B, and 0.315 mL of 0.1 M potassium phosphate buffer (pH 7.4) for each 
tested compound. To each well of the 96-well plate, 22.5 μL of the NADPH regenerating 
agent was added to initiate the reaction, and the plate was incubated at 37 °C for each 
time point. The reaction was quenched by adding 225 μL of cold acetonitrile containing 
warfarin (4 μg/mL) as internal control to each well. All of the plates were centrifuged at 
4000 rpm for 20 min, and the supernatants (100 μL) were transferred to another 96-well 
plate for analysis on UPLC–MS (Waters Acquity UPLC linked to Waters Acquity 
photodiode array detector and Waters Acquity single quadrupole mass detector) on 
Acquity UPLC BEH C18 1.7 μm (2.1 mm × 50 mm) column by running 90–5% gradient 
for water (+0.1% formic acid) and acetonitrile (+0.1% formic acid). The area under the 
single ion recording (SIR) channel for the test compound divided by the area under the 
SIR for internal control at 0 time concentration was considered as 100% to calculate 
remaining concentration at other time points. The terminal phase rate constant (ke) was 
estimated by linear regression of logarithmic transformed concentration versus the data, 
where ke = slope × (−ln 10). The half-life t1/2 was calculated as ln 2/ke. 
 
 
Tubulin Polymerization Assay 
 
 The polymerization reaction contains 100 ul of volume of Bovine brain tubulin (3 
mg/ml) (Cytoskeleton, Denver, CO) and 10 μM of the test compounds in general tubulin 
buffer (80 mM PIPES, 2.0 mM MgCl2, 0.5 mM EGTA, and 1 mM GTP) at pH 6.9. The 
absorbance of wavelength at 340 nm was monitored every 1 min for 50 min by the 
SYNERGY 4 Microplate Reader (Bio-Tek Instruments, Winooski, VT). BioTek Gen5 
data analysis software was used to calculate the Vmax values. The spectrophotometer was 
set at 37 °C for tubulin polymerization. 
 
 
Confocal Microscopy 
 
 WM-164 cells were seeded on glass coverslips in six-well plates (125 000 
cells/well) and incubated overnight. Cells were treated with 100 nM compounds or 
equivalent vehicle (DMSO) control for 18 h. Microtubules were visualized after 
incubating with anti-α-tubulin antibody (Thermo Scientific, Rockford, IL) and Alexa 
Fluor 647 goat anti-mouse IgG (Molecular Probes, Eugene, OR). The coverslips were 
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mounted with Prolong Diamond Antifade mounting medium with DAPI (Invitrogen, 
Eugene, OR) and images acquired with a Zeiss 710 confocal microscope and Zen 
imaging software (Zeiss, Thornwood, NY). 
 
 
X-Ray Crystallography Method 
 
 Protein Expression and Purification. X-Ray crystallography was performed by 
Dr. Yuxi Wang (Sichuan University, in China). The stathmin-like domain of RB3(RB3-
SLD) was overexpressed in E. coli and purified by anion-exchange chromatography and 
gel filtration chromatography. The final sample was concentrated to 10 mg/mL and 
stored at -80 ?. The TTL protein was also expressed and purified from an E. coli 
expression system as described previously (Section 2.2.7-2.2.8.) The final sample was 
concentrated to 20 mg/ml and saved at -80 ?. The purity of RB3 and TTL were assessed 
by SDS-PAGE. Porcine brain tubulin (Catalog # T-238P, Cytoskeleton, Inc.) was 
supplied at 10 mg/ml in G-PEM (General tubulin buffer: 80 mM PIPES pH 6.9, 2 mM 
MgCl2, 0.5 mM EGTA and 1 mM GTP) as a frozen liquid and saved at -80 ? until use.  
 
 Crystallization and Crystal Soaking. Crystals of T2R-TTL were obtained by 
vapor diffusion using the sitting-drop method following published protocols. Briefly, the 
protein solution containing tubulin (10 mg/ml), TTL (20 mg/ml) and RB3 (6 mg/ml) at 
the molar ratio of 2 : 1.3 : 1.2 (tubulin:RB3:TTL) was incubated on ice, supplemented 
with 1 mM AMPPCP, 5 mM tyrosinol and 10 mM DTT, and then concentrated to 20 
mg/ml at 4 ?. Crystallization drops contained equal volumes (1.0 μl) of the T2R-TTL 
protein solution and the precipitant solution (6% PEG, 5% glycerol, 0.1 M MES, 30 mM 
CaCl2, 30 mM MgCl2, pH 6.7) and were incubated at 20 ?. The seeding method was 
used to obtain single crystals. Crystals appeared after two days and grew to 200-300 μm 
within 3-5 days. Compounds were soaked into the crystals to obtain the complex 
structures. Each compound (4a and 6a) was dissolved in DMSO at 10 mM concentration 
and 0.1 μl was added to the mother liquor at 20 ? for 12 h. The crystals were 
cryoprotected in 20% glycerol (30 mM MgCl2, 30 mM CaCl2,0.1 M MES, 20% glycerol, 
pH 6.7) and flash-frozen at 100 K for synchrotron X-ray data collection. 
 
 X-Ray Data Collection and Structure Determination. Crystals of the T2R-
TTL-ligand complexes were mounted in nylon loops and maintained at 100 K in a 
nitrogen stream. Diffraction data were collected on beamlines BL17U1 and BL19U1 at 
Shanghai Synchrotron Radiation Facility (SSRF) in Shanghai, China. Data were indexed, 
integrated and scaled using HKL2000. Initial phases were determined by molecular 
replacement using the previously published T2R-TTL structure (PDB ID: 4I55) as a 
template. The initial model was completed manually using Coot and iteratively refined 
with the phenix refine module of the Phenix program (191). The final quality of the 
structure was checked and validated using the PDB validation server. Analysis was 
determined in coordination with Dr. Stephen White’s group (St. Jude Children’ Research 
Hospital). 
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Colony Assay 
 
 To test the effects of clonogenic potential and proliferation, A375 cells were 
seeded in 6 well plates at a density of 500 cells/well (n=4). After overnight incubation in 
at 37 °C cells were treated with the compound or media only control and incubated for 10 
days. Cells were then fixed with methanol and stained with 0.5% crystal violet. Images 
were taken, and colony area was quantified with ImageJ software (NIH, Bethesda, MD).   
 
 
Endothelial Cell Tube Formation Assay  
 
 Matrigel (Corning, Manassas, VA) was thawed on ice overnight then diluted with 
serum-free media for a final concentration of 10 mg/mL. Matrigel (50 μl) was plated in 
96 well plates and incubated at 37 °C for 1 hr. Low passage number HUVECs (<5) in 
logarithmic growth phase were trypsinized and suspended in endothelial cell growth 
media. Cells (1.5 x104 suspended in 50 μl) were plated on the Matrigel plates in 
quadruplicate containing the desired drug concentrations. Images were captured after 4 hr 
incubation with Evos Fl Imaging System (LifeTechnologies, Carlsbad, CA). Analysis 
was performed with angiogenesis tool plug-in with ImageJ software (NIH, Bethesda, 
MD). 
 
 
Wound Healing Assay 
 
 A375 and RPMI-7951 cells were seeded in 12-well plates (200 000 cells/well) in 
replicates of 3 and incubated overnight. Using a 200 μL pipet tip, a straight line was 
scratched through the cell monolayer to remove an area of cells, and cells were washed 
several times to remove any debris and uprooted cells. Medium was replaced containing 
5 or 25 nM of 4a or colchicine. Control wells received medium without drug. Images 
were obtained at 0 h and 18 h (RPMI-7951 cells) and 22 h (A375 cells) with Evos Fl 
imaging system (Life Technologies, Carlsbad, CA). Analysis of the scratch area was 
performed with ImageJ software (NIH, Bethesda, MD). 
 
 For real time cell migration analysis, A75 or M14 cells were seeded 96-well 
Image-Lock plates (Essen bioscience, Ann Arbor, MI) at a density of 30,000 cells/well 
and incubated overnight. The WoundMaker™ tool (Essen bioscience, Ann Arbor, MI) 
was used to create uniform identical scratches in all the wells of a 96-well plate. After 
creating the wound, the medium was aspirated, and the wells were washed twice with 
fresh medium to remove any cell that had been uprooted from the scratched area. 100 μL 
of medium containing the indicated concentrations of the 5a or colchicine were then 
added to each well (n=4). The plate was fitted into the IncuCyte Imaging System 
chamber, and images of the cell migration were recorded every 2 hours for a total 
duration of 24 hours. The affiliated IncuCyte ZOOM™ live cell imaging software 
calculated scratch closure in real time and determined the relative wound density within 
the scratch-channel area at each time point. The relative wound density was calculated as 
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the ratio of the occupied area compared to the total area of the initial scratched area. Rate 
of change was calculated as % change in relative wound density/ hour. 
 
 
Cell Cycle Analysis 
 
 To determine cell cycle distributions in the G2 and M phases, 1 x 106 cells A375 
cells plated in 10 cm tissue culture-treated dishes, incubated overnight, and then serum-
starved for 24 hours to synchronize. They were then treated for 24 hrs with 10 or 50 nM 
of drug in full media. Cells were harvested with trypsin, fixed with 4% 
paraformaldehyde, and stained using P-Histone H3 rabbit antibody (Cell Signaling 
Technologies, Danvers, MA) and Alexafluor-488 secondary antibody AlexaFluor® 488 
IgG (Invitrogen, Eugene, OR) followed by stained using PI/RNase solution (Sigma, 
Sigma-Aldrich, St. Louis MO) for 30 minutes at room temperature and protected from 
light. Data was collected with Bio-Rad ZE5 flow cytometer (Bio-Rad, Hercules, CA) and 
the acquisition software used was Everest v2.1.07, plotting at least 20,000 events per 
sample. Analysis was performed using FlowJo v10.3. 
 
 
Apoptosis Assay 
 
 A375 cells were seeded, treated, and harvested in the same manner as described 
above. Apoptosis analysis was performed using the Annexin V-FITC Apoptosis 
Detection Kit (Abcam, Cambridge, MA) as per manufactures instructions utilizing 
fluorochrome-conjugated annexin V and propidium iodide solution. Data was collected 
with Bio-Rad ZE5 flow cytometer (Bio-Rad, Hercules, CA) and the acquisition software 
used was Everest v2.1.07, plotting at least15,000 events per sample. Analysis was 
performed using FlowJo v10.3. 
 
 
Western Blot 
?
 1 x 106 cells A375 or M14 cells were seeded in 10 cm tissue culture-treated 
dishes, incubated overnight, then treated for 24 hours with indicated compounds and 
concentrations of 0, 15, 40, or 100 nM. Harvested cells were collected in RIPA lysis 
buffer including protease inhibitors and sonicated. The lysates were centrifuged at 13,000 
? g for 15 min at 4 °C. The concentration of total protein was measured using the BCA 
assay method and absorbance was read at 562 nm on a plate reader (BioTek Instruments 
Inc., Winooski, VT)(n=2). Protein samples were separated with 15% SDS-PAGE and 
transferred onto the methanol-activated PVDF membranes. Primary antibodies PARP, c-
PARP, Akt, p-Akt, PH3, and GAPDH and secondary anti-rabbit and anti-mouse were all 
obtained from Cell Signaling Technologies (Danvers, MA.) Images were obtained using 
the ChemiDoc-It2 Imaging System (Bio-Rad, Hercules, CA). 
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In Vivo Xenograft Studies 
 
 All animal experiments were performed in accordance with the NIH animal use 
guidelines and protocol approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Tennessee Health Science Center (UTHSC, Memphis, TN). 
Nude mice, 6–8 weeks old, were purchased from Envigo. We first estimated the acute 
MTD for 4a and 6a formulated in PEG300. The MTD following a single dose was 
estimated to be at least 100 mg/kg for 4a and at least 60 mg/kg for 6a. To ensure an 
adequate safety margin for the xenograft study, the maximum dose was scaled down to 
30 mg/kg for 4a and 15 mg/kg for 6a. 
 
 Logarithmic growth phase A375, PC-3, or PC-3/TxR was prepared in phenyl red-
free, FBS-free medium and mixed with Matrigel immediately before injecting into mice. 
Tumors were established by injecting 100 μL of this mixture subcutaneously in the dorsal 
flank of each mouse (2 × 106 A375 cells or 2.5 × 106 prostate cancer cells). After tumor 
volumes reached approximately 100 mm3 mice were randomized into control or 
treatment groups (n = 8 for A375 and PC-3 model, n = 7 for PC-3/TxR xenograft model). 
4a, 6a, or paclitaxel was dissolved in a 2:1 ratio of PEG300/PBS solution to produce 
desired concentrations. The vehicle control solution was formulated with equal parts 
PEG300 and PBS only. 100 μL of the drug treatment or vehicle control was administered 
via i.p. injection every other day for 2–3 weeks. 
 
 Tumor volume was measured three times a week with a caliper and calculated by 
using the formula a × b2 × 0.5, where a and b represented the larger and smaller 
diameters, respectively. Tumor growth inhibition (TGI) at the conclusion of the 
experiments was calculated as 100 – 100 × ((T – T0)/(C – C0)), where T, T0, C, and C0 are 
the mean tumor volume for the specific group on the last day of treatment, mean tumor 
volume of the same group on the first day of treatment, mean tumor volume for the 
vehicle control group on the last day of treatment, and mean tumor volume for the vehicle 
control group on the first day of treatment, respectively. Animal activity and body 
weights were monitored during the entire experiment period to assess potential acute 
toxicity. At the end of the experiment, mice were sacrificed and the tumors were 
weighed. Tumors and tissues were dissected out and fixed in 10% buffered formalin 
phosphate solution prior to pathology staining analysis. 
 
 
Histology and Immunohistochemistry 
 
 The fixed tumor xenograft tissues were embedded in paraffin. Serial sections were 
obtained and stained with hematoxylin and eosin (H&E) and immunohistochemistry. IHC 
staining was performed with rabbit anti-cleaved caspase 3 antibody (Cell Signaling 
Technology Inc., Danvers, MA) and rabbit anti-CD31 (Cell Signaling Technology Inc., 
Danvers, MA) following ABC-DAB methods. Antigen retrieval was performed with H-
3300 antigen unmasking solution (Vector Laboratories, Burlingame, CA). Slides were 
scanned, and representative images were obtained at 100× magnification with Aperio 
ImageScope (Lecia Biosystems Inc., Buffalo Grove, IL). 
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Statistical Analysis and Calculations 
 
 Data was analyzed using Prism Software 5.0 (GraphPad Software, Inc., San 
Diego, CA). Data was provided as mean ± SD unless otherwise indicated. Non-linear 
regression of transformed data was used to calculate IC50 values for cytotoxicity assays. 
Log P was calculated using Schrödinger Molecular Modeling Suite (Schrödinger LLC, 
New York). The statistical significance (P < 0.05) was calculated by one-way ANOVA 
followed by Dunnett’s multiple comparison test, comparing each treated group at the 
final time point to the control group for the migration, colony, capillary-like formation in 
vitro assays, and the tumor weight and final tumor volume in vivo studies.  
 
 
Results and Discussion 
 
 
Drug Design, Potency, and Metabolic Stability 
 
 We designated a four-ring system similar to 1f, and the starting scaffold (ring A in 
red, ring B in purple, ring C in green, and ring D in pink) is shown at the top of Table  
4-1. First, we designed and synthesized a series of seven heteropyrimidine derivatives 
with a diverse A/B ring. These include pyridopyrimidines (4a and 4b), furopyrimidine 
(6a), thiophenopyrimidine (6b), N-Methyl-pyrazolopyrimidine (8a), N-methyl-purine 
(10), and 1H-pyrazolopyrimidine derivatives (14). The two pyridopyrimidines, 4a and 
4b, showed exceptional IC50 values against melanoma cell lines (IC50 ~ 6 nM) and 4b 
(IC50 ~ 4 nM) relative to the lead 1d (IC50 ~ 2 nM). These compounds also showed 
increased water solubility (1d; logP = 4.5, 4a; logP = 3.7, 4b; logP = 4.0). The 
furopyrimidine compound, 6a, also was highly active against the 3 tested cancer cell 
lines, with an average IC50 of 3.9 nM.  
 
 Next, we synthesized three C ring modified derivatives, including a keto-
pyridopyrimidine (16), alcohol-pyridopyrimidine (17) and a morpholino-
pyridopyrimidine (19). While the alcohol-pyridopyrimidine showed moderate potency, 
with an average IC50 of 45.5 nM, the other modifications were detrimental to activity 
(Table 4-1). 
 
 Then, we investigated a series of modifications that involved opening the C ring, 
and increasing the number of methoxy substituents on ring D, since many reported 
tubulin inhibitors, including colchicine, contain trimethoxy groups. Dimethoxy (21a), 
trimethoxy (21b) and dioxymethylene (23) and naphthyridin (25) analogs were 
synthesized. The dimethoxy compound (21a) was found to possess moderate activity 
with an IC50 value 42 nM, however, the more sterically hindered trimethoxy compound 
(21b), the dioxymethylene compound (23) was and the naphthyridin compound (25) had 
reduced or abolished activity against cancer cells (Table 4-1).  
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Table 4-1. Cytotoxic effects heterocyclic-fused pyrimidine analogs against 
malignant melanoma cancer cell lines and log P values.  
 
 
ID Structure 
IC50 ± SEM (nM) 
aLog 
P 
A375 M14 RPMI-7951 Average 
A/B ring 
4a 
 
5.6 ± 1.6 5.5 ± 1.0 8.2 ± 1.5 6.4 3.7 
4b 
 
4.0 ± 0.2 4.2 ± 0.8 4.4 ± 0.6 4.2 4 
6a 
 
3.2 ± 0.5 3.3 ± 0.4 5.1 ± 0.9 3.9 3.9 
6b 
 
49.0 ± 3.3 52.6 ± 5.6 91.3 ± 9.8 64.3 4.8 
8a 
 
> 1000 > 1000 > 1000 > 1000 3.8 
8b 
 
16.1 ± 1.4 18.8 ± 1.0 17.6 ± 1.1 17.5 2.8 
10 
 
39.6 ± 2.9 41.2 ± 3.2 58.9 ± 3.1 46.6 3.4 
14 
 
> 1000 > 1000 > 1000 > 1000 2.9 
C ring  
16 
 
> 1000 > 1000 > 1000 > 1000 2.5 
17 
 
36.1 ± 2.8 52.6 ± 5.6 41.9 ± 7.5 43.5 2.9 
19 
 
223.3 ± 22.2 268.9 ± 17.0 404.5 ± 49.9 298.9 3.2 
C/D ring 
21a 
 
39.0 ± 4.3 39.5 ± 3.0 47.5 ± 4.4 42 3.4 
21b 
 
> 1000 > 1000 > 1000 > 1000 3.5 
23 
 
161.7 ± 14.0 164.1 ± 12.4 178.9 ± 21.4 168.2 2.8 
25 
 
> 1000 > 1000 > 1000 > 1000 4.5 
 colch  6.4 ± 0.3 6.5 ± 0.4 6.6 ± 0.5 6.5 3.5 
 
aLog P was calculated using Schrödinger Molecular Modeling Suite. 
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 Finally, we designed new pyridopyrimidine analogs with a dihydroquinoxalinone 
head group, as compared to the tetrahydroquinoline head group in 4a analogs. We 
hypothesize that switching to the dihydroquinoxalinone head group would make the 
phenyl ring of the head group electron deficient, leading to a more inert and 
metabolically stable methoxy group. Additionally, incrementing hydrogen bonds with the 
tubulin binding site should render stronger binding and lead to improved anticancer 
efficacy. We synthesized two different analogs, 5a and 5b, for this series and tested them 
for their in vitro activity. In addition to melanoma cell lines tested for the previous 
compounds, 5a and 5b were tested in additional melanoma cell lines including the P-gp 
overexpressing M14/MDR1 cell line, as well as other cancer cell types including prostate, 
lung, and breast cancers. (Table 4-2). We found that both compounds were highly potent, 
particularly 5b, which demonstrated greater cytotoxic activity than colchicine against all 
tested cell lines, with IC50s ranging from 1.2-10.3 nM. It is also notable that the P-gp 
overexpressing M14/MDR1 cell line was significantly less sensitive to colchicine 
treatment than the parental M14 cell line, whereas 5b was nearly equipotent against the 
resistant cell line (RI=1.25). Similarly, PC-3/TxR cells were not resistant to treatment 
with 5a or 5b but were about ~7-times more resistant to colchicine treatment.  
 
 Because we wanted to see if the modifications that improved the potency of the 
analogs would also improve metabolic stability, we measured the half-life and clearance 
of compounds 4a, 6a, 5a, and 5b in human, mouse, and rat liver microsomes (Table 4-3). 
The modification of the A ring to a pyridopyrimidine or furopyrimidine (4a and 6a) 
resulted in significant improvement in metabolic stability. In human liver microsomes, 4a 
demonstrated a half-life of 84 mins, comparable to Azixa (79 mins), whereas 1d 
previously reported a half-life of only 10 minutes (145). We also found that 5b had 
improved metabolic stability, with a half-life in human liver microsomes 5.54 ± 0.32 hrs, 
and 5a showed even greater improvement, with a half-life greater than 8 hours. Based on 
these initial findings of our compounds on cell viability, metabolic stability, and water 
solubility, the most promising compounds, 4a, 6a, 5a and 5b were selected to undergo 
additional biological analysis (Structures shown in Figure 4-2A).  
 
 
Mechanism of Action via the Colchicine Domain  
 
 To experimentally validate whether the newly designed analogs preserve their 
mechanisms of action as tubulin polymerization inhibitors, we evaluated the lead 
compounds (4a, 6a, 5a, and 5b) in a cell-free microtubule polymerization assay (Figure 
4-2B).  The greatest maximal velocity of tubulin polymerization was demonstrated by 
paclitaxel, a potent enhancer to tubulin polymerization. The vehicle control treated group 
also displayed robust polymerization. 4a, 6a, and 5b potently inhibited the tubulin 
polymerization, while colchicine and 5a suppressed tubulin polymerization altogether. It 
is interesting to note that while 5b had stronger efficacy against cancer cell lines, 5a 
demonstrated greater inhibitory action on tubulin polymerization. 
 
 Next, we investigated the effect of drug treatment on microtubule networks in 
vitro via confocal immunofluorescent microscopy. WM-164 melanoma cells were treated  
 88 
Table 4-2. Cytotoxic effects of 5a and 5b against melanoma, prostate, lung, and 
breast cancer cell lines.  
 
Cancer Type Cell Line 
IC50 ± SEM (nM) 
5a 5b Colchicine 
Melanoma 
A375 14.9 ± 1.3 4.1 ± 0.2 11.7 ± 0.2  
RPMI-7951 20.6 ± 4.7 3.3 ± 0.5 16.8 ± 3.1 
WM-164 50.3 ± 5.6 4.9 ± 0.2 14.4 ± 2.9 
SK-MEL-1 44.0 ±12.4 2.6 ± 0.3 4.1 ± 0.6 
M14 58.7 ± 4.8 8.2 ± 0.5 21.7 ± 1.3 
M14/MDR1 258. ± 49.7 10.3 ±0.3 ~800 
Prostate 
PC-3 6.8 ± 0.6 4.4 ± 0.3 5.3 ± 1.5 
PC-3/TxR 7.7 ± 0.4 4.3 ± 0.1 35.4 ± 4.2  
DU-145 17.7 ± 1.8 6.2 ± 0.5 47.5 ±11.7 
DU-145/TxR 65.8 ± 5.8 7.7 ± 0.3 846.1 ± 270.6 
Lung 
A549 182.6 ± 14.3  6.9 ± 0.5 75.8 ± 6.6 
H460 169.8 ± 32.4 5.2 ± 0.7 27.6 ± 6.2 
H1299 7.1 ± 0.8 2.5 ± 0.5 13.6 ± 2.5 
Breast 
MDA-MB-453 6.2 ±0.9 1.2 ± 0.4 3.9 ± 0.9 
MDA-MB-231 7.7 ± 0.5 3.5 ± 0.7 11.1 ± 0.6 
MDA-MB-468 8.8 ± 3.2 6.1 ± 2.1 6.2 ± 0.8 
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Table 4-3. In vitro metabolic stability of 4a, 6a, 5a and 5b in liver microsomes. 
 
Compound 
Metabolic Stability 
(Human) 
 Metabolic Stability 
(Mouse) 
 Metabolic Stability 
(Rat) 
t1/2 
(hr) 
Clint  
(mL/min/kg) 
 t1/2 
(hr) 
Clint 
(mL/min/kg) 
 t1/2 
(hr) 
Clint 
(mL/min/kg) 
Azixa 1.32 ± 0.10 15.80  0.06 ± 0.003 987.69  0.81 ± 0.07 57.53 
4a 1.39 ± 0.08 15.0  0.15 ± 0.01 379.6  0.74 ±0.06 63.0 
6a 0.32 ± 0.02 65.3  0.08 ± 0.003 748.2  0.09 ± 0.01 511.2 
5a 36.00 ± 19.13 0.58  16.90 ± 2.79 3.38  ND ND 
5b 5.54 ± 0.32 3.75  1.02 ± 0.03 56.12  5.07 ± 0.20 9.23 
Verapamil 1.40 ± 0.10 14.82  1.51 ± 0.12 37.74  3.39 ± 0.24 13.80 
 
Data obtained by Lei Yang (St. Jude Children’s Research Hospital). 
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Figure 4-2. New analogs potently inhibit tubulin polymerization. 
A) Structures of lead compounds 4a, 6a, 5a, and 5b. B) Polymerization of purified 
tubulin in a cell-free assay. Tubulin (3.33 mg/ml) was exposed to vehicle control or 
compounds at the indicated concentrations (n=2). Absorbance at 340 nm was monitored 
at 37°C every minute for 50 min. 
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with 100 nM of compound 4a, 6a, 5a, 5b, docetaxel, or left untreated. The 
immunofluorescent images obtained visually demonstrate how the microtubules are 
affected by stabilizing or destabilizing agents (Figure 4-3A). The control cells display 
fibrous microtubules extending throughout the cell, providing cellular shape and 
structure. The newly synthesized lead compounds all induced extensive fragmentation of 
the microtubules, decreased polymeric tubulin filaments, and increased cytoplasmic 
soluble tubulin. Docetaxel treatment caused the opposite action on microtubules, and 
dense tubulin accretion, representative of aggressive polymerization, can be observed. 
These results clearly demonstrate that the Azixa analogs exhibit characteristics of tubulin 
polymerization inhibitors and have a mechanism of action that is opposite of stabilizing 
agents.  
 
 Unlike the paclitaxel or vinblastine binding sites, the colchicine binding site in 
tubulin can accommodate diverse scaffolds of ligand structures which do not seem to 
have apparent similarities (192). A seemingly minor change to a potent colchicine site 
ligand could significantly compromise its binding and diminish antiproliferative potency 
(144). The high flexibility of the loop α-T5 (Ala174-Val182 loop) in the α-tubulin 
monomer and the loop β-T7 (Phe242-Asp249 loop) in the β-tubulin monomer are 
partially responsible for the unique characteristics at the colchicine binding site. 
However, this flexibility is also responsible for significant challenges in using molecular 
modelling to predict correct binding poses of one ligand scaffold with existing crystal 
structures of different ligand scaffolds. This proves an even greater obstacle for the Azixa 
scaffold because of the structural similarity of the upper and lower part of the molecule 
separated by the middle nitrogen atom. 
 
 Therefore, to unambiguously determine the real binding modes of these analogs to 
tubulin and to correctly determine the detailed molecule interactions, we determined the 
co-crystal structures of tubulin-RB3_SLD-TTL protein, in complex with two of the most 
potent analogs, 4a, and, 6a (Figure 4-3B) In the un-liganded complex, the β-T7 loop has 
a ‘closed’ conformation and it interacts with the α-T5 loop from α-tubulin (PDB ID: 
4I55). These loops move apart as colchicine binds at the interface and occupies a pocket 
in β-tubulin (Figure 4-3C). This loop opens to make a pocket in β-tubulin to 
accommodate colchicine (PDB ID: 4O2B, violet color). 
 
 In case of our compounds, the α-T5 loop in α-tubulin remains in place as seen in 
case of un-liganded complex, but β-T7 loop of β-tubulin opens as seen in case of 
colchicine bound structure, although the two conformations of the loop are slightly 
different. Both compounds bind at the site created as a result of loop opening, with ring A 
and B occupying the pocket that contains the TMP moiety of colchicine, sandwiched 
between the side chains of Cys239, Leu253 and Ala314 of β-tubulin. Ring C and D are 
facing α-T5 loop of α-tubulin, sandwiched between side chains of Asn256 and Lys350 of 
β-tubulin (Figure 4-3D and E). The chlorine attached to ring B interacts with the 
hydrophobic side chain of Leu240 from β-tubulin. The D-ring with its methoxy group 
also makes hydrophobic interactions with the side chain of Met257 from β-tubulin. There 
is a water-mediated hydrogen bond between the 1-position N atom of ring B and main  
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Figure 4-3. Compounds destabilize microtubules and target the colchicine binding site.  
(A) Microtubules of WM-164 cells following 18 hr treatment with 100 nM of 5a, 5b, 4a, 6a, compared to docetaxel or untreated 
control, visualized by α tubulin primary and AlexaFluor 647 secondary antibody via confocal microscopy. B) X-ray crystal structures 
of the tubulin-RB3-SLD-TTL complex with the ligand. C) Superimposed un-liganded (grey), colchicine bound (violet) and 4a bound 
(gold) tubulin-RB3-SLD-TTL complex showing the different loop conformations resulting from binding of ligands. D) High 
resolution X-ray crystal structures of tubulin protein in complex with 4a (resolution 2.3 ?), and E) 6a (resolution 2.7 ?). The α-tubulin 
monomer is shown in green and the β-tubulin monomer is shown in cyan. Crystallographic data obtained by Yuxi Wang (Sichuan 
University, China) and interpreted by Dr. Stephen White and Dr. Gyanendra Kumar (St. Jude Children’s Research Hospital). 
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chain -NH of Cys239. Additionally, the main chain C=O of Val236 is also within 
hydrogen bonding distance of this water molecule. These crystal structures not only 
provide a rationale for the affinity of these compounds, they also provide opportunities 
for improving these compounds further. Surprisingly, the actual binding poses for these 
Azixa derivatives determined by this  X-ray crystallography study showed different 
binding pose than previously published molecular modelling predictions of Azixa and its 
derivatives, using available X-ray crystal structures containing colchicine (PDB ID: 
4O2B) or its close analog DAMA-colchicine (PDB ID: 1SA0)(102, 145, 167, 250, 256). 
In those molecular modelling predictions, the pyrimidine ring was oriented towards the α-
monomer, and the 6-methoxyphenyl moiety overlapped the trimethoxyl moiety in 
colchicine, which is oriented towards the β-monomer.  In contrast, the high-resolution X-
ray crystal structures revealed that the 6-methoxyphenyl moiety is actually oriented 
towards the α-monomer, instead of the β-monomer. These two dramatically different 
binding poses would guide structural optimizations for the Axiza analogs in very 
different directions. Thus, the current X-ray findings provide, for the first time, insight 
into the true molecular interactions of Azixa analogs with the colchicine binding site of 
tubulin and will help future X-ray crystallography-guided synthesis of more efficient 
derivatives. It also underscores the complications associated with reliability of using 
molecular modelling and the superiority of definitive X-ray crystallographic analysis. 
 
 
Interference with Cellular Functions 
 
 To investigate the interference of cellular functions inflicted on cancer cells in 
vitro by the selected compounds, we next tested their actions against anchorage-
dependent colony formation and proliferation. A375 cells were challenged with long-
term exposure to 5a, 5b, and colchicine at concentrations ranging from 0.25 nM to 2 nM, 
which are below their determined IC50s. 5b was able to reduce colony number 
proportionally to the dug concentration (Figure 4-4A). 5a and colchicine showed a 
nominal decrease in total colony number at the lower concentrations compared to the 
control, and there was not a significant difference between the counted colony numbers 
for the lower or higher concentrations within a treatment group. However, based on the 
overall colony area coverage, there was a significant difference for all treated groups 
compared to the control, as well as a trend within groups receiving different 
concentrations of the same compound. This may indicate that 5a and colchicine can 
inhibit proliferation at low concentrations but do not have as great of an effect on the 
clonogenic potential, while 5b, the most potent compound, was able to inhibit the 
clonogenicity and cellular propagation.  
 
 Since microtubule targeting agents can interfere with microtubule networks to 
inhibit cell proliferation, migration, expansion and consequently cause morphological 
changes to endothelial morphology, we wanted to determine if 5a and 5b would exhibit 
similar actions against HUVECs in vitro (222). The capillary-like tubular network 
collapse of HUVECs grown on Matrigel was measured as total tube length and number of 
formed junctions (Figure 4-4B). 5a decreased total tube length by 31.9%, 54.0% and  
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Figure 4-4. Compounds reduce formation of cancer cell colonies and HUVEC 
tube cell networks. 
A) Colony formation assay of A375 cells treated with 5a, 5b or colchicine at 
concentrations from 0 to 2 nM (n=3). Colony assays were treated for 10 days in 6-well 
plates and quantified as total number of colonies and colony surface area ± SD as 
determined by VisionWorks software. B) Representative images of HUVEC capillary 
formation on Matrigel taken after 4 hr incubation with indicated concentrations of 5a, 5b, 
or colchicine. Quantification of total tube length and junction number was performed 
with ImageJ analysis and expressed as mean ± SD (n=4). Statistical analysis for both 
assays was performed using one-way ANOVA followed by Dunnett’s multiple 
comparison test of treatment groups to the untreated control. (*p< 0.05, **p< 0.01, ***p< 
0.001, ****p< 0.0001). 
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47.4% at 25, 50, and 100 nM concentrations, respectively. Even at the highest 
concentration, colchicine only reduced overall network length by 28.1%. 5b showed 
reductions in total length between 49.5% and 52.8% at all concentrations. Junctions were 
also quantified and provide more information on the extent of angiogenic inhibition. 5a 
showed a linear trend, decreasing junction number by 58.2% at the lowest concentration 
and up to 77.6% at the highest concentration. All tested 5b concentrations reduced the 
total number of junctions formed by at least 74.4%. Colchicine, on the other hand, was 
only able to decrease the junction number by 45.4% at the highest concentration of 100 
nM. Statistical analysis was determined by comparing each treated group to the untreated 
control group. Both 5a and 5b were more effective than colchicine by both measures 
(network length and number of junctions). Because of the significant inhibition achieved 
by 5b at the lowest concentration of 25 nM and the concentration-dependent effect 
observed by 5a, these results show that the compounds impair formation and structure of 
the capillary-like networks formed by HUVECs cultured on a Matrigel basement 
membrane matrix. This offers further support that 5a and 5b may have additional actions 
as VDAs/anti-angiogenic agents. 
 
 Drugs that target microtubules have also been reported to interfere with cell 
migration and motility at low concentrations. We tested the ability of 4a to decrease cell 
migration compared to colchicine and untreated control cells in a wound healing assay 
(Figure 4-5A). The control A375 and RPMI-7951 cells that were not treated showed an 
average wound closure of 60.7% ± 3.5% and 71.8% ± 1.8%, respectively. At 5 nM 
concentrations, 4a caused less A375 and RPMI-7951 cells to migrate into the wound, 
closing the gap by 36.4% ± 2.5% and 46.4% ± 2.0%. At higher concentrations of 25 nM, 
even greater migration inhibition was observed by the cells, where cells migrated into 
only 16.9% ± 1.7% and 25.5% ± 5.8% of the wound area for A375 and RPMI-7951, 
respectively. A significant decrease in wound closure was observed by cells treated with 
4a by both concentrations and against both cell lines compared to the control.  Colchicine 
showed less inhibition than 4a, where the A375 wound channel was closed by 46.0% 
±1.4% and 20.7% ± 2.2% when treated with 5 nM and 25 nM of the drug, respectively. 
The RPMI-7951 cells treated with 25 nM of colchicine migrated into 42.8% ± 5.8%, and 
a significant decrease in migration was not observed when treated with 5 nM of 
colchicine. 5b was also tested in scratch migration assay against A375 and M14 
melanoma cells in a time-dependent and concentration-dependent manner (Figure 4-5B). 
The wound density covered by the migrating cells was measured in real-time compared 
to the starting wound area, and rate of change was calculated by the change in relative 
wound density % per hour. For A375 cells, there was an obvious reduction in migration 
for the 5b treated cells at concentrations as low as 2.5 nM compared to the control. 
Treatments with 5b at 5 and 10 nM concentrations showed similar inhibitory effects but 
to a greater degree. Colchicine did not show a concentration-dependent inhibition against 
A375 cells from 2.5- 10 nM concentrations, though it still slowed cell migration more 
than the untreated cells. The M14 cells demonstrate different results. Treatment with 
colchicine was not effective at hindering cell migrations at concentrations up to 10 nM. 
While little efficacy was apparent for 5b at 2.5 nM concentrations against this cell line, it 
induced concentration-dependent action against cell migration at 5 and 10 nM  
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Figure 4-5. Compounds inhibit melanoma cell migration.  
A) Scratch migration assay of A375 (top) and RPMI-7951 (bottom) cell lines (n=4). Cells 
were treated with 4a or colchicine at 5 or 25 nM for 24 hours and migration is presented 
as mean percent of the area closed ± SD. ImageJ software was used to calculate scratch 
area. Scale bar = 1000μm. Statistical significance was determined by one-way ANOVA 
followed by Dunnett’s multiple comparison test, comparing each treatment group to the 
control group. (**p< 0.01, ***p< 0.001, ****p< 0.0001). B) Wound density for A375 
(left panels) and M14 (right panels) after treatment with 5b or colchicine at indicated 
concentrations (n=4). Real-time analysis was performed with Incucyte live cell imagine 
system every 2 hours for 24 hours. The top graph shows % relative wound density ± SD 
and the bottom graphs show rate of change represented as change in relative wound 
density per hour ± SD. 
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concentrations. At the highest concentration, cell death became apparent beginning 
around 18 hours, as evidenced by the decrease in wound density and increase in rate of 
change during this time.  
 
 
Compounds Induce G2/M Phase Cell Cycle Arrest and Apoptosis 
 
 A common feature of tubulin inhibitors targeting the colchicine binding site is that 
they arrest cells in the G2/M phase of the cell cycle (100). To determine whether 5a and 
5b would arrest cancer cells in a similar fashion, we carried out cell cycle analysis 
utilizing flow cytometry to see if there was a dose-dependent effect. After syncing A375 
the cells by serum-starvation, they were treated with a low or high concentration (10 or 
50 nM) of 5a, 5b, or colchicine for 24 hrs (Figure. 4-6A). Compared to untreated control 
cells, where 11.7% of the population were indicated to be in the G2/M phase of the cell 
cycle after 24 hours after synchronization, 5a, 5b, and colchicine all increased cell 
distribution at 50 nM concentrations, arresting 15.9%, 38.9% and 31.6% of the cells is 
this phase, respectively. At lower concentrations of 10 nM, only 5b arrested cells in the 
G2/M phase significantly more than the control cells, showing 35.4% of the population 
arrested in this phase. Even though 5a and colchicine did not dramatically induce arrest at 
10 nM, it is clear from the cell cycle distribution that the G2/M phase arrest is 
concentration-dependent. 
 
 We also wanted to confirm that 5a and 5b treatment would lead to apoptotic cell 
death. Therefore, we quantified the percentage cells that were undergoing early stage 
apoptotic events (Annexin V positive stained cells) and late stage apoptotic events 
(Annexin V and propidium iodide positive stained cells) compared to synchronized A375 
cells (Figure 4-6B). Untreated cells only showed 4.6% of the population undergoing 
apoptosis, while 50 nM of colchicine treatment led apoptosis for 33.7% of cells after 24 
hrs. There was a modest increase in apoptotic events for 5a treated cells at 50 nM 
concentrations, where 7.2% of cells were apoptotic. 10 nM treatment of 5b caused a 
significant increase in the cells undergoing apoptosis, where 19.1% of the cell population 
was apoptotic. At higher concentrations of 50 nM, there was not a proportional increase 
in cell death initiation (20.7% apoptotic). However, these results correlate with the trend 
we observed from the cell cycle analysis, where the higher concentration (50 nM) of 5b 
yielded only a slight increase in the percentage of cells arrested in the G2/M compared to 
cells treated at lower (10 nM) concentration. We concluded that 24 hr treatment of 5b 
with these concentrations (10 and 50 nM) will demonstrate similar efficacy, and either 
lower concentrations or time-dependent analysis would be needed to demonstrate a more 
palpable trend. Targeted cleavage of the Poly(ADP-ribose) polymerase (PARP), a nuclear 
protein, is another signature biomarker in the apoptotic process (257). We investigated 
total vs cleaved PARP in A375 and M14 cells after treatment with our compounds to 
determine if the results would correlate with our previous findings (Figure 4-6C). In both 
cell lines, no cleaved PARP was evident from the control cell lysates, but 5a treatment 
exhibited concentration-dependent PARP cleavage from 15-100 nM after 24 hrs. 5b  
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Figure 4-6. Compounds induce G2/M phase arrest and apoptotic events.  
A) Representative flow cytometry diagram of cell cycle distribution. Synchronized A375 
cells were treated with 10 or 50 nM of 5a, 5b, or colchicine for 24 hours. B) Apoptosis 
analysis under the same conditions and determined by Annexin V and PI staining, where 
Q1 represents early state apoptosis and Q2 is late state apoptotic cells. C) Western blot 
analysis for protein levels of A375 (top) and M14 (bottom) cell lines after 24 hr treatment 
with 15, 40, or 100 nM concentrations of 5a, 5b, or colchicine. Apoptotic proteins (total 
and cleaved PARP), cell survival proteins (total and phosphorylated Akt), and cell cycle 
dependent protein phospho-histone3 are shown.  
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treatment showed strong expression of the cleaved PARP protein at all concentrations in 
the cell lystates, whereas colchicine-treated cells showed similar cleaved PARP levels to 
5b at the highest concentration, but lower levels than 5b at 15 nM.  
 
 The phosphatidylinositol-3-kinase serine/protein kinase B (Akt) signaling 
pathway plays an important role in regulating cell survival, and constitutive activation of 
this pathway is commonly implicated in a variety of cancers, including melanomas (258, 
259). The phosphorylation of Akt at Thr308 and Ser473 leads to its full activation, and 
elevated expression levels of phospho-Akt (p-Akt) is correlated with melanoma 
pathogenesis and progression, and it is inversely related to patient survival (260). We 
found that treatment with 5a or 5b in melanoma A375 cells reduced p-Akt expression 
levels. 5a caused the greatest reduction at 100 nM concentrations, and 5b was equally 
effective at concentrations as low as 15 nM.  
 
 Finally, we looked at phospho-histone H3 levels, which distinguish cells between 
the G2 and M phase of the cell cycle, and its expression is negligible or absent in other 
stages (261). In M14 melanoma cells, 5a treatment caused only a slight increase in 
phospho-histone H3 levels compared to the control cells. On the other hand, significant 
protein expression was observed in the 5b and colchicine treated cells. This corroborates 
the cell cycle analysis findings, which showed relatively weaker induction of cell cycle 
arrest for the 5a treated cells compared to the profound effects observed from the 5b 
treated cells. These in vitro studies verify that our compounds, particularly 5b, induce 
apoptosis and arrest melanoma cells in the G2/M phase of the cell cycle in a similar 
manner as colchicine.  
 
 
In Vivo Antitumor Efficacy 
 
 We first determined the MTD in mice for compounds 4a and 6a (prior to full 
xenograft studies) and found that i.p. administration of 50 mg/kg (4a) or 30 mg/kg (6a) 
for 5 consecutive days was well-tolerated in mice and no apparent acute toxicities were 
observed. This is in contrast with Azixa and its reported analogs, where 1~4 mg/kg doses 
by i.v. injection were generally lethal for mice (145, 252, 254, 255, 262). We did consider 
though, that plasma concentration following systemic administration by intravenous 
injection does not necessarily proportionally reflect the drug levels achieved following 
intraperitoneal intervention. Therefore, we also tested the MTD for Azixa formulated at 
10 mg/kg via i.p. injection, and while we did not have an Azixa-treated comparison group 
in our subsequent xenograft study, we did find that this was not a tolerable dose for the 
mice. 4a and 6a have comparable in vitro potency to Azixa and demonstrated higher 
MTDs, suggesting that our analogs may have an improved therapeutic index over Azixa 
with this route of administration.  
 
 We next investigated the antitumor effects of these compounds in an A375 
xenograft model in nude mice, following our previously reported protocols. Once tumors 
developed, mice were randomized and treated by i.p. injection for two weeks with 
compound 4a, 6a, paclitaxel, or a vehicle solution. Tumor growth inhibition (TGI) was 
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calculated for the treatment groups compared to the vehicle control group (Figure 4-7A 
and B). 4a treatment caused 57.1% and 72.3% TGIs for15 mg/kg and 30 mg/kg treatment 
groups, respectively. 15 mg/kg doses of 6a was also able to inhibit tumor growth by 
66.5%. The group receiving 15 mg/kg doses of paclitaxel was used as a positive control 
and resulted in an overall TGI of 76.5%. Final tumor weights were also recorded prior to 
IHC analysis and reiterated the effect of 4a and 6a treatment on tumor inhibition. We 
found that 15mg/kg treatments with 4a and 6a reduced tumor weight by ~45%, and 
higher doses of 30 mg/kg of 4a or paclitaxel treatment caused ~60% reduction compared 
to the control group (Figure 4-7C). Abnormal deviations in animal body weight 
indicative of acute toxicities were not observed (Figure 4-7D). One-way ANOVA 
followed by Dunnett’s multiple comparison test demonstrated that each of the treatment 
groups caused a significant reduction in tumor size compared to the control group, 
yielding P values < 0.001.  
 
 After tumors were fixed, histological analysis was performed and IHC staining 
revealed that there was an increase in the number of cells undergoing apoptosis for the 
groups receiving treatment with 4a, 6a, or paclitaxel (Figure 4-7E). Furthermore, CD31 
staining showed that tumors from the treated groups displayed less overall microvessel 
density and exhibited morphological changes in the vessel structure. Although 
comparable in vivo testing for 5a and 5b is still underway, the initial in vitro results 
showing elevated apoptosis by flow cytometry, increased apoptotic activity indicated by 
cleaved PARP, and endothelial network disturbance of HUVECs closely shadows the in 
vivo results for 4a and 6a. Future testing in animal models with 5a and 5b is warranted to 
confirm their efficacy in biologically relevant models and compare their anticancer 
efficacy to their Azixa analog counterparts and other tubulin inhibitors.  
 
 
Compound 4a Overcomes Taxane Resistance 
 
 To determine if 4a is capable of escaping resistance associated with taxanes, we 
first tested the potency in parental prostate cancers PC-3 and DU-145, as well as 
paclitaxel resistant PC-3/TxR and docetaxel resistant DU-145/TxR cell lines (Figure  
4-8A). 4a was the most potent against PC-3/TxR cancer cells, with an IC50 of 8.7 ± 0.9 
nM and a resistance index of 0.7. Colchicine treatment to PC-3/TxR cells revealed a 
resistant index of 3.5, and PC-3/TxR cells were even less susceptible to paclitaxel and 
docetaxel treatment (RI > 30). We then proceeded to determine the anticancer action of 
4a in a PC-3/TxR xenograft model in nude mice. To prove the efficacy of paclitaxel 
against non-resistant tumors, we conducted a study in parallel in a PC-3 xenograft model 
and confirmed that the non-resistant tumors were highly prone to paclitaxel treatment 
(Figure 4-8B). However, when paclitaxel was administrated to mice bearing paclitaxel 
resistant tumors, there was no difference in tumor volumes compared to group that was 
administered only the vehicle solution (Figure 4-8C and D). Additionally, mouse weight 
began to drop moderately after 2 weeks of treatment, possibly as a result of toxicity 
(Figure 4-8G). On the other hand, treatment with 30 mg/kg of 4a at the same frequency 
resulted in a significant decrease in tumor volume (p < 0.01), with a calculated TGI of  
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Figure 4-7.  Inhibition of tumor growth in vivo.  
A) A375 xenograft model in nude mice for 4a, 6a, and paclitaxel treatment groups. 
Graph represents mean tumor volume ± SEM (n=8). B) Individual tumor final volumes 
represented as mean tumor volume for each group ± 95% confidence interval. C) Tumor 
weights ± SEM. D) Mouse body weights represented as a % change of the initial weight 
± SEM values. Statistical significance was determined by Dunnett’s multiple comparison 
test for the treatment groups compared with the vehicle control group (****P <0.0001, 
***P <0.001). E) Representative images of tumor samples for treatment groups by H&E 
and IHC staining. Compared to the control, treatment groups displayed elevated cleaved 
caspase-3 expression indicative of apoptosis (middle column), and decreased density of 
CD31-stained microvessels (right column). 
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Figure 4-8. 4a overcomes taxane resistance and demonstrates antitumor efficacy. 
A) Cytotoxicity of 4a against parental and taxane-resistant prostate cancer cells lines. 
Curve was fitted by nonlinear regression to determine IC50 values (n=4). B) Prostate 
cancer xenograft models in nude mice for PC-3 tumors and C) paclitaxel-resistant PC-
3/TxR tumors represented as mean tumor volume ± SEM (n=7). D) Individual PC-3/TxR 
tumor final volumes. Bar graph represents the mean tumor volume for each group ± 
SEM. E) PC-3/TxR tumor weights ± SEM.  F) Representative images of PC-3/TxR 
tumors. G) Mouse body weights in the PC-3/TxR xenograft model represented as mean 
body weight change as a percentage compared to initial weight ± SEM values. Statistical 
significance was determined by ANOVA analysis followed by Dunnett’s multiple 
comparison test for final tumor volumes and weights compared to the corresponding 
control group (****P < 0.0001, **P < 0.01, *P < 0.05). 
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55.6%. There was also a considerable difference in tumor weight for the 4a treated group 
(p < 0.05) and observable differences in tumor size (Figure 4-7 and F). One-way 
ANOVA showed statistical significance between groups based on final tumor volume (p 
= 0.0007) and weight (p = 0.002). 
 
 In this paclitaxel-resistant PC-3/TxR prostate cancer cell line model, more than 
200 genes are upregulated in addition to P-gp overexpression, representing a large 
number of potentially clinically relevant taxane-resistant mechanisms (174, 175). The 
efficacy of compound 4a in suppressing tumor growth in this highly aggressive, tumor 
model suggests that these new analogs have the potential to overcome resistance 
mechanisms employed by MDR tumors. This is also consistent with the general 
properties of Azixa or its related analogs targeting the colchicine binding site in tubulin 
(101, 242, 252).    
 
 
Conclusions 
 
 In summary, we have reported the design and potency of new conformationally 
restricted Azixa analogs with a heteropyrimidine scaffold as well as dihydroquin-
oxalinone pyridopyrimidine analogs. Biological assays indicated that two of the most 
potent compounds of the series, 4a and 6a, had IC50 values in the low nanomolar range 
against a panel of metastatic melanoma cell lines, similar to that of colchicine and 
existing Azixa analogs. However, 4a and 6a showed significantly improved metabolic 
stability in human liver microsomes than similar conformationally restricted Azixa 
analogs (quinazoline analogs) reported by Xie et al. The 5a and 5b analogs showed even 
greater improvement in metabolic stability and demonstrated strong anticancer potency in 
a multitude of cancer types, including melanoma, prostate, lung, and breast cancer, as 
well as including P-gp overexpressing M14/MDR1 cells and taxane resistant PC-3/TxR 
and DU-145/TxR cell lines.  
 
 These new analogs inhibit tubulin polymerization, promote microtubule 
destabilization, and directly target colchicine binding site, which was confirmed with 
high-resolution crystal structures for representative compounds 4a, and 6a, in complex 
with tubulin. Binding poses for these compounds revealed by the X-ray crystal structures 
were dramatically different than binding conformations predicted from molecular 
modeling, and this underscores the complexity and flexibility of the colchicine binding 
site. The ability of the compounds to impede cellular activities was demonstrated though 
a variety of mechanisms including migration, clonogenicity, endothelial cell network 
formation. They also share trademark characteristics with other potent antimitotic agents 
such as inducing G2/M phase cell cycle arrest and promoting apoptosis. In vivo, 4a and 
6a significantly reduced tumor growth in a xenograft model in nude mice challenged with 
A375 melanoma at the respective doses of 30 mg/ kg and 15 mg/kg after 2 weeks of 
treatment. Subsequent immunohistochemistry analysis of the tumors also indicated that 
treatment with 4a and 6a caused elevated apoptosis and extensive vascular disruption 
within the tumors.  Finally, compound 4a demonstrated the ability to overcome paclitaxel 
resistance in vitro and in vivo (30 mg/kg), substantiating the efficacy of colchicine 
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binding site inhibitors against resistant cancers. These studies demonstrate the potential 
of 4a, 6a, 5a, and 5b as anticancer agents, provide proof-of-concept for their mechanisms 
of action, and reveal the structural basis to support the continued development for these 
lead compounds as tubulin inhibiting and vascular disrupting chemotherapeutic agents. 
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CHAPTER 5.    INTRODUCTION TO TARGETING THE INHIBITOR OF 
APOPTOSIS PROTEINS4  
 
 
Inhibitor of Apoptosis Proteins 
 
 Apoptosis is a critical component of cell regulation, homeostasis, and 
programmed cell death. While cell death can proceed through several pathways such as 
autophagy or necroptosis, apoptosis is perhaps the best-understood and primary pathway 
through which programmed cell death is carried out. Dysregulation of apoptosis is 
observed in many human diseases and is one of the hallmarks of cancers (263, 264). In 
principle, evasion of programmed cell death is the result of failure to propagate apoptosis 
and caspase activation pathways (265). Inhibitor of apoptosis proteins (IAPs) are up-
regulated in many types of cancer and contribute to tumor progression, treatment 
resistance, and poor prognosis. They suppress apoptosis induced by an array of stimuli, 
including death receptor activation, growth factor withdrawal, ionizing radiation, viral 
infection, endoplasmic reticulum stress, and genotoxic damage (266, 267). IAPS also 
promote cell survival through regulation of signaling pathways. While many traditional 
treatment approaches such as radiation and chemotherapy seek to treat cancer by 
inducing apoptosis, cancer cells often develop resistance to these treatment strategies, 
particularly when IAP’s are upregulated. Targeting these apoptotic regulators and 
suppressing their inhibitory function to promote cell death is an attractive anticancer 
strategy (264, 268-270). Substantial progress has been made in the development small 
molecules that are capable of penetrating the cell membrane and potent enough to restore 
apoptotic function via IAP suppression. IAP inhibitors may induce cell death and tumor 
regression as single agents by direct IAP interaction or synergize with additional 
cytotoxic agents to sensitize cancer cells to apoptosis and overcome drug resistance. 
Increased knowledge and greater insight of the biological mechanisms and structure of 
IAPs has laid the groundwork for the targeting strategy of small-molecule IAP inhibitors 
and has greatly contributed toward their translation and incorporation into clinical 
practice. 
 
 
Structure of IAP Proteins 
 
 IAP proteins are a family of endogenous anti-apoptotic proteins that hinder 
apoptosis by interfering with caspase activation. In addition to their roles in apoptosis, 
they can also influence non-apoptotic processes such as cell differentiation, invasion, 
migration, and metastasis (271-273). The first IAP family member was identified during 
a genetic screening of SF21 baculoviruses, where a 1.6kB gene encoding a 31kDa anti-
apoptotic protein with a zinc finger-like motif was discovered (274). To date, there are 
eight mammalian Baculoviral IAP repeat-containing (BIRC) protein family members: 
                                                 
 
4Reprinted with permission from Bentham Science. Kinsie Arnst and Wei Li. Targeting the Inhibitor of 
Apoptosis Proteins with Small Molecules: Recent Advances and Clinical Challenges. Frontiers in Clinical 
Drug Research-Anti-Cancer Agents. 2015; 2:165-208 
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neuronal IAP (NIAP, BIRC1), cellular IAP1 (cIAP1, BIRC2), cellular IAP2 (cIAP2, 
BIRC3), X chromosome-linked IAP (XIAP, BIRC4), survivin (BIRC5), apollon 
(BRUCE, BIRC6), melanoma IAP (ML-IAP, livin, BIRC7), and IAP-like protein 2 (ILP-
2, BIRC8) (275) (Fig. 1). Among these, XIAP, cIAP1, cIAP2, and ML-IAP are known to 
participate in the inhibition of apoptosis through caspase inhibition and cell signaling 
(276, 277).  
 
 Proteins in this family are characterized by at least one (but up to three) 
baculoviral IAP repeat (BIR) domains in the N-terminal portion of the protein. The BIR 
domains are highly conserved, comprised of ~80 amino acids, and contain histidine and 
cysteine residues that coordinate a zinc ion. In the C-terminus they may also contain a 
Really Interesting New Gene (RING) domain with E3-ligase activity, caspase activation 
recruitment domain (CARD), a ubiquitin-conjugating (UBC) domain, or a ubiquitin-
associated (UBA) domain (276)(Figure 5-1). Only X-linked IAP has been shown to 
potently inhibit apoptosis through caspase interaction and suppression. The BIR domains 
are largely responsible for binding to caspases, whereas RING domain-containing IAPs 
can regulate apoptosis through their E3 ligase activity (278, 279). Dimerization of the 
RING domain potentiates their E3 ubiquitin ligase activity, which induces IAP-mediated 
ubiquitylation by recruiting E2 ubiquitin-conjugating enzymes and facilitating the 
transfer of ubiquitin to target proteins and binding partners (280, 281). The function of 
the CARD domain in cIAP1 and cIAP2 is largely unknown, though it has been indicated 
to play regulatory role in auto-inhibition of E3 ligase activation by preventing RING 
dimerization (282). The UBA domain enables IAP proteins to bind to mono-ubiquitin as 
well as Lys 63- and Lys 48-linked poly-ubiquitin chains and is implicated in cell survival 
and oncogenesis (283). Survivin is the smallest member of the IAP family, containing a 
single BIR domain, but plays a versatile role in a multitude of cellular processes. While 
its function is still somewhat controversial, it influences cell death by both anti-apoptotic 
and pro-proliferation mechanisms. The direct interaction of survivin with caspases is 
unclear, but it can interact with apoptotic proteins to induce caspase-independent cell 
death (284, 285).  
 
 
IAP Proteins Regulate Cell Death Pathways 
 
 All apoptotic signaling converges upon the activation of caspases, making their 
activity a crucial determinant in programmed cell death (286). Caspases, or cysteine-
dependent aspartate specific proteases, are a family of cysteine proteases that cleave 
target proteins after specific aspartic residues (287). They are synthesized as inactive 
zymogens and remain latent until activated by cell death stimuli. Apoptotic caspases are 
further classified as initiator or executioner caspases according to their mechanism of 
action and manner of activation. Initiator caspase-8 and caspase-9 are activated by 
dimerization and responsible for activating downstream executioner caspase-3, caspase-6 
and caspase-7 by cleaving their catalytic domain (288, 289). Executioner caspases 
catalyze a proteolytic cascade by cleaving cellular substrates that promote the ordered  
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Figure 5-1. Domains of mammalian IAP proteins 
The domain organization for the 8 identified mammalian IAP proteins is shown. The 
defining characteristic is the presence of one or three baculoviral IAP repeat domains. 
These domains are required for the majority of protein-protein interactions with caspases 
or other apoptotic proteins. Several IAPs (XIAP, cIAP1, cIAP2, ML-IAP, and ILP-2) 
contain an E3 ubiquitin ligase zinc-finger at the carboxy-terminus. Both cellular 
inhibitors of apoptosis contain a caspase recruitment domain in the region between the 
BIR and the RING domains. Ubiquitin-associated (UBA) domains of XIAP, cIAP1, 
cIAP2, and ILP-2 are capable of binding to ubiquitin chains, and apollon contains a 
ubiquitin-conjugating (UBC) E2 domain. IAPs with roles in mitosis (survivin and 
apollon) have a slightly longer, type 2 BIR domain compared with the other IAPs. 
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disassembly and destruction of the cell. Caspases propagate apoptosis through two major 
pathways: the mitochondrial (intrinsic) pathway and the death receptor (extrinsic) 
pathway (Figure 5-2). 
 
 Intrinsic and Extrinsic Pathways. The mitochondrial pathway is activated by a 
vast array of non-receptor-mediated intracellular stress signals and pro-apoptotic stimuli 
such as cellular injury by toxins, viral infections, radiation, free-radicals, hypoxia or 
DNA damage. These stimuli cause permeability changes in the mitochondrial outer 
membrane, a process which is tightly regulated by several BCL-2 family proteins, and 
results in the loss of transmembrane potential (290, 291). Upon activation, BCL-2 family 
proteins BAK and BAX form pores in the outer mitochondrial membrane and direct the 
release of cytochrome c from the intermembrane space to the cytosol. Cystolic 
cytochrome c then binds to apoptotic protease-activating factor 1 (Apaf-1) to form a 
complex called the apoptosome (292, 293). The apoptosome recruits and processes 
procaspase-9 into active caspase-9,  forming a holoenzyme complex (294). Caspase-9 
then cleaves and activates executioner caspase-3, which in turn targets downstream 
substrates to induce the final stages of apoptosis and cell death (295). Concurrent with 
cytochrome c efflux from the mitochondria, SMAC is also introduced into the cytosol 
and neutralizes the inhibitory effects IAP proteins (296). SMAC and its functions will be 
covered in greater a detail. 
 
 The extrinsic apoptosis pathway is initiated by the binding of death ligands such 
as FasL/CD95 ligand, TNF-related apoptosis-inducing ligand (TRAIL), or tumor necrosis 
factor α (TNFα), to their respective cell death receptors, Fas/CD95, DR4 or DR5, and 
TNFR1. Binding of death receptors ligands such as TRAIL or FasL stimulates receptor 
oligomerization and leads to the recruitment of the adaptor protein Fas-associated death 
domain (FADD/Mort-1) and procaspase-8. This forms the death-inducing signaling 
complex (DISC), which processes and activates caspase-8. Alternatively, the binding of 
TNFα with TNFR1 stimulates the formation of two complexes (297-299). Firstly, 
complex I is assembled at the membrane in conjunction with TNFR1 and consists of TNF 
receptor-associated death domain (TRADD), TNF receptor-associated factor 2 (TRAF2) 
and receptor-interacting protein 1 (RIP1). Complex I can translocate into the cytosol and 
recruit FADD and procaspase-8 form complex II assembly. Complex I internalization can 
be inhibited by cIAP1/2-mediated ubiquitylation of RIP1, which consequently suppresses 
apoptotic signaling (300, 301). As with DISC, complex II generates active caspase-8, 
which can then cleave and activate caspases-3 and caspase-7. Additionally, caspase-8 can 
advance apoptosis by cleaving and activating Bid, a pro-apoptotic BCL-2 family protein 
that is critical in pathway convergence (302, 303). The activated form of Bid, truncated 
Bid (tBid), migrates to the mitochondria and leads to activation of BAX and BAK, 
mitochondria membrane permeabilization, cytochrome c release, and induction of the 
intrinsic pathway (304-306). Executioner caspases-3 and caspase-7 elicit downstream 
apoptotic protein activation, including the nuclear enzyme poly ADP ribose polymerase 
(PARP), ultimately resulting in DNA fragmentation, degradation of nuclear and 
cytoskeletal proteins, formation of apoptotic bodies, expression of ligands for phagocytic 
uptake and cell death (307, 308). 
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Figure 5-2. Cell death pathways. 
The extrinsic (death receptor) pathway is activated by the binding of cell death ligands to 
their respective receptors, which trigger the formation of signaling complexes that 
activate caspase-8. Caspase-8 can either process Bid to truncated Bid (tBid), which 
stimulates the activation of the mitochondrial pathway, or it can directly interact with and 
activate downstream caspases. The mitochondrial pathway is stimulated by a variety of 
death stimuli and results in the release of SMAC and cytochrome c from the 
mitochondria through mediator proteins BAK and BAX. Cytochrome c release leads to 
the activation of initiator caspase-9 and then subsequent executioner caspases, whereas 
SMAC promotes apoptosis by inhibiting XIAP. cIAP proteins can block the formation of 
complex II by ubiquitylation of RIP1. 
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 A third minor pathway involves granzyme B, a granule-associated serine protease 
found in cytotoxic T-cells and natural killer cells. It can initiate cell death by caspase-3 
activation, Bid cleavage, and digestion of regulatory proteins (309, 310). 
 
 Mechanisms of Action of Different IAP Proteins. XIAP is probably the best-
categorized IAP in terms of its role in apoptotic regulation and can potently suppress 
apoptosis through direct binding of caspase-3, caspase-7, and caspase-9 (311). The linker 
region between the BIR1 and BIR2 domain of XIAP is essential for caspase-3 and 
caspase-7 inhibition and competitively binds at the active site. Inhibition of caspase-3 
requires only the linker region, whereas caspase-7 requires binding of both the linker 
region and the subsequent binding of the XIAP BIR2 domain (312-314). The BIR3 
domain of XIAP inhibits caspase-9 by binding to its monomeric, inactive form.  This is 
achieved by forming a heterodimer with procaspase-9, which prevents its dimerization 
and activation (315, 316). Another mechanism by which XIAP regulates apoptotic 
function involves the E3 ubiquitin-ligase activity of the RING domain. Studies have 
shown that removal of the RING domain resulted in an increase in caspase-3 activation, 
accelerated rate of apoptosis, and enhanced organism survival in a Eμ-Myc mouse 
lymphoma model (317). This underscores the importance of the ubiquitin-ligase function 
of XIAP for the inhibition of caspases and tumorigenicity. In addition to caspase 
inhibition, XIAP proteins participate in cell signaling and NF-κB activation. One surface 
of the BIR1 domain of XIAP binds with the N-terminal domain of the TGF-β activated 
kinase 1 (TAK1) binding protein, TAB1, while the opposite surface is responsible for 
BIR1 dimerization. This interaction and dimerization propagates XIAP-induced TAK1 
activation and stimulates NF-κB signaling (316, 318, 319). Altogether, inhibiting 
caspases through direct interaction is the primary mechanism by which XIAP suppresses 
apoptosis, but it can also influence cell survival through cell signaling pathways. 
 
 IAPs do not all obstruct apoptosis in the same manner. Weak inhibitors of 
caspases, such as ML-IAP, influence cell survival by binding and sequestering SMAC, an 
endogenous inhibitor of IAP proteins. In the absence of SMAC, XIAP is uninhibited and 
may more freely promote cell survival (320, 321). On the other hand, while cIAPs can 
participate in caspase binding, they mainly regulate apoptosis via the E3 ubiquitin ligase 
activity of their RING domain (322, 323). They are capable of inducing both cross-
ubiquitylation of a multitude of substrates as well as auto-ubiquitylation and subsequent 
degradation (281, 324, 325). For example, cIAP1 can promote ubiquitylation of caspase-
3 and caspase-7 and can also mediate ubiquitylation of other IAP proteins including 
cIAP2 and XIAP (326). In the death receptor pathway, cIAPs impede apoptosis by 
maintaining constitutive ubiquitylation of RIP1, preventing its association with FADD 
activation of caspase-8 (327). Unlike XIAP, the BIR1 domains of cIAP1 and cIAP2 
interact with TRAF2 and regulate intracellular signal transduction of TNF receptors (328, 
329).  cIAPs are also implicated in MAPK signaling and regulate TNFα-mediated NF-κB 
activation (330, 331).  
 
 The mechanism of action of survivin regarding the inhibition of apoptosis is not 
as clearly defined and further complicated by its involvement in other cellular processes, 
particularly cell division. There is support for a variety of mechanisms by which survivin 
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regulates apoptosis, including direct binding to effector caspases (332), interacting with 
SMAC and releasing bound IAPs (333, 334), reducing DNA fragmentation by decreasing 
levels of mitochondrial apoptosis-inducing factor (AIF) in the nucleus (335), and forming 
a complex with cofactor hepatitis B X-interacting protein (HBXIP), which binds to 
procaspase-9 and obstructs subsequent processing (336). Survivin also cooperates with 
XIAP to inhibit caspase activity by forming an XIAP-survivin complex that increases 
XIAP stability and protects it against ubiquitylation and proteasomal degradation (337). 
Survivin is prognostically important because of its minimal expression in normal 
differentiated adult cells compared to its elevated levels of expression in a wide range of 
cancers (338). It has been suggested that this could serve as diagnostic tool and 
biomarker for detection of malignancy (339). 
 
 
IAP Proteins Regulate Cell Signaling Pathways 
 
 Nuclear factor-κB (NF-κB) signaling mediates many facets of biological activity 
including inflammation, proliferation, and survival. Its activation stimulates the 
expression of many proteins that promote cell cycle progression, resist apoptosis, and 
facilitate cell adhesion, angiogenesis, and metastasis. It is not surprising that NF-κB is 
strongly correlated with carcinogenesis and enables malignant transformation and tumor 
progression (340). As mentioned previously, IAPs, especially cIAP1 and cIAP2, play a 
critical role in apoptotic suppression by ubiquitylation of NF-κB protein substrates and 
mediating cell signaling. cIAPs positively regulate the canonical NF-κB pathway and 
negatively regulate non-canonical NF-κB signaling (341) (Figure 5-3). 
 
 The canonical pathway is initiated by the binding of TNFα to TNFR1, followed 
by the recruitment of TRADD and RIP1. TRADD then engages TRAF2 and 
cIAP1/cIAP2, which are bound to TRAF2 through their BIR1 domain. cIAPs induce E3 
ligase-mediated poly-ubiquitylation of RIP1 (300, 327) to generate a binding platform for 
the induction and activation of the inhibitor of κB kinase (IKK) complex, composed of 
IKKα, IKKβ, and NF-κB essential modulator (NEMO). Additionally, the TAK1-TAB1 
complex and the linear ubiquitin chain assembly complex (LUBAC) are recruited to the 
binding platform. The activated IKK complex phosphorylates and degrades the inhibitor 
of NF-κB (IκB), causing the release of its p50 and RelA dimers (342). p50 and the 
transcription factor RelA then translocate into the nucleus to activate transcription of 
targeted genes and NF-κB signaling (343). Therefore, the presence of cIAP1/cIAP2 
promotes cell survival through activation of the NF-κB pathway by ubiquitylation of 
RIP1 (344). 
 
 In the non-canonical pathway (also referred to as the alternative pathway), 
constitutive degradation of NF-κB inducting kinase (NIK) by cIAP1/2 in a complex with 
TRAF3/TRAF2 represses the activation of NF-κB signaling (324). In the absence of 
activation signals, TRAF3 recruits TRAF2-bound-cIAP proteins to NIK in the cytoplasm. 
cIAP-mediated ubiquitylation of NIK causes its subsequent destabilization and 
degradation, which prevents activation of IKKα proteins downstream. When the TNF-
related weak inducer of apoptosis (TWEAK) ligand binds to the FN14 receptor, it  
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Figure 5-3. NF-κB signaling pathways. 
cIAP proteins are positive regulators in the canonical pathway and negative regulators in 
the non-canonical signaling. In the canonical pathway, ubiquitination of RIP1 forms a 
binding platform for the IKK complex (composed of NEMO, IKKα, and IKKβ), the 
TAB1-TAK1 complex, and the linear ubiquitin chain assembly complex (LUBAC). 
Activated IKKβ leads to proteasomal degradation of inhibitor of NF-κB (IκB) and 
subsequent translocation of p50/RelA into the nucleus to activate of target genes. In the 
non-canonical pathway, constitutive degradation of NIK by cIAP proteins represses NF-
κB signaling. Degradation of cIAP proteins (either initiated by binding of ligands such as 
TWEAK to FN14 or by IAP antagonists), allows NIK to stabilize and accumulate. This 
leads to phosphorylation of IKKα, processing of p100 to p52, and the translocation of the 
p52/RelB dimer into the nucleus to activate NF-κB signaling.  
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engages the TRAF proteins and induces lysosomal degradation of cIAP1-TRAF2 (345). 
Alternatively, IAP antagonists may induce rapid proteasomal degradation of cIAPs. The 
absence of cIAP proteins allows for stabilization and accumulation of NIK, which can 
then phosphorylate IKKα (346). Activated IKKα causes a chain of events resulting in the 
dissociation of p100 from p52, its dimerization with RelB, and transcription of NF-κB  
target genes (347). Thus, the E3 ubiquitin ligase function of cIAPs and their ability to 
bind to TRAF2 are essential elements in the regulation of NF-κB pathways and 
promotion of cell survival. 
 
 IAPs also play a role in the other signaling pathways such as Jun N-terminal 
kinase (JNK), p38 mitogen-activated protein kinase (MAPK), TGF-β, Myc, and 
PI3K/Akt (348). In the Myc pathway, cIAP1 catalyzes ubiquitylation and degradation of 
a cellular antagonist of Myc and promotes cellular proliferation (349). cIAPs also 
orchestrate NOD-induced signaling by poly-ubiquitylation of RIP2, which leads to the 
activation of TAK1 and MAPK signaling (350). In addition to its role in TAK1-mediated 
NF-κB signaling, XIAP can serve as a cofactor to several TGF-β proteins and potentiate 
TGF-β signaling (351). Also, XIAP, NAIP, and ML-IAP can activate the JNK1 pathway 
through their interactions TAK1 (352). This data further demonstrates the anti-apoptotic 
functions of IAPs by activation and regulation of pro-survival pathways. 
 
 
IAP Proteins in Cancer 
 
 IAPs are aberrantly expressed in a multitude of human cancer, and the elevated 
levels have been linked with tumor progression and aggressiveness, treatment resistance, 
and poor prognosis. For example, high nuclear XIAP expression in breast carcinoma 
patients significantly increases risk of relapse (353) and shortened overall survival (354). 
XIAP expression is also indicative of poor prognosis in colorectal cancer (355), bladder 
cancer (356, 357), chronic lymphocytic leukemia (358), and numerous other cancers 
(359). XIAP expression also increased with advanced tumor stage and was correlated 
with tumor aggression in clear-cell renal carcinomas (360, 361) and metastatic 
melanomas (362).While XIAP expression levels in gastric adenocarcinomas were not 
significant independently, disturbances in the balance of XIAP to XIAP-associated factor 
1 (XAF1), particularly increased ratios of XIAP:XAF1, were substantial determining 
factors in metastasis and patient survival (363, 364). Similarly, its overexpression has 
been linked to chemoresistance in ovarian carcinoma cells after cisplatin treatment (365) 
and XAF1 expression was drastically lower than XIAP in malignant versus non-
malignant tumors (366). In hepatocellular carcinoma, elevated XIAP expression 
increased the risk of relapse after total liver resection and orthotopic liver transplantation, 
promoted metastasis, increased CDK4/Cyclin D1 expression, and corresponded with poor 
overall prognosis (97, 367, 368).  
 
 IAP expression is not necessarily an indicator of unfavorable outcome in every 
case. Studies have indicated there is no correlation between XIAP, cIAP1, or cIAP2 
expression and predictive response to chemotherapy in non-small cell lung cancer 
(NSCLC) patients (369, 370) nor is XIAP expression pertinent to disease stage and 
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patient survival in cervical carcinoma (371). The relevance of XIAP expression in acute 
myeloid leukemia is somewhat ambiguous, as contradicting results have been reported 
(372). Some studies indicated no prognostic relevance of XIAP or survivin levels (373), 
though numerous other studies demonstrated lower XIAP expression was in accordance 
with longer survival and remission duration (374-376).While elevated expression of 
several IAP proteins is evident in prostate cancer, XIAP expression has been reported to 
actually correlate with lower incidences of reoccurrence (377, 378).  Nevertheless, 
targeting specific IAPs in relevant subgroups of cancer patients still warrants 
investigation, and additional studies are needed to define these parameters and identify 
prognostic biomarkers.   
 
 Genetic aberrations contribute to overexpression of IAPs and resistance to 
apoptosis. Amplification of 11q21-11q23, which contains the genes encoding cIAP1 and 
cIAP2, occurs frequently in a multitude of cancers including cervical carcinomas (379), 
esophageal carcinomas (380), liver cancer (381), glioblastomas (382), lung carcinomas 
(383), and renal cell carcinomas (270). The amplification of 11q22, specifically cIAP1, 
increased the risk of radiotherapy resistance in cervical cancer patients (379) and related 
to carcinogenesis in esophageal cancer patients (380). Additional proof demonstrating 
that cIAPs are oncogenic drivers is evidenced by the amplification of chromosome 9A1, 
the syntenic region the human chromosome 11q22, in murine osteosarcoma and 
hepatocellular cancer models (381, 384). 
 
 Another genetic error affiliated with cIAP expression and its oncogenic potential 
involves translocation events in mucosa-associated lymphoid tissue (MALT) lymphomas. 
The  t(1;14)(p22;q32) and t(14;18)(q32;q21) affect the regulation of Bcl10 and Malt1 
genes and promote NF-κB signaling (385). The t(11;18)(q21;q21) is the most frequently 
genetic abnormality associated with MALT lymphoma and is found in about half of all 
low-grade MALT lymphomas (386). This translocation fuses the protein 1 (MALT1) 
gene on chromosome 18 with the cIAP2 gene on chromosome 11 (341, 387, 388). The 
anti-apoptotic cIAP2-MALT1 fusion protein, containing the N-terminal BIR domains of 
cIAP2 (but not the RING domain) and the caspase-like domain in C terminal of MALT1, 
forces constitutive activation of both pathways of NF-κB signaling and promotes 
tumorigenesis (389-392). Several mechanisms have been proposed for activation of 
canonical signaling, including IKK stimulation by cleavage of A20, a negative regulator 
of NF-κB, binding to TRAF2 and/or TRAF6, and enhancement by Bcl10 interaction with 
the fusion protein (393). Whereas potent activation has been attributed to the 
functionality of both domains in the fusion protein for canonical signaling, the loss of E3 
ubiquitin ligase function in the RING-deficient cIAP2-MALT1 fusion protein is 
sufficient to induce non-canonical signaling through NIK stabilization (394).  In addition 
to their oncogenic properties, cIAPs also play a tumor-suppressing role because of their 
ability to both positively and negatively regulate NF-κB signaling. For instance, in 
multiple myeloma, genetic deletion of cIAP1/2 results in aberrant non-canonical pathway 
stimulation (395-397). Though cIAPs can act as tumor suppressors or oncogenes, 
dysregulation of cIAP expression in human malignancies always results in elevated NF-
κB signaling, leads to cell survival, and enhances tumorigenesis (270). 
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 Survivin expression is elevated in most hematologic malignancies, and is 
associated with chemotherapy resistance, relapse, and lower patient survival. In most 
tumor types, it is a significant independent prognostic indicator of unfavorable outcome, 
some exceptions being gastric cancer, non–small-cell lung cancer and osteosarcoma 
(398). Discrepancies in prognostic value may occur due to differing functions of splice 
variants, detection methods, or subcellular localization (nuclear or cytoplasmic). Survivin 
regulates multiple pro-survival processes, especially in the mitotic stage, such as 
cytoprotection, cell cycle regulation, and evasion of cell death. Because of its ubiquitous 
expression in cancers and undetectable levels in most transformed cells, it is an attractive 
therapeutic target. However, there is recent evidence that it is also expressed in primitive 
hematopoietic cells, progenitor cells, T lymphocytes, polymorphonuclear neutrophils, and 
vascular endothelial cells, and is necessary for their proliferation and normal cell function 
(398). The pathways through which survivin regulates proliferation of tumor cells and 
normal cells and the overlap between the two needs to be further defined, though it seems 
that mitochondrial survivin is exclusive to tumor transformation (399). Clarification of its 
differential expression, propagation, and function in malignant and housekeeping 
regulation, especially in hematopoietic and immune systems, is needed to maximize 
therapeutic benefit and minimize toxicity in anticancer strategies targeting survivin.  
Similar to survivin, ML-IAP is not expressed in differentiated adult tissue but is 
preferentially and highly expressed in cancers such as melanoma and renal cell carcinoma 
(400, 401). High ML-IAP expression is indicative of poor prognosis in neuroblastoma 
patients (402) and correlated with tumor stages and pathogenesis of esophageal 
carcinoma (403). Nuclear expression in patients high-grade central osteosarcoma patients 
dramatically patient shortened life-span compared to those with only cytoplasmic 
expression (404) but was a favorable independent predictor of cancer-specific survival 
and progression-free survival in RCC patients (405). Its expression in childhood acute 
lymphoblastic leukemia (ALL) was associated with sensitivity to chemotherapy and 
positive prognosis (406), but found to be a negatively correlated with survival in adult 
ALL (407). Another study showed that ML-IAP expression was not detectable in 
malignant mesothelioma, even when other IAPs were found (408). The inconsistency 
with the correlation between ML-IAP expression and prognosis can probably be 
attributed to its dual functionality. It has been redefined as a regulator of apoptosis rather 
than anti-apoptotic protein due to the discovery that its different isoforms promote 
opposite effects on cell survival. Not only do its alpha and beta isoforms contribute 
differently to tumorigenicity, its anti-apoptotic role is reversed by cleavage to its 
truncated (tLivin) form by a strong apoptotic stimulus (409, 410).  Cleavage of Livin-β 
potently suppresses tumor proliferation, and the balance between the full-length and 
cleaved protein, subsequent processing of tLivin, and its subcellular localization all 
influence its regulation of apoptosis (411). 
 
 
SMAC: The Endogenous Inhibitor of IAP Proteins 
 
 SMAC, also referred to as DIABLO (direct IAP-binding protein with low pI), is 
an endogenous antagonist of IAP proteins. It promotes caspase activation in the 
mitochondrial pathway by binding to IAPs, particularly XIAP (412, 413). preSMAC is 
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translated in the cytosol and then transported into the mitochondrial intermembrane space 
to undergo processing, where it remains until activated by apoptotic stimuli (414). The 
mature form of SMAC is generated from the monomeric SMAC precursor molecule by 
proteolytic cleavage of the 55 amino acid residue sequence in the N-terminus and 
undergoes subsequent homodimerization formed through extensive hydrophobic 
interactions (296, 414). SMAC efflux into the cytosol is also mediated by BCL-2 family 
proteins but is a caspase-catalyzed event that occurs downstream of cytochrome c release, 
whereas cytochrome c release is largely independent of caspase activity (415). 
 
 The mature form of SMAC has only four amino acid residues (Ala-Val-Pro-Ile) 
located in the amino terminal that make up the IAP binding motif responsible for the 
interaction with IAPs (296, 416-418). This AVPI tetra-peptide is able to bind to the BIR2 
and BIR3 domains of XIAP, but not BIR1 (296, 419). SMAC suppresses XIAP-mediated 
inhibition of apoptosis by binding to the BIR3 domain of XIAP and disrupting its 
interaction with the ATPF tetra-peptide binding motif in the linker region of caspase-9 
(420). SMAC simultaneously binds to the BIR2 domain of XIAP, reduces exposure of 
the linker region in XIAP through steric hindrance, and relives executioner caspase 
inhibition (421-423). The presence of both BIR2 and BIR3 domains of XIAP is required 
for effective and efficient antagonism by the SMAC dimer. Also, while not directly 
interacting with XIAP BIR1, SMAC antagonizes the XIAP-TAB1 interaction via steric 
exclusion when it concurrently binds to the BIR2 and BIR3 domain of XIAP and 
therefore prevents XIAP-induced NF-κB activation (319). 
 
 Another important method by which SMAC antagonizes IAPs is by promoting 
proteasomal degradation of cIAP proteins. The AVPI binding motif of SMAC interacts 
with the BIR domains of cIAP1 and cIAP2 and induces RING domain-mediated auto-
ubiquitylation (324, 424). Overall, SMAC is an effective antagonist against several 
critical IAP proteins and capable of promoting apoptosis, thereby supporting the rationale 
for designing small-molecule drugs mimicking SMAC for anticancer therapy. 
 
 
Targeting IAP Proteins for Cancer Therapy 
 
 In the past decade, great strides have been taken in implementing inhibitors of 
IAPs to restore apoptotic function in laboratory and clinical settings. Some strategies to 
inhibit IAPs target mRNA and down-regulate protein levels with antisense 
oligonucleotides, ribozymes, or small-interfering RNAs (425-427). Another approach 
utilizes antigen-based vaccinations to target IAPs and promote immune-mediated tumor 
destruction (428-431). One of the most appealing strategies for targeting IAPs has been 
with the use of small-molecule IAP antagonists, and several of these compounds have 
reached clinical trials (341, 432, 433). Two classes of small-molecule IAP inhibitors are 
SMAC mimetics and survivin-specific antagonists. There have been other small-molecule 
XIAP antagonizing compounds identified, such as embelin, a naturally occurring 
compound that comes from a Japanese Ardisia herb (434). However, its poor solubility 
has prevented further preclinical development (435). Other screening strategies have led 
to the discovery of polyphenylurea-based antagonists 1396-12 and 1396-34 (436) and 
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aryl sulfonamide analogs including TWX006 and TWX024 (437), which can block (or 
reverse) XIAP-mediated caspase-3 inhibition. But again, these compounds also have not 
undergone additional clinical development. Therefore, the scope of this review will be 
limited to the design, development, and therapeutic potential small-molecule SMAC 
mimetics and survivin inhibitors, focusing on a selection of compounds that are 
undergoing clinical advancement. 
 
 
SMAC Mimetics: Design and Mechanism of Action 
 
 The design of SMAC mimetics was initially based on the crystal structure (416) 
and NMR (418) of SMAC in complex with the BIR3 domain of XIAP. These structural 
studies revealed that the AVPI binding region of SMAC recognizes and binds to a surface 
groove on BIR3 domain of XIAP.  The exact mode of binding at each peptide and 
structural basis for the design of SMAC mimetics was previously described by Sun et al. 
(438). To summarize, the methyl group on the first alanine fits into a hydrophobic pocket 
in the surface grove of the XIAP BIR3 domain and the free amino group forms hydrogen 
bonds with Glu314 and Gln319 in BIR3. The carbonyl backbone can participate in 
hydrogen bonding to Trp323 in BIR3. In the second position, valine’s amino and 
carbonyl groups can form optimal hydrogen bonds with Thr308. In the third position, 
proline participates in van der Waals interactions with Trp323 and Tyr324. In the final 
position of the AVPI tetra-peptide, the amino group of isoleucine forms a hydrogen bond 
with Gly306. The side chain of isoleucine fits into a hydrophobic pocket formed by the 
side chains of Leu292 and Val298, as well as the hydrophobic portion of Lys297 and 
Lys299 (438) (Figure 5-4). Based on these monumental structural findings revealing the 
binding interactions between XIAP and SMAC, both peptidic and non-peptidic SMAC 
mimetics have been developed. 
 
 Through biochemical analysis of peptide variations and modifications, the 
minimum sequence requirements to still achieve potent binding were determined, as well 
as favorable and undesirable substitutions of SMAC-based peptides (439, 440). In the 
first position, the alanine residue cannot tolerate replacement with another amino acid 
without significantly reducing its binding affinity but demonstrated comparable binding 
affinity when it was replaced by 2-aminobutyric acid, indicating that a methyl or ethyl 
side chain is ideal in the first position for activity. The second position is flexible to 
replacement by an array of amino acids or residues, however replacement with proline, 
aspartic acid, or valine is not favorable. The replacement of the cyclic proline with a 4 or 
6-member ring decreases binding affinity, but activity can be enhanced if a hydrophobic 
group is attached to the proline ring. A hydrophobic substitution in the fourth position is 
desirable, with phenylalanine showing the greatest affinity, whereas polar molecules 
obliterate activity (438). While SMAC-based peptides could attain potent binding 
affinities to XIAP, they were not cell-permeable without a carrier to facilitate delivery 
into the cell. Extensive chemical modifications had to be made for generation of the first 
SMAC-based peptidomimetic that demonstrated cell-permeability and XIAP antagonism 
(441). It was also established that demethylation at position 1 reduced activity, an L- 
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Figure 5-4. Crystal structure of the SMAC in complex with XIAP. 
Detailed interactions of the AVPI binding motif of SMAC in complex with the BIR3 
domain of XIAP (Protein Data Bank access code: IG73). Hydrogen bonds for Ala1, Val2, 
and Ile4 are shown in yellow. Van der Waals interactions are between Pro3 and the side 
chains of Trp323 and Tyr324. A hydrophobic pocket is formed by the Leu292 and 
Val298 side chains and the hydrophobic portion of Lys297 and Lys299 side chains. 
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configuration was required for position 2, adding hydrophobic groups to position 3 
increases affinity, and the position 4 favors hydrophobic entities, particularly 
phenylalanine and phenylglycine (418, 438, 441). These compounds provided the first 
proof-of concept for small-molecule SMAC peptidomimetics as potential anticancer 
agents and served as prototypes for small-molecule SMAC mimetics. Another significant 
improvement to the design of these compounds was incorporation of a conformationally 
constrained scaffold, which improved affinity and permeability (442-444).  
 
 To date, there are two types of SMAC mimetics: monovalent compounds 
designed to mimic a single IAP binding site of SMAC and bivalent compounds 
containing two SMAC mimetics tethered together by a chemical linker. Because mature 
SMAC can form an elongated homodimer that interacts with both BIR2 and BIR3 
domains, it was reasoned that bivalent, non-peptidic SMAC mimetics resembling the 
SMAC dimer should be more potent and effective in promoting apoptosis by 
concurrently interacting with both domains to restore caspase activity. The first bivalent 
molecules that were discovered demonstrated that bivalent compounds did achieve 
greater affinity than their monomeric analogs, leading to this new category of IAP 
inhibitors (268). In addition to increased affinity, bivalent SMAC mimetics are 
remarkably more potent in inducing apoptosis in tumor cells, with some studies 
suggesting by a factor pf 100-1000 fold (438). The significant increase in potency is 
partially due to their ability to promote cIAP dimerization, auto-ubiquitylation, and 
proteasomal degradation, thereby inducing the autocrine/paracrine TNFα signaling loop 
and NF-κB signaling (324, 445). However, it has been suggested that the more profound 
effect on potency is due to the ability of bivalent compounds to engage in binding 
multiple domains of XIAP, resulting in activation of executioner caspase-3 and caspase-7 
in addition to caspase-9 (341, 446).  
 
 Though SMAC mimetics were designed around the SMAC-BIR3 interaction of 
XIAP, they can also interact with the BIR domains of cIAP1, cIAP2 and ML-IAP. The 
inactivated cIAP1 is conformationally constructed such that its RING domain is 
sequestered within its monomeric structure and unable to dimerize. IAP antagonists 
preferentially bind to the BIR3 domain and cause conformational changes that induce 
dimerization of the RING domain and generate the E3 ligase function (447). The BIR3, 
UBA, and CARD domains of cIAP1 are inhibitory elements to RING dimerization but 
can be overcome by SMAC mimetics (448). Upon binding, cIAP1 undergoes rapidly 
auto-ubiquitylation and depletion, whereas the cIAP2 dimer has a higher intrinsic E3 
ligase activity, is more stable, and less influenced by SMAC mimetics. Elevated E3 ligase 
activity causes cIAP-mediated ubiquitylation and activation of RIP1 and promotes 
canonical NF-κB signaling pathway. This activation is merely transient, however, since 
cIAPs are subsequently degraded. Since cIAPs negatively regulate the non-canonical 
pathway by consistent ubiquitylation of NIK, cIAP inhibitors activate this pathway by 
inducing cIAP degradation. Additionally, the combination of TNFα production and the 
loss of cIAPs lead to RIP1/FADD association, triggering caspase-8 activation and 
extrinsic apoptosis (300, 324, 445). Therefore, inhibitors of IAP proteins are capable of 
reversing the pro-survival action of cIAP proteins by triggering E3 ligase mediated-cIAP  
  
 121 
degradation, inducing non-canonical TNFα production, and stimulating extrinsic TNFR1-
mediated apoptosis. 
 
 IAP inhibitors were initially designed to be non-specific and able to bind to 
different families of IAP proteins. However, to understand the divergent apoptotic 
mechanisms of different IAPs, cIAP-specific inhibitors were developed. Selective 
targeting of cIAP by antagonists demonstrated that inhibition of cIAP alone can induce 
cell death in tumor cells and did not require binding to the XIAP BIR3 domain (449). 
Nevertheless, molecules that simultaneously target both cIAP and XIAP proteins are 
more potent and can more efficiently induce cell death than by cIAP-only antagonism 
(450). Site-specific SMAC mimetics that bind to a single BIR domain have also been 
developed. BIR2-selective SMAC mimetics have demonstrated the ability to sensitize 
TRAIL-resistant breast cancer cells (451) and TRAIL-resistant prostate cancer cells (452) 
to apoptosis in vitro but were not toxic as a single agents. Discovery of BIR2-specific 
benzazepinones has provided useful insights to the apoptotic events that differ 
mechanistically from pan-IAP inhibitors, but initially had shortcomings that limited their 
clinical utility (453). Optimization of these compounds provided further proof-of-concept 
of their ability to promote apoptosis in xenograft models by caspase-3 and caspase-7 
activation without inducing TNFα release (454). Still, it is suggested that BIR2 and BIR3 
should instantaneously be targeted for optimal activation and potency (341, 359). Several 
SMAC mimetics showing strong IAP inhibition and favorable toxicity profiles have 
moved into clinical trials and are being evaluated as single agents and in combination 
therapy. The chemical structure, clinical stage, and developer for the following selection 
of compounds can be found in Figure 5-5A. 
 
 
Clinical Development of SMAC Mimetics 
 
 GDC-0152 and GDC-0917/CUDC-427. The first SMAC mimetic to enter 
clinical trials was designed by Genentech and was one of a series of monovalent 
compounds developed to mimic the AVPI binding motif. Initial studies have shown 
GDC-0152 to be a potent antagonist of cIAP1/2, ML-IAP, and XIAP (455). Using a 
peptidomimetic approach, each position was assessed for its overall contribution to 
binding affinity and evaluated to see if substitutions could be made to improve its 
binding.  For example, it was learned that while the P1 alanine was buried within a 
hydrophobic pocket of the BIR domain, positions 2-4 were more amenable to 
substitution. GDC-0152 demonstrated a Ki binding affinity of <50nM, and induced auto-
ubiquitylation and proteasomal degradation of cIAP1 in melanoma cells. GDC-0152 
promoted cell death in MDA-MB-231 breast cancer cells without affecting human 
mammary epithelial cells in cell viability assays. Additionally, GDC-0152 inhibited 
tumor growth in MDA-MB-231 xenograft models. A phase 1a first-in-human standard 
dose-escalation study revealed linear pharmacokinetics with moderate clearance and 
volume of distribution (455). Another study showed that GDC-0152 was able to induce 
apoptosis through the down-regulation of IAPs and inhibit growth of K562 and HL60 
leukemia cells in a dose-and time-dependent manner (456). Its toxicity and efficacy are 
driven by TNFα levels as a result of increased NF-κB transcriptional activity (457). 
 122 
 
 
Figure 5-5. Preclinical and clinical development of small-molecule SMAC 
mimetics and survivin inhibitors 
A) SMAC mimetics in the preclinical stage include SM-164 (University of Michigan) 
and BV6 (Genentech). Phase I SMAC mimetics include SM-406/AT-406/Debio 1143 
(University of Michigan/Ascenta Therapeutics/Debiopharm), GDC-0152 (Genentech), 
GDC-0917/CUDC427 (Genentech/Curis), and AEG40826/HGS1029 (Aegera 
Therapeutic) (not shown). Compounds advancing to Phase II clinical trials include 
LCL161 (Novartis), and Birinapant/TL32711 (TetraLogic Pharmaceuticals). B) Survivin 
inhibitors in preclinical stages include FL118 (Canget BioTekpharma) and Shepherdin 
(University of Massachusetts). Phase II inhibitors include YM155 (Astellas) and AICAR 
(PeriCor Therapeutics).   
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 Also developed by Genentech, GDC-0917 (CUDC-427) is an orally bioavailable, 
second-generation IAP antagonists. While much of the assessment of this drug was built 
on its predecessor, GDC-0152, a combination of mathematical modeling, simulation 
techniques, and in-vivo pharmacokinetic studies demonstrate its potential as an anticancer 
agent. GDC-0917 binds with affinities similar to that of GDC-0152 and has a more robust 
effect MDA-MB-231 breast cancer cells while still exhibiting little toxicity to normal 
human mammary epithelial cells. Favorable pharmacokinetic properties in terms of 
hepatic clearance, volume, and half-life have been reported (458). One of its main 
advantages is that it can be administered orally unlike its predecessor, which was given 
by IV every 2 weeks. Human simulations to determine ED50 and ED90 are expected to be 
72mg and 660mg assuming a 5 mg starting dose. These expectations were based on 
MDA-MB-231 xenograft models and were predicted to be reached in a time frame of 
about 1-2 years (458). Curis licensed GDC-0917 from Genentech, and it has since been 
renamed CUDC-427. Phase 1 trials in patients with advanced or refractory solid tumors 
or lymphoma are ongoing. 
 
 LCL161. Novartis is responsible for the development of the monovalent, orally 
bioavailable SMAC mimetic LCL161. It targets cIAP1 to induce apoptotic activity 
through E3 ubiquitylation ligases, thereby promoting TNFα secretion and NF-κB 
pathway activation (459). Cleavage of caspase-3 was confirmed in mouse xenograft 
models. Further evaluation in TNFα mRNA indicated a strong correlation between TNFα 
expression and LCL161 dose, where the greatest inhibitory growth response was 
presented by tumors with the highest basal TNFα levels.  LCL161 has been investigated 
as both a single agent and in combination and has produced mixed results. Studies done 
by Pediatric Preclinical Testing Program did not show significant LCL161 activity as a 
single agent in SCID mice xenograft models and pediatric cell lines, which they 
concluded was due to LCL161 being ineffective in a majority of cell lines (460). This 
remains somewhat controversial, as previous reports had indicated efficacy in multiple 
tumor models and cell lines (461). Another study concluded that paclitaxel sensitized 
hepatocellular carcinoma cells to LCL161, but there was significant inhibition of off-
target proteins such as pERK and pJNK, suggesting apoptosis resulted from toxicity as 
opposed to direct action of LCL161-mediated IAP inhibition (462). Additionally, the 
anticancer mechanism was mainly by anti-proliferative effects instead of apoptotic 
stimulation. In a phase 1 first-in-human study of LCL161 as a single agent, it was 
determined that a dose of 1800 mg was above what would be required to achieve target 
inhibition. However, because of the lack of efficacy, sensitivity to LCL161 as single 
agent was not conclusive. Adverse effects included cytokine release syndrome consistent 
with robust NF-κB activity (461). Finding an appropriate level of inflammatory cytokine 
production may ultimately be the key to success if the primary function of the drug 
involves NF-κB pathway activation and TNFα production (463). In a phase 1b study, 
increasing doses of LCL161 were combined with paclitaxel  in patients with advanced 
tumors and was well tolerated with manageable toxicities, predominantly neutropenia, 
fatigue, and neuropathy (464). Altogether, these results suggest that LCL161 is a 
promising anticancer agent, particularly in combination therapy, and warrants further 
investigation to optimize its therapeutic value. 
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 SM-406/At-406/Debio 1143. SM-406, renamed AT-406 for Ascenta 
Therapeutics, is a small-molecule, non-peptidic SMAC mimetic capable of binding 
XIAP, cIAP1 and cIAP2 (465). As it was previously discovered that designing SMAC 
mimetics that are conformationally constrained improved their binding affinity, the 
design of these molecule incorporated a rigid scaffold (442, 443, 446). Preclinical trials 
show good antagonists activity of XIAP at the BIR3 domain and restored caspase-9 
activity, induced rapid cIAP degradation, and increased cell death in a time-and-dose 
dependent manner in MDA-MB-231 cells (465). SM-406 effectively inhibited tumor 
growth in MDA-MB-231 xenograft models with minimal toxicity and achieved complete 
tumor inhibition at 100 mg/kg oral dosing. AT-406 was further evaluated as a single 
agent and in combination therapy with carboplatin, a first line platinum therapy (466). As 
a single agent, AT-406 induced apoptosis in 3 out of 5 carboplatin resistant cancer cell 
lines. The primary function of AT-406 is down-regulating XIAP protein levels, which 
have greater expression in chemoresistant ovarian cancer cells compared to normal ovary 
cells. These provide additional evidence that reduction of cIAP1 alone is not sufficient to 
induce apoptosis. AT-406 also showed the ability to sensitize resistant cells to carboplatin 
in vitro and in vivo, as indicated by prolonged mouse survival (466). Phase 1 trials have 
been completed for Debio 1143 (AT-406) for patients with advanced solid tumors and 
lymphomas and phase II studies are ongoing. 
 
 SM-122 and SM-164. SM-122 is a monovalent, non-peptidic mimetic of SMAC 
and SM-164 is a bivalent analog created from two SM-122 analogs tethered together by a 
chemical linker (467). The bivalent properties of SM-164 allow for binding to BIR2 and 
BIR3 domains of XIAP simultaneously. SM-122 and SM-164 both bind to cIAP1 and the 
BIR3 domain of cIAP2 and exhibit Ki values ranging between .31 and 2.7 nmol/L, where 
SM-122 showed a slightly greater affinity. SM-164 was 300 times more potent than SM-
122 in binding to XIAP and 1000 times more potent in inducing apoptosis. These results 
clearly demonstrate the impact of XIAP antagonism on apoptosis (467). It was then 
shown to effectively promote cell death in MDA-MB-231 tumor tissues of mouse models 
at a 5mg/kg dose. Within an hour, there was a significant decrease in cIAP1 levels, and 
by 3 hours, activation of caspase-8, caspase-9 and caspase-3 and PARP cleavage was 
observed. Damage was limited to the tumor tissue and normal, even highly proliferative 
tissues were unaffected.  More impressively, tumor growth was reduced by 65% without 
causing toxicity or weight loss by day 36. In order to achieve stronger apoptotic 
activation, SM-164 has also been tested in combination with TRAIL (468). While TRAIL 
demonstrates low cytotoxicity and is well tolerated, its applications have previously been 
limited (469, 470). SM-164 was highly synergistic with TRAIL in 12 out of 19 TRAIL-
resistant and TRAIL-sensitive cancer cell lines of breast, prostate, and colon tumor types.  
While these two compounds failed to achieve appreciable antitumor activity as single 
agents, they reduced tumor volume by an average of 80% after two weeks of combination 
treatment in a 2LMP xenograft model. The synergy between TRAIL and SMAC 
mimetics relies on the interaction of procaspase-8 with RIP1 and enhanced by the 
ablation of cIAP1 and XIAP (468). In a separate combination study with doxorubicin, 
SM-164 sensitized hepatocellular carcinoma cells to TNFα-related apoptosis and 
suppressed activation of Akt in vitro (471). These preclinical data provide support for the 
potential of combination therapy with SM-164 for a variety of cancers. 
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 Birinapant. Birinapant (TL32711), by Tetralogic Pharmaceuticals, is a bisindole-
based bivalent SMAC mimetic that binds with high affinity to the BIR3 domains of 
XIAP, cIAP1, cIAP2, and the single binding domain of ML-IAP (472, 473). Though its 
first-generation analog had a greater biding potency to the BIR3 domains of XIAP and 
cIAP2, birinapant exhibited greater tolerability in an MDA-MB-231 xenograft model and 
demonstrated dose-dependent tumor regression. The improvements are attributed to 
decreased potency against cIAP2, lower affinity for XIAP BIR3 and activation of 
caspase-dependent apoptosis while avoiding inhibition of XIAP-dependent NF-κB 
signaling (473). Potent activation of apoptosis was evidenced by cleavage of PARP, a 
substrate of caspase-3, in MDA-MB-231 cells 72 hours post treatment. Subsequent 
corresponding studies showed that birinapant induced rapid degradation of TRAF-bound 
cIAP1 and cIAP2 to inhibit TNFα-mediated NF-κB activation and promoted cell death as 
a single agent (472). Birinapant also promoted activation of caspase-8 via DISC complex 
formation in birinapant-sensitive cells following TNF stimulation and was active in 
approximately 60% of a panel of 111 cell lines tested as a single agent or in combination 
with TNFα and TRAIL. In vivo studies revealed observable antitumor activity after 5 
treatments of 30mg/kg in approximately one third of the 50 patient-derived 
xenotransplant models tested and potentiated the cytotoxicity of certain chemotherapeutic 
agents including SN-38 (the active metabolite of irinotecan), gemcitabine, and 5-
azacytidine. Consistent with these findings, an aggressive, inflammatory breast cancer 
model increased apoptotic activity in TRAIL-insensitive ErbB2-overexpressing cells and 
significantly increased potency of TRAIL-induced cell death in aggressive TRAIL-
sensitive tumors (474). In combination with TNFα, it inhibited proliferation in melanoma 
cells with acquired resistance to BRAF (475). A Phase I first-in-man study of adult 
patients with advanced solid tumors and lymphoma showed that it was well tolerated 
when administered intravenously with no dose-limiting toxicities (476). Birinapant has 
been evaluated in combination with multiple chemotherapies including liposomal, 
doxorubicin, gemcitabine, docetaxel, irinotecan, and paclitaxel at standard dosing and 
demonstrated excellent tolerability (477). Phase 2 studies of birinapant in combination 
with irinotecan in colorectal patients showed an overall clinical benefit rate of 57%, 
supporting the hypothesis of synergy between birinapant and irinotecan as a TNFα-
inducing agent (478). Clinical investigations of birinapant in patients with solid tumors 
and hematological malignancies are ongoing. 
 
 BV6. BV6, another of compound by Genentech, is a bivalent SMAC mimetic that 
is able to engage in binding of both cIAP and XIAP to produce apoptotic activation. Like 
other SMAC mimetics, BV6 effectually diminishes the pro-survival effects cIAP1 and 
cIAP2 through induced auto-ubiquitylation and degradation and it inhibits XIAP through 
antagonism of caspase binding (324). This study made profound contributions to the 
understanding of IAP antagonist-induced cell death dependent on NF-κB signaling. BV6 
is capable of sensitizing several cell lines to radiation-induced apoptosis of non-small cell 
lung carcinoma in vitro, including the SMAC mimetic resistant cell line, H460 (479). 
Another study investigated whether BV6 could sensitize tumor cells to non-specific 
cytokine-induced killer cells (480). While it was shown that BV6 did sensitize 
hematologic and solid malignancies to CIK cells, it also promoted apoptosis in the CIK 
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cells themselves as well as other peripheral mononuclear cells (PMNCs). Despite its 
effect on CIK cells, the fact that it still sensitized non-malignant cells such as PMNCs 
toward CIK cell-mediated killing limits its potential in combination with CIK immune-
based therapies. On the other hand, BV6 has been shown to interact synergistically with 
glucocorticoids such as dexamethasone to enhance glucocorticoid-triggered cell death in 
pediatric acute lymphoblastic leukemia (481). Additional trials with BV6 in combination 
therapy are warranted. 
 
 AEG40826/HSG1029. AEG40826, renamed HSG1029, is a bivalent SMAC 
mimetic developed by Aegera Therapeutics and licensed by Human Genome Sciences for 
clinical development. The results of phase 1 HGS1029 trials indicate a favorable safety 
profile with IV administration and good tolerability in patients with advanced solid 
malignancies. However, dose limiting toxicities such as dose-dependent short-lived 
lymphocytopenia and possibly a transient neutrophilia in some patients were observed 
(482). As expected, HGS1029 stimulated decrease in cIAP1 and up-regulation of 
monocyte chemoattractant protein 1 levels. No structural data has been published. 
 
 
Small-Molecule Survivin Inhibitors 
 Though survivin is reported to inhibit apoptosis, the exact mechanism by which it 
does so remains elusive. This is further complicated by the myriad of cell cycle processes 
in which it is involved, including cellular homoeostasis, cell division, intracellular 
signaling and apoptosis (338). Several strategies that selectively target survivin are under 
development, but there are only a handful that do so by targeting the protein with small 
molecules. Even so, these small molecules do not seek to inhibit survivin by forcing 
suppression by direct binding but rather target promoter regions or disrupt protein-protein 
interactions in survivin complexes (270, 339, 427). The chemical structure, clinical stage, 
and developer for the following selection of compounds can be found in Figure 5-5B. 
 
 
Clinical Development of Survivin Inhibitors 
 
 YM155. YM155, or sepantronium bromide, is a small imidazolium-based 
molecule that was identified by high-throughput screening (HTS) of chemical libraries of 
compounds that diminished survivin expression in a survivin promoter-luciferase assay. 
YM155, unlike SMAC mimetics, suppresses survivin expression by interfering with the 
promoter transcription region (483).  The molecular mechanism by which YM155 
inhibits survivin is at least in part by dissociation and subcellular relocalization of 
transcription factors such as Sp1 from its DNA binding sites and acts in cell cycle-
independent manner without G1 cell arrests (484). Preclinical studies of YM155 
demonstrated inhibition of cell growth in a broad spectrum of cancer cell lines including 
non-Hodgkin’s lymphoma, hormone-refractory prostate cancer, ovarian cancer, sarcoma, 
non-small-cell lung cancer, breast cancer, leukemia and melanoma (485). Additionally, 
YM155 was able to produce antitumor activity in p53-defective human tumor xenograft 
models. Because abnormal p-53 expression is associated with increased survivin 
expression, this could provide an advantage over current therapies. In phase 1 trials, it 
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was shown to be well tolerated in patients with advanced solid tumors or hematologic 
malignancies (485). Phase 2 studies have been less encouraging though: while severe side 
effects were uncommon, it only achieved modest efficacy at best as a single agent or in 
combination therapy (372, 486, 487). YM155 is a substrate for p-glycoprotein-mediated 
transport, making it susceptible to multidrug resistance and therefore limiting its 
therapeutic applications (488). 
 
 FL118. FL118 is a small-molecule identified through HTS of compound libraries. 
It not only inhibits survivin promoter activity, but also inhibits anti-apoptotic Mcl-1, 
XIAP and cIAP2 expression without disrupting control genes (489). FL118 had superior 
antitumor activity in mouse xenograft models when compared with YM155 and acts in a 
p53-independent manner. It was even able to completely eradicate colon and head-and-
neck tumors in a mouse model. Furthermore, it is suggested that FL118 is not a substrate 
for the ABCG2 pump and could potential bypass multiple treatment-resistant mecha-
nisms (490). Its clinical potential has been further realized by improvements on its 
formulation and route of administration (491). Based on these findings, it is a favorable 
candidate for clinical trials. 
 
 Shepherdin and AICAR. Shepherdin is a small-molecule peptidomimetic that 
was designed to interfere with the interaction between survivin and Heat-shock protein90 
(Hsp90) (492, 493). Hsp90 is a molecular chaperone protein that binds to and stabilizes 
survivin. Disruption of the Hsp90-survivin complex leads to survivin degradation and 
mitochondrial-dependent apoptosis (494). Within the BIR1 domain, residues Lys79 –
Leu87 are essential for the association of survivin with Hsp90. Shepherdin exploits that 
interaction and binds extensively to the ATP pocket of Hsp90 to destabilizes survivin and 
induce tumor cell death by both apoptotic and non-apoptotic mechanisms (492). Not only 
does it disrupt the Hsp90-survivin interface, is acts as a global inhibitor of Hsp90 
function by competition with ATP. Systemic administration of shepherdin in vivo was 
found to be well-tolerated and inhibited human tumor growth in mice without significant 
toxicity. It also achieved anticancer activity in vivo in an acute myeloid leukemia 
xenograft model as determined by loss of expression of survivin and Akt without causing 
toxicity to normal tissue (495). Clinical evaluation of shepherdin in patients has not yet 
been reported. Other small molecules targeting of Hsp90 include nonpeptidic 5-
aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR). Other studies yielded 
similar results, indicating that destabilization of Hsp90 led to apoptosis in multiple tumor 
cell lines while not affecting proliferation of normal human fibroblasts (493). However, 
because AICAR is a potent agonist of AMP-activated protein kinase (AMPK), 
deleterious side effects such as significant drop in plasma potassium levels have been 
reported (496). Further studies are needed to address concerns associated with survivin 
antagonism. 
 
 
Challenges for Clinical Development 
 
 Though IAP antagonists have demonstrated antitumor efficacy in a variety of 
cancer types, there are still challenges that need to be addressed in order to incorporate 
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them into practical anticancer regimens. One potential issue observed is due to the potent 
activation of cIAP-dependent NF-κB signaling. While up-regulation of this pathway and 
its targeted genes such as TNFα are responsible for the TNFα-mediated apoptosis, they 
can also pose the threat of provoking toxic side effects associated with stimulation of 
inflammatory cytokine production (463). Some IAP antagonists may therefore cause 
adverse side effects such as Cytokine Release Syndrome, exemplified by LCL161 in a 
phase 1 dose escalation study (461). Because it is the same pathway that both drives 
apoptosis and causes unintended side effects associated with inflammatory cytokines, 
additional studies are warranted to optimize a therapeutic window to effectively inhibit 
antitumor activity and decreases risk of cytotoxicity. Other issues correlated with 
elevated NF-κB signaling include increased osteoclastogenesis and osteoporosis 
development as a result of NIK stabilization (497).  
 
 Another challenge encountered is determining suitable biomarkers in patient 
population to assess susceptibility to IAP antagonist treatment. Preclinical and clinical 
studies have identified several biomarkers for potential response, including serum 
cytokines and cIAP levels (498). However, SMAC mimetics may induce cIAP 
degradation at non-toxic concentrations, in non-tumor tissues, and in non-response 
malignancies, so cIAP loss would not be indicative of therapeutic relevance (341). 
Baseline TNFα levels may serve as more suit able biomarkers and additionally may 
induce non-apoptotic forms of cell death, such as by necroptosis (499, 500). However, it 
is still unknown if there are other cytokines or apoptotic markers that may have serve as a 
more reliable source for predicting therapeutic efficacy (463). Furthermore, IAP 
expression is not always directly correlated with adverse prognosis. For example, XIAP 
is elevated in prostate cancer, but recent studies indicate that elevated levels decrease the 
risk of tumor reoccurrence compared to subjects with lower levels (378). Studies on 
patients with advanced non-small cell lung cancer indicate no relation between XIAP 
expression and clinical outcome (501). Additional studies are required to determine 
indicators of potential efficacy to IAP antagonist treatment. Caution should be exercised 
with therapies targeting XIAP concomitantly with death receptors. The corresponding 
increased rate of apoptosis can become deleterious for type II cells, such as hepatocytes 
pancreatic beta cells, and lead to liver toxicity (502).  
 
 Small-molecule survivin antagonists may also produce deleterious effects. 
Because it is a chromosomal passenger protein complex that participates in multiple 
facets of cell division, survivin antagonism can cause generation of polyploidy cells and 
are more susceptible to mutations, genetic variation and instability. This may result in 
increased tumor aggression and resistance to treatment (270, 503). Moreover, although 
survivin is not expressed in adult differentiated cells, it is still expressed in proliferating 
cells, such as in the immune system. Loss of survivin can affect T-cell maturation and 
proliferation (504).  Also, because of the dynamic role of survivin in numerous biological 
processes including mitosis, apoptosis, cell cycle regulation, and autophagy as well as its 
interaction with numerous endogenous molecules, it is difficult to evaluate the efficacy 
and target specificity of its clinical candidates by any high throughput assay. These 
complexities also obscure the therapeutic significance of small-molecule survivin 
antagonists (338, 505). 
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 Another crucial question lies in the synergism between IAP inhibitors in 
combination with other agents to achieve cell death. As single agents, SMAC mimetics 
trigger apoptosis in only a small subset of cancer cell lines. In combinations with death 
receptor ligands such as TNFα, TRAIL, and CD95, IAP antagonists have a greater 
capacity to elicit potent activation of apoptosis in a variety of cell lines (506). The answer 
may lie in determining which combination regimen produces the most robust effect on 
tumor regression without toxicity to healthy tissues. Additionally, IAPs can prime cancer 
cells toward apoptosis by lowering the apoptotic threshold and rendering them vulnerable 
to a variety of cytotoxic factors including chemotherapeutic agents (507). The 
combination of IAP antagonists with chemotherapeutics, radiation therapy, and kinase 
inhibitors is being explored but is still largely unknown. 
 
 
Summary 
 
 In summary, IAPs inhibit cell death pathways, promote pro-survival signaling, 
and are up-regulated in many types of cancer, making them desirable molecular targets 
for anticancer therapy. Significant progress has been made in developing IAP inhibitors, 
particularly with small molecules, and these drugs represent a promising strategy for 
inducing cell death in human diseases and malignancies. SMAC mimetics have shown 
the ability to interact with XIAP and suppress their inhibitory action on caspases as well 
as the ability to bind cIAPs and produce apoptotic effects by regulating NF-κB signaling 
and extrinsic cell death pathways. Other small-molecule inhibitors also aim to suppress 
the anti-apoptotic effects of survivin but must overcome additional complexities due to its 
multifaceted role in many cellular processes. While a handful of small molecules have 
progressed into clinical trials, there are still many challenges that need to be addressed 
such as off-target toxicities associated with increased NF-κB signaling, identifying 
appropriate biomarkers that correlate with elicited response, and developing synergistic 
combination therapies, especially to avoid development of multiple drug resistance. 
Overall, small-molecule IAP antagonists have great potential as anticancer drugs as 
single agents or in combination with existing therapies. 
 
 
Hypothesis for Novel Survivin Inhibitors 
 
 In Chapter 6, we investigate a series of new survivin inhibitors modified from the 
UC-112 scaffold, which was previously identified through virtual screening. UC-112 
demonstrated favorable properties over the most widely studied survivin inhibitor 
YM155 in that it was shown to be highly effective against drug efflux pump mediated 
resistance (508). SAR analysis of a predecessor drug, MX-106, revealed pertinent 
structural information for optimizing the UC-112 scaffold and suggested that a 
hydrophobic substituent on the benzene is amenable to activity. We therefore 
hypothesized that further modification to the benzyloxy moiety in MX-106 would yield 
potent analogs and that these analogs would maintain activity against P-gp 
 130 
overexpressing cell lines, selectively inhibit survivin over other IAP family members, and 
demonstrate strong tumor growth inhibition against xenograft tumors in mice. 
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CHAPTER 6.    INDOLE-BASED UC-112 ANALOGS AS POTENT AND 
SELECTIVE SURVIVIN INHIBITORS5 
 
 
Introduction 
 
 Survivin is the smallest member in the IAP protein. Its expression is very low in 
healthy tissues and is highly expressed in tumors (509). The overexpression of survivin in 
tumor cells has been positively correlated with their development of multidrug resistance 
and radiation resistance (510, 511). For example, it is well established that cancer cells 
with high expression of survivin (e.g., prostate, ovarian and colorectal cancer cells) 
develop resistance to cisplatin and vincristine much easier than tumors cells with low 
expression of survivin (512). Survivin is therefore considered as a cancer specific 
biomarker and an attractive therapeutic target for the development of anticancer therapy 
(339) (513).  
 
 Several reported strategies have been applied to block the anti-apoptotic ability of 
survivin. These strategies include but are not limited to introducing recombinant cell-
permeable dominant-negative survivin protein (514, 515), obstructing protein translation 
using antisense oligonucleotides (516), and developing small-molecule based survivin 
antagonists (517, 518). The crystal structure of human survivin was obtained in the early 
of this century, revealing its unusual bow tie-shape dimer structure (519). However, 
targeting survivin using small-molecule survivin inhibitors has been proven to be 
challenging because no experimentally validated binding pocket in survivin has been 
identified yet. The difficulty in developing a survivin specific small-molecule inhibitor 
also lies in the fact that survivin interacts with many other proteins to mediate apoptosis 
and mitosis, such as p53, STAT3, caspases and elements in the notch signaling pathway 
(520-523). A number of scaffolds have been reported in the literature to significantly 
suppress the expression of survivin and some have entered clinical trials for cancer 
treatment (483, 489, 505, 508, 524-529). However, none of these molecules have gained 
FDA approval. The most widely studied survivin inhibitor is YM155 which was initially 
discovered by Astellas Pharma in 2007. YM155 has an IC50 in the sub-nanomolar range 
against several types of cancer cell lines (484). It inhibits survivin expression by 
inhibiting survivin promotor activity instead of directly degrading survivin protein. In 
clinical trials, YM155 was evaluated as monotherapy or combinational forms for patient 
with different cancer types, including blood cancer and solid tumors (530). 
Unfortunately, YM155 was withdrawn in phase II clinical trials due to its low ability to 
degrade survivin and high systemic toxicity.  
 
 We have recently discovered UC-112 through virtual screening followed by 
biological validation (Figure 6-1)(508). UC-112 is a potent survivin inhibitor that  
                                                 
 
5Modified with permission from Elsevier. Qinghui Wang*, Kinsie Arnst*, Yi Xue*, Zi-Ning Lei, Zhe-
Sheng Chen, Duane D. Miller, Wei Li. Synthesis and biological evaluation of indole-based UC-112 analogs 
as potent and selective survivin inhibitors. European Journal of Medicinal Chemistry. 2018; 149:211-224. 
*Equally contributing authors. 
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Figure 6-1. Structure of UC-112 and MX-106. 
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selectively degrades survivin protein via the proteasome pathway, activating caspases 3/7 
and 9, and thus leads to cancer cell apoptosis. Unlike YM155 which is highly susceptible 
to P-gp mediated drug efflux pump mediated drug resistance, UC-112 was shown to be 
effective against P-gp overexpressing multidrug-resistant cancer cell lines. Subsequent 
structural modifications of UC-112 results in MX-106 (Figure 6-1), which showed 
improvements in suppressing survivin expression both in vitro and in vivo (531). 
According to the SAR analyses, the 8-hydroxyquinoline and the pyrrolidine in UC-112 
are essential for maximum activity; hydrophobic substituent on the benzene is beneficial 
to activity. With this observation, we created analogs with modifications to the benzyloxy 
moiety in UC-112 as well as conformational restricted analogs formed by reducing the 
flexibility of the benzyloxy moiety in this scaffold to improve the activity. In this chapter, 
we reveal our results from modifying the benzyloxy moiety in the UC-112 scaffold and 
the biological investigation that followed. Thirty-three UC-112 analogs were synthesized 
and evaluated for their initial potency activities and lead compounds were further 
evaluated for their selective survivin inhibition and in vivo efficacy. 
 
 
Materials and Methods 
 
 
Cell Culture and Reagents 
 
 Human melanoma A375, M14, WM-164, RPMI-7951, and M14/MDR1 cell lines 
were purchased from ATCC (American Type Culture Collection, Manassas, VA, USA), 
and cultured in DMEM media (Mediatech, Inc., Manassas, VA) at 37 ?C in a humidified 
atmosphere containing 5% CO2. The culture media were supplemented with 10% fetal 
bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 1% antibiotic-antimycotic 
mixture (Sigma-Aldrich, St. Louis, MO). Compounds were dissolved in dimethyl-
sulfoxide (DMSO; Sigma-Aldrich) to make a stock solution of 10 mM. Compound 
solutions were freshly prepared by diluting stocks with cell culture medium before use 
(final solution contained less than 0.5% DMSO). 5000 cells in logarithm growing phase 
were seeded overnight into each well of a 96-well plate. Then the cells were continuously 
incubated for 48 h with sequential diluted compound solution (100 μM to 3 nM, 100 μL 
per well) in cell culture medium. The cell viability was determined in MTS assay and 
IC50 was calculated (n = 4), following similar procedures as described previously (100, 
143, 508, 531). Dulbecco’s modified Eagle’s Medium (DMEM), fetal bovine serum 
(FBS), penicillin/streptomycin and trypsin 0.25% were purchased from Hyclone (GE 
Healthcare Life Science, Pittsburgh, PA). Phosphate buffered saline (PBS) was purchased 
from Invitrogen GIBCO (Grand Island, NY). Dimethyl sulfoxide (DMSO) and 3-(4,5-
dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide (MTT) were purchased from 
Sigma Chemical Co (St. Louis, MO). The P-glycoprotein (P-gp) overexpressing KB-C2 
cell line was established from a parental human epidermoid carcinoma cell line KB-3-1, 
by a step-wise selection of KB-3-1 in increasing concentrations of colchicine up to 2 
μg/mL (532). SW620/Ad300, which is also a P-gp overexpressing drug resistant cell line, 
was established by stepwise exposure of the parental human colon cancer cell line 
SW620 to increasing concentrations of doxorubicin up to 300 ng/mL(533). The KB-3-1 
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and KB-C2 cell lines were generously provided by Dr. Shin-Ichi Akiyama (Kagoshima 
University, Japan), and the SW620 and SW620/Ad300 cell lines were kindly provided by 
Dr. Susan E. Bates (Columbia University, NY, USA) and Dr. Robert W. Robey (NIH, 
MD, USA). All the cell lines were grown in DMEM supplemented with 10% FBS and 
100 unit/mL penicillin/streptomycin in a humidified incubator containing 5% CO2 at 37 
°C. 
 
 
Cytotoxicity Assays  
 
 A375, M14, WM-164, RPMI-7951, and M14/MDR1 were seeded in 96-well 
plates at a concentration of 1,000–5,000 cells per well, depending on growth rate of the 
cell line. After overnight incubation, the media was replaced, and cells were treated with 
the test compounds at 10 concentrations ranging from 0.03 nM to 1 μM plus a vehicle 
control for 72 h in four replicates. Following treatment, the MTS reagent (Promega, 
Madison, WI) was added to the cells and incubated in dark at 37°C for at least 1 h. 
Absorbance at 490 nm was measured using a plate reader (DYNEX Technologies, 
Chantilly VA). Percentages of cell survival versus drug concentrations were plotted, and 
the IC50 (concentration that inhibited cell growth by 50% of untreated control) values 
were obtained by nonlinear regression analysis using GraphPad Prism (GraphPad 
Software, San Diego, CA). 
 
 Cytotoxicity against P-gp overexpressing cell lines by the MTT assay was 
obtained by Zi-Ning Lei (St. John’s University). Cells were seeded in 96-well plates at 
5000 cells/well (KB-3-1 or KB-C2 cells) or at 7,000 cells/well (SW620 or SW620/Ad300 
cells) in 180 μL completed medium and cultured overnight. Then various concentrations 
of the compounds (20 μL) were added to the designated wells. After 72 hr continuous 
drug incubation, 20 μL of MTT reagent (4 mg/mL) was added to each well and the plates 
were incubated at 37 °C for 4 hr. Subsequently, the medium was removed and 100 μL of 
DMSO were added to dissolve the formazan crystals in each well. The absorbance was 
determined at 570 nm by the accuSkan™ GO UV/Vis Microplate Spectrophotometer 
(Fisher Sci., Fair Lawn, NJ). The IC50 values of each compound on each cell line were 
calculated from the survival curves to represent the cytotoxicity of the compounds. The 
fold of drug resistance was calculated by dividing the IC50 of the P-gp overexpressing 
cells by that of the parental cells. Two known P-gp substrates, YM155 and paclitaxel, 
were used as positive controls for P-gp overexpressing cell lines. On the other hand, 
cisplatin, which is not a substrate of P-gp, was used as negative control.  
 
 
Liver Microsomes Stability Assay 
 
 Liver microsome assays were performed by Dr. Lei Yang (St. Jude Children’s 
Research Hospital). NADPH regenerating agent solutions A (catalog#: 451220) and B 
(catalog#: 451200) and mouse liver microsomes (CD-1, mixture of male, 
catalog#:452701, and female, catalog#: 452702) were obtained from BD Gentest 
(Woburn, MA). Liver microsomes stability assay was conducted following literature 
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reports (238, 239). For each test compound, the mouse liver microsomal solution was 
prepared by adding 0.058 mL of concentrated mouse liver microsomes (20 mg/mL 
protein concentration) to 1.756 mL of 0.1 M potassium phosphate buffer (pH 7.4) 
containing 5 μL of 0.5 M EDTA to make a 0.6381 mg/mL (protein) microsomal solution. 
Each test compound (2.2 μL of 10 mM DMSO solution) was added directly to 1.79 mL 
of mouse liver microsomal solution and 90 μL was transferred to wells in 96-well plates 
(0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The NADPH regenerating agent 
was prepared by mixing 0.113 mL of NADPH regenerating agent Solutions A, 0.023 mL 
of solution B and 0.315 mL of 0.1 M potassium phosphate buffer (pH 7.4) for each tested 
compound. To each well of the 96-well plate, 22.5 μL of the NADPH regenerating agent 
was added to initiate the reaction, and the plate was incubated at 37 °C for each time 
point (0, 0.25, 0.5, 1, 2, and 4 h time points each in triplicate). The reaction was quenched 
by adding 225 μL of cold acetonitrile containing warfarin (4 mg/mL) as internal control 
to each well. All of the plates were centrifuged at 4,000 rpm for 20 min and the 
supernatants (100 μL) were transferred to another 96-well plates for analysis on UPLC–
MS (Waters Acquity UPLC linked to Waters Acquity Photodiode Array Detector and 
Waters Acquity Single Quadrupole Mass Detector) on Acquity UPLC BEH C18 1.7 mm 
(2.1x50 mm) column by running 90–5% gradient for water (+0.1% formic acid) and 
acetonitrile (+0.1% formic acid) in 2 min. The area under the single ion recording (SIR) 
channel for the test compound divided by the area under the SIR for internal control at 0 
time concentration was considered as 100% to calculate remaining concentration at each 
time point. The terminal phase rate constant (ke) was estimated by linear regression of 
logarithmic transformed concentration versus the data, where ke = slope × (−ln 10). The 
half-life t1/2 was calculated as ln 2/ke. The intrinsic clearance (CLint,app)= (0.693/in vitro 
t1/2) x (1 mL incubation volume/0.5 mg of microsomal protein) × (45 mg microsomal 
protein/gram of liver) x (55 g of liver/kg body weight) . 
 
 
Western Blot 
 
 To determine the change of protein levels of survivin and closely related IAPs, 
lysates of A375 or M14 melanoma cells treated by the compound solution for 24 h were 
used for western blotting analysis and determined by Dr. Yi Xue (UTHSC). Primary 
rabbit antibodies against IAP proteins including survivin (#2808), XIAP (#2045), cIAP1 
(#7065), Livin (#5471), Cleaved PARP (#9185) and the loading control protein GAPDH 
(HRP Conjugate) (#3683) were purchased from Cell Signaling Technology, Inc. 
(Danvers, MA) and used according to manufacture instructions as reported previously. 
 
 
Molecular Modeling 
 
 Molecular modeling data was provided by Dr. Wei Li (UTHSC). The molecular 
docking studies were conducted in Schrodinger Molecular Modeling Suite 2014 
(Schrodinger Inc., Portland, OR) following previously described procedures (508, 531). 
Ligand was prepared to generate various conformation before being docked into the 
SMAC AVPI binding site of a human survivin crystal structure (Protein Data Bank entry: 
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3UIH). Prior to molecular dynamic calculation, the docking to minimize the energy of 
potential ligand binding poses was performed. Results were visualized using the Maestro 
interface of the Schrodinger software. 
 
 
In Vivo Xenograft Model 
 
 All animal experiments were performed in accordance with the NIH animal use 
guidelines and protocol approved by the Institutional Animal Care and Use Committee at 
the University of Tennessee Health Science Center. Nude mice, 6–8 weeks old, were 
purchased from Envigo (Indianapolis, IN).  
 
 Logarithmic growth phase A375 cells (5 × 107 cells per mL) were prepared in 
phenyl red-free, FBS-free media and mixed with Matrigel immediately before injecting 
into mice. Tumors were established by injecting 100 μL of this mixture subcutaneously in 
the dorsal flank of each mouse (2.5 × 106 cells). After tumor volumes reached 
approximately 150 mm3 mice were randomized into control or treatment groups (n=7~8). 
10f or paclitaxel was dissolved in a 1:1 ratio of PEG300: PBS solution to produce desired 
concentrations. The vehicle control solution was formulated with equal parts PEG300 and 
PBS only. 100 μl of the drug treatment or vehicle control was administered via i.p. 
injection every other day two weeks.  
 
 Tumor volume was measured three times a week with a caliper and calculated by 
using the formula a×b2×0.5, where a and b represented the larger and smaller diameters, 
respectively. Tumor growth inhibition (TGI) at the conclusion of the experiments was 
calculated as 100 – 100 ×((T − T0)/(C − C0)), where T, T0, C and C0 are the mean tumor 
volume for the specific group on the last day of treatment, mean tumor volume of the 
same group on the first day of treatment, mean tumor volume for the vehicle control 
group on the last day of treatment and mean tumor volume for the vehicle control group 
on the first day of treatment, respectively. Animal activity and body weights were 
monitored during the entire experiment period to assess potential acute toxicity. At the 
end of the experiment, mice were sacrificed and the tumors were weighed. Tumors and 
tissues were dissected out and preserved in 10% buffered formalin phosphate solution. 
 
 
Results and Discussion 
 
 
UC-112 Analogs with Modification of the Benzyloxy Moiety 
 
 Our preliminary SAR investigation of UC-112 emphasized the replacement of the 
benzyloxy with other substructures and has led to the syntheses of analogs 2a-2d, 6a-6f, 
8 and 10a (Table 6-1). Compared to the reference compound MX-106, 2a (5-
fluoroindazole analog), 2b (benzotriazole analog) and 2c (4-chloropurine analog) 
exhibited 3~5-fold reduced activities. Replacement of the benzyloxy with the other  
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Table 6-1. In vitro cytotoxic effects of UC-112 analogs with modification to the 
benzyloxy moiety. 
 
IC50 ± SEM (μM) 
aRI 
A375 WM-164 
RPMI-
7951 
M14 M14/MDR1 
2a 3.6 ± 0.2 8.6 ± 1.1 11.1 ± 0.7 5.4 ± 0.3 7.0 ± 0.1 1.3 
2b 
 
1.9 ± 0.1 >30.0 6.5 ± 0.2 2.3 ± 0.1 3.1 ± 0.1 1.3 
2c 
 
3.9 ± 0.1 56.4 ± 1.1 17.4 ± 1.2 4.1 ± 0.2 7.9 ± 0.1 1.9 
2d 
 
14.1 ± 0.7 33.9 ± 1.1 21.0 ± 0.4 11.5 ± 0.4 14.3 ± 0.2 1.2 
6a >30.0 13.0 ± 0.5 >30.0 >30.0 >30.0 bND 
6b 4.7 ± 0.2 3.7 ± 0.3 26.2 ± 6.2 5.1 ± 0.1 10.7 ± 1.2 2.1 
6c 3.5 ± 0.3 2.8 ± 0.2 18.4 ± 0.3 8.6 ± 0.2 7.4 ± 1.2 0.9 
6d 1.5 ± 0.1 1.6 ± 0.1 12.9 ± 0.2 >30.0 12.2 ± 0.2 ND 
6e 6.0 ±1.3 24.9 ±1.0 25.3 ± 2.4 6.7 ± 0.3 12.2 ± 0.5 1.8 
6f 2.9 ± 0.15 ND 6.8 ± 0.6 2.4 ± 0.1 3.3 ± 0.2 1.4 
8 
 
>30.0 20.18 ± 0.49 17.3 ± 0.3 >30.0 8.7 ± 0.2 ND 
10a 
 
0.8 ± 0.1 0.9 ± 0.1 4.4 ± 0.3 0.8 ± 0.1 2.1 ± 0.1 2.6 
UC-112 
 
1.9 ± 0.6 ND ND 2.1 ± 0.4 3.2 ± 0.5 1.5 
MX-106 
 
0.9 ± 0.1 1.1 ± 0.2 ND 0.8 ± 0.2 1.8 ± 0.4 2.3 
 
aRI: Resistance index is calculated by dividing the IC50 values on multidrug-resistant cell 
line by IC50 by the matching parental cell line.  
bND: Not Determined.   
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moiety as shown in compounds 2d resulted in significant reduction of inhibitory effects 
(> 3-fold). Replacing the benzyloxy with phenyl acetamides (analogs 6a-6d) was 
detrimental to the antiproliferative activities. Shortening the linkage by one methylene in 
6b and 6d resulted in analogs 6e-6f and was revealed to not affect the activities. The 
introduction of a benzylurea (analog 8) dramatically attenuated the antiproliferative 
activity. Among all analogs in this series, non-substituted indole analog 10a, exhibited 
the most potent activity and was comparable to that of MX-106, having an average IC50 
of 0.9 μM. 
 
 
UC-112 Analogs with Substitutions on the Indole Moiety 
 
 Because the indole analog 10a had an equipotency to that of MX-106, we 
subsequently focused our effort to investigate the substitutional effect on the indole ring. 
Analogs 10b-10p with mono-substituent and analogs 10q-10v with di-substituents were 
then synthesized (Table 6-2). For the 2-position substituted analogs, 10b with a methyl 
group and 10c with an ethyl group showed slightly reduced activities compared to 10a. 
Introducing substituents to the 4-position on the indole diminished the antiproliferative 
activity, which was demonstrated by analogs 10d and 10e. For analogs that had 
substituents on the 5-position of indole, comparable activities to that of 10a were 
observed, for example, compounds 10f, 10g and 10h had IC50 values ranging from 0.7 to 
1.1 μM; analog 10i that had bulky ester functional group showed ~2-fold reduced activity 
in comparison with MX-106. In the series of analogs with substituents on the 6-position 
of the indole (10j-10n), they were generally equipotent to MX-106 and 10a, having IC50 
values as low as 0.7 μM. Analogs having substituents on the 7-position of indole were 
slightly less potent than corresponding 5- or 6-position substituted counterparts. All the 
six di-substituted analogs did not show any improvement of activity compared to their 
mono-substituted counterparts. 10s-10v were designed based on the most potent mono-
substituted analogs 10f, 10k, and 10n. Incorporation of a secondary substituent to 5-
fluoroindole, 6-chloro, or 6-methoxyindole generally was not beneficial to activity; for 
example, 10s and 10u showed reduced cytotoxicities compared to 10f and had IC50 values 
of >1.5 μM; the 3-cyano-6-methoxy indole analog 10t was less potent than the mono- 
substituted counterpart 10n; 5,6-dichloroindole analog 10v showed cytotoxicity 
comparable to that of 5-chloroindole analog 10k. 
 
 
Potency Against P-gp Overexpressing Cell Lines 
 
 P-gp belongs to the family of ABC transporters and is encoded by the ABCB1 
gene. P-gp is responsible for the decline of concentrations of extensive anticancer drugs 
in multidrug resistant cells. Therefore, the ability to overcome P-gp mediated drug-
resistance is a favorable property for drug candidates. In addition to the M14 melanoma 
cell line, its P-gp overexpressed daughter line M14/MDR1 was also tested to evaluate the 
abilities of new analogs to overcome P-gp mediated drug-resistance (Table 6-2). 
According to assay result, more than twelve of the twenty-two indole analogs exhibited  
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Table 6-2. In vitro cytotoxic effects of UC-112 analogs with mono- and di-
substituents on the indole moiety. 
 
Structure ID R 
IC50 ± SEM (μM) 
aRI 
A375 WM-164 
RPMI-
7951 
M14 
M14/MD
R1 
 
Mono- 
substituent 
10a H 0.8 ± 0.1 0.9 ± 0.1 4.4 ± 0.3 0.8 ± 0.1 2.1 ± 0.1 2.6 
10b 2-Me 2.2 ± 0.2 7.5 ± 1.2 2.2 ± 0.2 1.4 ± 0.2 0.7 ± 0.1 0.5 
10c 2-Et 2.0 ± 0.1 8.9 ± 1.4 3.2 ± 0.4 1.5 ± 0.2 1.1 ± 0.1 0.7 
10d 4-F 1.6 ± 0.3 6.5 ± 0.6 2.2 ± 0.2 1.2 ± 0.2 0.8 ± 0.1 0.7 
10e 4-NO2 1.8 ± 0.1 7.0 ± 0.3 0.6 ± 0.1 2.1 ± 0.1 0.6 ± 0.1 0.3 
10f 5-F 0.7 ± 0.2 0.7 ± 0.2 bND 1.9 ± 0.4 ND ND 
10g 5-CN 1.0 ± 0.1 1.1 ± 0.1 ND 5.1 ± 0.3 ND ND 
10h 5-NO2 0.7 ± 0.1 0.8 ± 0.1 3.7 ± 0.3 ND 2.2 ± 0.1 ND 
10i 5-COOEt 1.9 ± 0.2 4.7 ± 0.6 1.5 ± 0.1 2.4 ± 0.2 0.8 ± 0.1 0.3 
10j 6-F 0.9 ± 0.1 0.7 ± 0.1 2.7 ± 0.5 1.3 ± 0.1 1.3 ± 0.1 1.0 
10k 6-Cl 0.9 ± 0.4 0.9 ± 0.4 7.7 ± 0.5 0.8 ± 0.4 3.8 ± 0.1 4.8 
10l 6-Br 0.9 ± 0.1 1.4 ± 0.2 5.3 ± 0.6 3.5 ± 0.3 0.7 ± 0.1 0.2 
10m 6-NO2 0.9 ± 0.1 0.7 ± 0.1 4.3 ± 0.7 2.8 ± 0.2 2.8 ± 0.2 1.0 
10n 6-OMe 0.8 ± 0.2 0.7 ± 0.1 6.2 ± 0.4 0.9 ± 0.4 2.8 ± 0.1 3.1 
10o 7-F 1.7 ± 0.2 1.9 ± 0.2 ND 2.6 ± 0.4 ND ND 
10p 7-Me 2.0 ± 0.2 11.5 ± 0.8 2.6 ± 0.2 1.4 ± 0.1 0.9 ± 0.1 0.6 
 
Di- 
substituent 
10q 2,3-(Me)2 1.9 ± 0.2 7.1 ± 0.8 8.2 ± 0.6 1.5 ± 0.2 1.0 ± 0.1 0.7 
10r 2-Me-5-
OMe 
1.9 ± 0.2 4.6 ± 0.1 2.1 ± 0.1 2.0 ± 0.1 1.0 ± 0.1 0.5 
10s 2-COOEt-
5-F 
2.0 ± 0.2 8.5 ± 0.8 3.6 ± 0.4 1.3 ± 0.1 1.0 ± 0.1 0.7 
10t 3-CN-6-
OMe 
1.7 ± 0.1 16.7 ± 0.5 3.7 ± 0.1 1.6 ± 0.1 1.9 ± 0.1 1.2 
10u 5-F-6-Cl 2.0 ± 0.2 4.5 ± 0.2 1.7 ± 0.1 2.0 ± 0.2 1.0 ± 0.1 0.5 
10v 5,6-(Cl)2 0.7 ± 0.1 0.9 ± 0.1 9.3 ± 1.1 8.5 ± 0.2 2.2 ± 0.1 0.3 
 
aRI: Resistance index is calculated by dividing IC50 values on multidrug-resistant cell line 
M14/MDR1 by IC50 values on the matching sensitive parental cell line M14. 
bND: Not Determined.  
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more potent inhibitory effects against P-gp overexpressing M14/MDR1 cell line than the 
parental drug sensitive M14 cell line and had resistance indexes pf less than 1, indicating 
that new indole analogs had significant ability to circumvent drug-resistance mediated by 
P-gp overexpression. It is worth noting that five out of the six di-substituted indole 
analogs have RIs less than 1, suggesting that a secondary substituent on the indole is 
beneficial for overcoming drug-resistance. 
 
 In addition to melanoma cell lines, cervical and colorectal carcinoma cell lines 
were also tested to confirm the capabilities of the new analogs to circumvent P-gp 
mediated drug resistance (Table 6-3). The small-molecular survivin inhibitor YM-155 
showed remarkable cytotoxicity against KB-3-1 and SW620 cell lines with IC50 values of 
4.9 nM and 3.9 nM, respectively. YM155, however, displayed significantly reduced 
activities against the corresponding P-gp overexpressing cell lines (KB-C2 and 
SW620/Ad300) and had IC50 values of more than 20 μM. Similarly, paclitaxel, a known 
substrate of P-gp, was not effective against P-gp overexpressing cell lines. In contrast, 
our indole analogs 10f, 10h, 10k, 10n and the previously reported MX-106 showed 
stronger inhibitory effects against P-gp overexpressing cell lines (KB-C2 and 
SW620/Ad300) than their corresponding parent cell lines (KB-3-1 and SW620). While 
the IC50 values range from 1.28 to 1.71 μM in the non-resistant KB-3-1 cell line for 10f, 
10h, 10k and 10n, their potency against the P-gp overexpressing KB-C2 cell line 
significantly increased (IC50 values range from 0.17 to 0.44 μM). Similarly, 10f, 10h, 10k 
and 10n had IC50 values ranging from 0.16 to 0.31 μM against non-resistant SW620 cell 
line while their activities in KB-C2 cell line were 3-6 folds more potent with IC50 values 
ranging from 0.027 to 0.1 μM. Collectively, these new indole analogs of UC-112 can 
show potential to reverse drug-resistance mediated by P-gp overexpression. 
 
 
In Vitro Metabolic Stability Study 
 
 Prior to in vivo study, the in vitro metabolic stabilities of analogs 10f, 10h, 10k 
and 10n were examined by measuring their half-life upon incubation with mouse, rat, and 
human liver microsomes in the presence of an NADPH regeneration system (Table 6-4). 
All compounds possessed acceptable stability profile in three microsome species. They 
were more stable in human microsome than in mouse and rat microsomes. Among the 
four analogs, 10f with a 5-fluoro was the most stable against mouse and human 
microsomes.  
 
 
UC-112 Analogs Maintain Selective Inhibition for Survivin among IAPs 
 
 To determine whether our new UC-112 analogs maintains their selective 
inhibition of survivin as the prototype UC-112 does, we measured protein levels of 
several IAPs including cIAP1, XIAP, Livin, and survivin after treatment with 10f, 10h, 
10k and 10n in A375 cells (Figure 6-2). All four compounds strongly inhibited survivin 
expression in A375 cell line in a concentration-dependent manner, while the other IAP  
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Table 6-3. In vitro cytotoxic effects UC-112 analogs against P-gp overexpressing 
cervical cancer and colorectal cell lines. 
 
Compound 
IC50 ± SD (μM) 
aRI 
IC50 ± SD (μM) 
RI 
KB-3-1 KB-C2 SW620 
SW620/ 
Ad300 
10f 1.36 ± 0.19 0.17 ± 0.09 0.13 0.16 ± 0.04 0.027± 0.006 0.17 
10h 1.39 ± 0.41 0.18 ± 0.05 0.13 0.19 ± 0.09 0.06 ± 0.02 0.32 
10k 1.71 ± 0.22 0.25 ± 0.05 0.15 0.24 ± 0.09 0.05 ± 0.03 0.21 
10n 1.28 ± 0.25 0.44 ± 0.28 0.34 0.31 ± 0.05 0.10 ± 0.04 0.32 
MX-106 1.25 ± 0.10 0.33 ± 0.12 0.26 0.15 ± 0.01 0.03± 0.01 0.20 
YM155 0.0049 ± 0.0005 37.30± 3.97 7612.24 0.0039 ± 0.0056 23.37 ± 2.37 5992.3 
Paclitaxel 0.0005 ± 0.0001 0.25 ± 0.01 500.00 0.030 ± 0.001 1.97 ± 0.36 65.67 
Doxorubicin 0.37 ± 0.07 1.69 ± 0.44 4.57 0.21 ± 0.03 15.24 ± 2.89 72.57 
Cisplatin 1.15 ± 0.13 1.73 ± 0.11 1.50 1.79 ± 0.06 5.12 ± 0.65 2.86 
 
Data obtained by Zi-Ning Lei (St. John’s University). 
aRI: Resistance index is calculated by dividing IC50 values for multidrug-resistant cell 
lines by IC50 values for the matching sensitive parental cell lines. 
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Table 6-4. In vitro metabolic stability of UC-112 analogs in liver microsomes. 
 
Compound 
Metabolic Stability 
(Human) 
 Metabolic Stability 
(Mouse) 
 Metabolic Stability 
(Rat) 
 t1/2 
(hr) 
Clint  
(mL/min/kg) 
 t1/2 
(hr) 
Clint 
(mL/min/kg) 
 t1/2 
(hr) 
Clint 
(mL/min/kg) 
10f 4.59 ± 0.39 4.5 
 
1.36 ± 0.06 42.1 
 
1.29 ± 0.03 4.5 
10h 2.16 ± 0.19 9.6 
 
1.17 ± 0.06 48.7 
 
1.20 ± 0.05 39.0 
10k 3.50 ± 0.36 5.9 
 
1.20 ± 0.07 47.8 
 
1.62 ± 0.10 29.0 
10n 2.80 ± 0.18 7.4 
 
0.88 ± 0.06 65.1 
 
1.26 ± 0.06 37.0 
 
Data obtained by Lei Yang (St. Jude Children’s Research Hospital). 
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Figure 6-2. UC-112 analogs selectively downregulate survivin. 
Western blot analysis A375 cells treated with 1, 3, or 10 μM of 10f, 10h, 10k and 10n for 
24 h. Protein levels of various IAP proteins show that UC-112 analogs selectively target 
survivin over other IAPs (cIAP1, XIAP, and Livin) and increase apoptotic protein 
cleaved-PARP. Western blot was performed by Dr. Yi Xue (UTHSC). 
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family proteins were not affected. This evidence indicates high selectivity of survivin 
inhibition among the IAP proteins. Consistent with survivin inhibition, all four analogs 
effectively induced cancer cell apoptosis, as indicated by the elevated level of cleaved 
PARP. 
 
 
Molecular Modeling of Lead Compound 
 
 To explain the observed strong potency of 10f, a molecular modeling study was 
developed using the complex of human survivin-SMAC AVPI (PDB entry: 3UIH) 
(Figure 6-3A and B). 10f formed appealing hydrogen bonding and π-π stacking 
interactions with the survivin protein BIR domain: (1) two hydrogen bonding interactions 
between the 8-hydroxyquinoline of 10f and residues Glu76 and Lys79; (2) two hydrogen 
bonding interactions between the pyrrolidine of 10f and residue Asp71; (3) π-π stacking 
interaction between the 8-hydroxyquinoline of 10f and residue His80; (4) π-π stacking 
interaction between the 5-F indole of 10f and residue His80; (5) π-cation interaction 
between the pyrrolidine of 10f and residue Trp67 (red line in Figure 6-3B). The 
molecular modeling result suggested that substitute on the 7-position of the indole ring 
will introduce the repulse between the 8-hydroxyquinoline and indole ring and further 
lead to attenuated π- π stacking interactions mentioned above, for example, 10p and 10q 
exhibited significantly decreased potency in comparison with 10a.  
 
 
In Vivo Antitumor Efficacy Assessment 
 
 As one of the most potent indole analog, 10f not only exhibited the most 
favorable stability against mouse and human liver microsomes but also significantly 
inhibited the survivin expression at a low concentration; therefore, 10f was selected for 
further evaluating antitumor efficacy in vivo. An A375 melanoma xenograft model in 
nude mice was used. Tumors were implanted by inoculating mice with A375 human 
melanoma cancer cells subcutaneously in their hindflank. After the development of viable 
tumors, mice were treated every other day for two weeks by i.p. injection with 20 mg/kg 
10f, 15 mg/kg paclitaxel, or vehicle solution only. After 15 days of treatment, the groups 
receiving 20 mg/kg 10f had significantly smaller tumor volumes than the vehicle control 
group with a calculated TGI of 68.6% (Figure 6-4A). This was very similar to the 
paclitaxel treated group which averaged a TGI of 70.6% compared to the vehicle control 
group. One-way ANOVA followed by Dunnett’s multiple comparison test also revealed 
that there was a significant reduction in final tumor volume (P < 0.0001) for all treatment 
groups compared to the vehicle control group. These results are in accord with the tumor 
final weights, where the average tumor weight for the control group was 2.08 ± 0.32 
grams, and 10f and paclitaxel groups averaged 0.85 ± 0.26 grams and 0.78 ± 0.12 grams, 
respectively (Figure 6-4B). Statistically analysis was performed the same and yielded an 
overall P value of 0.0012, and a significant difference (P < 0.01) for each treated group 
compared to the control group. Mouse body weight was measured, and animal activity 
was monitored throughout the experiment, and no significant deviations in animal weight 
or behavior were observed (Figure 6-4C).  
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Figure 6-3. Potential binding mode of 10f to survivin.  
A) The best docking pose of 10f binding in survivin (survivin PDB: 3UIH), shown with 
electron potential color-coded survivin surface (red: electron negative potential; blue: 
electron positive potential). Interactions between 10f and nearby residues in survivin are 
shown. B) Types of interactions are shown with color-coded lines between 10f with 
residues in survivin protein in this 2D interaction map. Molecular modeling generated by 
Dr. Wei Li (UTHSC). 
 
  
 146 
 
 
Figure 6-4. 10f inhibits tumor growth in vivo.  
A) Average tumor volumes ± SEM in an A375 xenograft model in nude mice (n=7-8). B) 
Individual tumor weights. Long line represents mean and error bars represent SEM. 
Statistical significance was determined by one-way ANOVA (P= 0.0012) analysis 
followed by Dunnett’s multiple comparison test for each treatment group compared to the 
control group (** P < 0.01). C) Average mouse body weights ± SEM. Graph represents 
percent change in body weight compared to the starting weight.  
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Conclusions 
 
 In this report, thirty-three new analogs of UC-112 were synthesized and their 
SAR was investigated. The results showed that most indole analogs exhibited potencies 
stronger than or comparable to UC-112 and MX-106. The most potent activities were 
observed in 10f, 10h, 10k and 10n. Compared to YM155, a widely studied survivin 
promoter inhibitor, our new indole analogs of UC-112 showed stronger activities against 
P-gp overexpressing cancer cell lines and parental cancer cell lines. Mechanistic studies 
revealed that new indole analogs of UC-112 selectively suppressed the expression of the 
survivin protein in a dose-dependent manner without affecting other members of the IAP 
family. In an in vivo xenograft model in nude mice, 10f exhibited significant tumor 
growth inhibition without signs of toxicity. These results support conducting detailed 
SAR investigation of novel scaffolds to develop optimized analogs and ultimately led to 
the discovery of 10f, a potent and selective survivin inhibitor with strong anticancer 
action. 
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CHAPTER 7.    SUMMARY AND FUTURE DIRECTIONS FOR TUBULIN 
INHIBITORS AND SURVIVIN INHIBITORS 
 
 
 In the tubulin project, we investigated several scaffolds of small molecules that 
specifically target the colchicine binding site on tubulin. Colchicine binding site agents, 
unlike vinca alkaloids or taxanes, have been reported to circumvent several mechanisms 
of multidrug resistance, particularly resistance mediated by the overexpression of P-gp 
and other drug efflux pumps. Therefore, we had the overall goal to develop compounds 
that would show broad anticancer effects, demonstrate improved IC50s, and disrupt 
microtubule networks and mitotic spindle formation. We also aimed to generate analogs 
that would optimally target the colchicine binding site and would thus maintain a low 
resistance index against ABC transporter overexpressing cell lines and show significant 
efficacy against taxane-resistant tumors in animal models.  
 
 In Chapter 2, we hypothesized that our lead indolyl-imidazopyridines, DJ95 and 
DJ101, would show strong potency to a variety of cell lines including those exhibiting 
MDR. This was confirmed by their cytotoxicity against our expanded melanoma cell 
panel and against the NCI-60 cell lines. DJ101 showed the greatest activity against 
melanomas, with IC50s below 10 nM. Both DJ101 and DJ95 showed low resistance 
factors to taxane-resistant prostate cancer cell lines, especially when compared to other 
tubulin inhibitors including colchicine, paclitaxel, and docetaxel. DJ95 was also 
evaluated against gene-transfected cell lines overexpressing ABCB1, ABCC1, and 
ABCG2, and additionally against drug-selected MDR cell lines. MDR cell lines were 
more receptive to DJ95 treatment than to colchicine, vincristine, and paclitaxel. To test 
our hypothesis regarding their effects on microtubule networks, we demonstrated their 
strong destabilizing action and disruption to mitotic spindles via confocal microscopy, 
followed by X-ray crystallographic analysis detailing their verified interaction at the 
colchicine domain. Finally, we hypothesized that the compounds would show potent 
anticancer activity in animal models. Both DJ95 and DJ101 demonstrated tumor growth 
inhibition in melanoma xenografts. DJ101 presented superior activity, where 30 mg/kg 
doses inhibited tumor growth by 92.8%. In a subsequent metastatic melanoma xenograft 
model, treatment with DJ101 using the same dosing regimen drastically reduced 
pulmonary metastatic nodules by 83.8% compared to the control group. Finally, DJ101 
treatments potently inhibited the growth of taxane-resistant prostate cancer tumors, 
confirming its activity in vivo and against MDR-presenting cancers. Therefore, we 
confirmed the hypothesis for this series of agents, with DJ101 showing the greatest 
anticancer activity. 
 
 In Chapter 3, we set out to test the assumption that the indole moiety and 3,4,5-
trimethoxyphenyl moiety of VERU-111 could be optimized to generate analogs with 
lower IC50s, greater activity against tubulin polymerization, and in vivo efficacy in mouse 
models. We identified the best candidate from each series of modifications: indole 
substitution (10ab), indolyl rotation (10bb) and TMP modification (13f). We then 
demonstrated their high efficacy against taxane-resistant cell lines and validated their 
mechanism of action through their ability to potently prohibit polymerization of purified 
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tubulin protein. Their destabilization action was further established with confocal 
microscopy, and their activity against microtubules resulted in fragmentation and 
decreased polymeric tubulin.  Even with its unique allosteric replacement of the critical 
TMP moiety, 13f still showed direct interactions with the colchicine binding site by X-
ray crystallography. Finally, based on their potency and metabolic stabilities in liver 
microsomes, we tested 10bb and 13f in melanoma xenograft models, and 30 mg/kg 
treatments suppressed tumor growth by 73.9% and 90.6%, respectively. 10bb also 
effectively inhibited metastasis and taxane-resistant tumor proliferation in two additional 
animal models without showing signs of toxicity. The pharmacological profile of 10bb 
did not indicate significant interactions with physiologically important off-targets based 
on the Safety Screen panel, nor did the toxicological analysis of major organs (heart, 
liver, kidney, lungs, and spleen) from the drug-treated xenograft model groups exhibit 
apparent drug-related injury to the tissues. Therefore, we identified improved analogs of 
VERU-111, and the most promising compound, 10bb, showed significant in vivo activity 
against MDR tumors, inhibited the development of metastases, and improved the 
therapeutic window. 
 
 In Chapter 4, we hypothesized we could design Azixa analogs that had improved 
metabolic stabilities, could induce vascular disrupting effects, interfere with cellular 
processes through tubulin inhibition, promote G2/M phase mitotic arrest, and finally, 
demonstrate potent antitumor effects. First, we selected 4a, 6a, 5a, and 5b from a series 
of heteropyrimidines based on their exceptional potencies in initial cell viability assays. 
5a and 5b were tested in additional cancer types, including malignant melanomas, 
prostate, lung, and breast cancer cell lines as well as several drug-resistant sublines. 5b 
outperformed colchicine in every instance and revealed that it was a poor substrate of P-
gp. Compared to Azixa, 4a, 5a, and 5b all showed better metabolic stabilities in human 
liver microsomes and were substantially better than other reported Azixa analogs. All 
four compounds showed robust destabilizing activity based on tubulin polymerization 
and microtubule morphology, and two compounds (4a and 6a) had confirmed binding to 
the colchicine site at the interface of the of the α and β tubulin subunit, all supporting 
their action as colchicine binding site inhibitors. 5a and 5b hindered cell migration, 
inhibited colony proliferation, induced G2/M phase cell cycle arrest and apoptosis in a 
concertation-dependent manner, and disturbed HUVEC capillary-like formation in vitro. 
4a and 6a were assessed in vivo and inhibited melanoma tumor growth by 72.3% and 
76.5%, respectively, following 30 mg/kg treatments, and 4a treatment also reduced 
taxane-resistant prostate cancer tumor volume by 55.6%. Tumor sections from the treated 
groups showed greatly diminished overall microvessel formation and morphologically 
distortion vasculature, and additionally revealed elevated levels of apoptosis compared to 
the control group. These in vivo results of 4a and 6a correlate with the in vitro data 
demonstrated by 5a and 5b, ultimately confirming our hypothesis and supporting their 
action as both tubulin inhibitors and as vascular disrupting agents capable of inducing 
strong anticancer action against clinically significant drug-resistant models. 
 
 In conclusion, from our overall evaluation of tubulin inhibitors, we optimized 
several scaffolds of colchicine binding site agents and generated lead analogs with 
improved potency, metabolic stability, and antitumor efficacy. After confirming their 
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cytotoxic effects against a variety of cell lines, lead compounds underwent additional 
biological analysis to confirm their mechanisms of action. We determined that they 
shared common characteristics with other colchicine binding site agents including; 
inhibiting tubulin polymerization, destabilizing microtubules and mitotic spindles, 
directly interacting with the colchicine binding site, inducing G2/M phase cell cycle 
arrest, and hindering migration. Furthermore, several of the compounds were evaluated in 
ABC transporter overexpressing cell lines, drug-selected resistant cell lines, and taxane-
resistant xenograft models, and showed improved efficacy. Two of the compounds were 
able to potently suppress the establishment of pulmonary metastases of melanoma in 
vivo, supporting their use for metastatic intervention. We also investigated the vascular 
disrupting potential of some of the compounds and presented their capacity to inhibit 
endothelial cell network formation and diminish intra-tumor vasculature. 
Pharmacological profile screenings revealed that the compounds minimally interact with 
off-target receptors, transporters, ion channels, kinases, and enzymes, which may reduce 
the attrition risk at later stages in the drug development process. Overall, we identified 
promising candidates, including indolyl-imidazopyridines (DJ95 and DJ101), VERU-111 
analogs (10ab, 10bb, and 13f), and heterocyclic pyrimidines (4a, 6a, 5a, and 5b), 
confirmed the mechanism of action as colchicine binding site agents, and demonstrated 
their anticancer potential, particularly against MDR cell lines and tumor models. 
 
 To effectively escape the shortcomings of current anticancer drugs, newer 
generations of tubulin inhibitors should exploit the colchicine binding site to decrease the 
susceptibility of transporter-mediated efflux and resistance to the βIII tubulin isoform. 
Additionally, drugs targeting this site often are effective as vascular disrupting agents and 
can accommodate a large range of structurally diverse scaffolds. Innovative strategies for 
microtubule targeting agents should capitalize on combination therapies to reduce the 
emergence of multidrug resistance. Other issues limiting the clinical potential of 
microtubule targeting agents are poor solubility, low metabolic stability, and dose-
limiting neural and cardiotoxicities. Several techniques have been employed to improve 
drug properties and limit toxicity such as delivery via nanoparticle formulations and 
antibody-drug conjugation. Finally, the emergence of dual kinase tubulin inhibitors 
provides several benefits for this class of drug, as these dual inhibitors may improve the 
therapeutic window and reduce the risk of drug resistance development by targeting 
multiple pathways. While the scaffolds of the tubulin compounds we investigated were 
quite diverse in structure, their common feature was that they all target the colchicine 
binding site and were highly effective against multiple mechanisms of resistance. We 
believe that of the investigated compounds, DJ101 is one of the strongest candidates to 
avidly push forward with characterization. Additional models could be used to test its 
efficacy, such as patient derived xenograft models, and further characterization of the 
biological events that ensue for it to maintain efficacy against MDR phenotypes will 
reveal the compound’s clinical potential. Ultimately, our studies collectively support the 
continued development of the investigated scaffolds as anticancer therapeutics, especially 
as an alternative treatment to taxane-resistant cancers. 
 
 In the survivin project, we explored analogs of UC-112, an IAP inhibitor selective 
to survivin. We hypothesized that by modifying the benzyloxy moiety, we could generate 
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analogs with improved potency against P-gp overexpressing cell lines, specifically target 
survivin with high selectivity, and show in vivo anticancer efficacy. After attempts to 
modify the benzyloxy with numerous other substructures, we determined that the non-
substituted indole analog had the most comparable potency to the parent compound. 
From there, we shifted our focus to determining the best substitution on the indole ring 
and identified 10f (containing a fluorine at the 5-position of indole). 10f, the most 
promising candidate, demonstrated exceptional potency against parental and resistant 
cancer cell lines and selectively suppressed the expression of the survivin protein in a 
dose-dependent manner without affecting other members of the IAP family. Finally, 10f 
treatment of 20 mg/kg significantly inhibited tumor volume in a xenograft model by 
68.6%, which was equally as effective as paclitaxel treatment (TGI of 70.6%), without 
causing toxicity to the animals. Therefore, our hypothesis regarding UC-112 
modification, survivin selectivity, and anticancer action was confirmed.  
 
 Identifying appropriate biomarkers that correlate with elicited response and 
developing synergistic combination therapies, especially to avoid development of 
multiple drug resistance, could prove to be invaluable strategies to maximize clinical 
efficacy for IAP inhibiting agents in general and particularly for survivin inhibitors. 
Because dynamicity of survivin and its implicated in many critical biological processes 
including mitosis, apoptosis, cell cycle regulation, and autophagy, it is important to 
evaluate the anticancer efficacy of survivin antagonism against the potential dysfunction 
of other cell regulating mechanisms that may provoke deleterious side effects. Overall, 
our results validated the in-depth investigation for this novel survivin inhibitor scaffold, 
and additional biochemical and mechanistic characterization is warranted in the future.  
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APPENDIX.  DOSE RESPONSE CURVES FROM NCI-60 CELL LINES 
 
 
 
 
Figure A-1. Dose-response curves of DJ101 against the NCI-60 cell line panel. 
Percent growth of NCI-60 cell lines treated with DJ101 in 5- dose assay as determined by 
the National Cancer Institute Developmental Therapeutics Program (NCI-DTP). 
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Figure A-2. Dose-response curves of DJ95 against the NCI-60 cell line panel. 
Percent growth of NCI-60 cell lines treated with DJ95 in one-dose (top) and 5-dose 
(bottom) assays as determined by the NCI-DTP.  
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